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The tumor suppressor p53 primarily functions as a transcription factor responding to a myriad of 
cellular stresses. It is a pivotal and pleiotropic regulator in the stress-induced cellular response 
networks. Diverse activities of p53 are important not only in DNA repair, induction of cell cycle 
arrest and apoptosis, but also in senescence, autophagy and metabolism. In cells infected with 
human papillomaviruses (HPVs), the viral oncoproteins E6 and E7 target the tumor suppressors 
p53 and pRb, respectively, for degradation and inactivation. HPV E6 and E7 synergistically act to 
promote uncontrolled cell divisions and inhibit apoptosis. Persistent infections with high-risk 
HPVs are closely linked to cervical cancer as well as other malignancies in the anogenital and 
oropharyngeal region. Our previous lab results found that HPV E6/E7 oncogenes are repressed 
under hypoxia, a condition that is frequently detected in solid tumors. Unlike the reactivation of 
pRb, p53 protein levels did not increase in E6/E7-repressed hypoxic HPV16-positive cancer cells, 
but even decreased further. The present study aimed to delineate the dynamics of p53 under 
hypoxic conditions as well as the mechanisms underlying this regulation and elucidate the role of 
p53 regulation for downstream responses and cellular outcomes/fates in hypoxic HPV16-positive 
cancer cells. It was revealed that despite a continuous repression of E6/E7 oncogenes, p53 did not 
immediately recover, but instead showed a biphasic regulation (rapid and strong depletion, then 
marked recovery). The initial hypoxic reduction of p53 was predominantly mediated via a 
lysosome-dependent mechanism. The biphasic regulation of p53 appears to serve as a survival and 
protective strategy of hypoxic HPV16-positive cancer cells under stress conditions. The 
modulation on p53 downstream target genes that coincides with p53 protein dynamics may 
contribute to enhance cellular adaptation to hypoxia. p53 target genes associated with terminal 
fates such as cell death (apoptosis) and permanent cell cycle arrest (senescence) are inactivated 
through p53 depletion by hypoxia, protecting cells from committing to an irreversible fate. After 
prolonged hypoxia, the restored p53 might be required by HPV16-positive cancer cells to 
maintain cellular homeostasis and select cells resistant to cell death by induction of apoptotic 
genes. Hypoxia-associated initial reduction of p53 facilitates the induction of autophagy, which is 
critical for the evasion of senescence by hypoxic HPV16-positive cancer cells. Collectively, these 
findings reveal a new regulation pattern of p53 by hypoxia and provide new insights into the role 
of p53 regulation in downstream responses and cellular adaptation to hypoxia in HPV16-positive 






Der Tumorsuppressor p53 fungiert hauptsächlich als Transkriptionsfaktor, der auf zahlreiche 
zelluläre Belastungen reagiert. Er ist ein zentraler und pleiotroper Regulator in stressinduzierten 
zellulären Antwortnetzwerken. Die verschiedenen Aktivitäten von p53 sind nicht nur für die 
DNA-Reparatur, die Induktion des Zellzyklusstillstands und die Apoptose wichtig, sondern auch 
für die Seneszenz, die Autophagie und den Metabolismus. In mit humanen Papillomviren (HPVs) 
infizierten Zellen vermitteln die viralen Onkoproteine E6 und E7 den Abbau bzw. die 
Inaktivierung der Tumorsuppressoren p53 und pRb. HPV E6 und E7 fördern synergistisch die 
unkontrollierte Zellteilung und hemmen gleichzeitig die Apoptose. Anhaltende Infektionen mit 
Hochrisiko-HPVs stehen in engem Zusammenhang mit Gebärmutterhalskrebs sowie anderen 
bösartigen Erkrankungen im Anogenital- und Hals-/Rachenbereich. Unsere früheren 
Laborergebnisse zeigten, dass HPV-E6/E7-Onkogene unter Hypoxie, einem Zustand, der häufig 
bei soliden Tumoren festgestellt wird, unterdrückt werden. Anders als bei der Reaktivierung von 
pRb stiegen die p53-Proteinspiegel in E6/E7-reprimierten hypoxischen HPV16-positiven 
Krebszellen nicht an, sondern sanken sogar weiter. Die vorliegende Studie zielte darauf ab, die 
Dynamik von p53 unter hypoxischen Bedingungen sowie die dieser Regulation 
zugrundeliegenden Mechanismen zu beschreiben und die Rolle der p53-Regulation für 
Downstream-Reaktionen und zelluläre Schicksale in hypoxischen HPV16-positiven Krebszellen 
zu klären. Es wurde gezeigt, dass sich p53 trotz kontinuierlicher Repression von E6/E7-
Onkogenen nicht sofort erholte, sondern eine biphasische Regulation (schnelle und starke 
Reduktion, dann deutlicher Anstieg) stattfand. Die anfängliche hypoxische Reduktion von p53 
wurde überwiegend über einen lysosomenabhängigen Mechanismus vermittelt. Die biphasische 
Regulation von p53 dient vermutlich als Ü berlebens- und Schutzstrategie für hypoxische HPV16-
positive Krebszellen unter Stressbedingungen. Die Modulation von p53-Zielgenen, die mit der 
Dynamik von p53-Proteinleveln übereinstimmt, kann dazu beitragen, die zelluläre Anpassung an 
Hypoxie zu verbessern. p53-Zielgene, die mit terminalen Schicksalen wie Zelltod (Apoptose) und 
permanentem Zellzyklusstillstand (Seneszenz) assoziiert sind, werden durch p53-Depletion durch 
Hypoxie inaktiviert und schützen die Zellen vor einem irreversiblen Schicksal. Nach längerer 
Hypoxie könnte das wiederhergestellte p53 von HPV16-positiven Krebszellen verwendet werden, 
um die zelluläre Homöostase aufrechtzuerhalten und Zellen auszuwählen, die gegen Zelltod durch 
Induktion apoptotischer Gene resistent sind. Die Hypoxie-assoziierte anfängliche Reduktion von 
p53 erleichtert die Induktion der Autophagie, die für die Umgehung der Seneszenz durch 
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hypoxische HPV16-positive Krebszellen von entscheidender Bedeutung ist. Zusammengenommen 
offenbaren diese Ergebnisse ein neues Regulationsmuster von p53 durch Hypoxie und liefern neue 
Erkenntnisse über die Rolle der p53-Regulation bei Downstream-Reaktionen und der zellulären 
Anpassung an Hypoxie in HPV16-positiven Krebszellen. Diese Studie hat weiterhin 






1.1 Infection and Cancer 
 
1.1.1 Cancer statistics 2018 
 
Cancer is a major global health burden, with approximately 18.1 million new cases and an 
estimated 9.6 million cancer deaths in 2018 worldwide (Figure 1.1) (source: Globocan 2018) [2]. 
Of these, 9,456,418 cases (52.31%) were male and 8,622,539 (47.79%) were female. Globally, about 
1 in 6 deaths is due to cancer, making it the second leading cause of death following cardiovascular 
diseases. The most commonly diagnosed cancer worldwide was lung cancer (11.58% of the total 
cases), followed by female breast cancer (11.55%), colorectal cancer (10.23%), and prostate cancer 
(7.06%) (Figure 1.1). In 2018, lung cancer was responsible for most deaths (18.43% of the total 
cancer deaths). The second on the list of cancer mortality was colorectal cancer (9.22%). Stomach 
cancer was the number three cause of cancer death (8.19%), closely followed by liver cancer 
(8.18%) (Figure 1.1). 
 
Figure 1.1 | Distribution of new cases and deaths for the 10 most common cancers in 2018 for both sexes. 
The area of the pie chart reflects the proportion of the total number of cases or deaths; non-melanoma skin 
cancers are included in the “other” category. Figure adapted from [2]. 
 
Among women, breast cancer was the number one diagnosed cancer (2,088,849 cases) and the 
leading cause of cancer death (626,679 deaths), followed by colorectal cancer (823,303 cases), lung 
cancer (725,352 cases) for incidence, and lung cancer (576,060 deaths) and colorectal cancer 
(396,568 deaths) for mortality; cervical cancer ranks fourth for both incidence (569,847 cases) and 
mortality (311,365 deaths) (Figure 1.2A) [2]. Among men, lung cancer was the most frequent 
Introduction 
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cancer (1,368,524 cases) and the leading cause of cancer death (1,184,847 deaths), followed by 
prostate cancer (1,276,106 cases) and colorectal cancer (1,026,215 cases) (for incidence) and liver 
cancer (548,375 deaths) and stomach cancer (513,555 deaths) (for mortality) (Figure 1.2B) [2]. 
 
Figure 1.2 | Distribution of new cases and deaths for the 10 most common cancers in 2018 for (A) Females 
and (B) Males. For each sex, the area of the pie chart reflects the proportion of the total number of cases or 
deaths; non-melanoma skin cancers are included in the “other” category. Figure adapted and modified from 
[2]. 
 
1.1.2 Cancer risk factors 
 
Cancer originates from the transformation of normal cells into tumor cells in a multi-step process 
that generally progresses from a pre-cancerous lesion to a malignant tumor. Accumulation of 
genome mutations over a period of time results in uncontrolled and rapid growth of abnormal 
cells leading to malignant transformation. These mutations can arise spontaneously and are 
Introduction 
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favored by external risk factors, including: 1) physical carcinogens, such as ultraviolet (UV) and 
ionizing radiation; 2) chemical carcinogens, such as asbestos, components of tobacco smoke, 
aflatoxin (a food contaminant); and 3) biological carcinogens, such as infections with certain 
viruses, bacteria, or parasites [3, 4]. The major human cancer risk factors therefore are tobacco use, 
alcohol abuse, occupational exposures, environmental contamination, and infectious agents. An 
estimated 15% (2,100,000 cases) of cancers diagnosed in 2012 were attributed to infections, 
including Helicobacter pylori, Human papillomavirus (HPV), Hepatitis B virus, Hepatitis C virus, 
and Epstein-Barr virus (Figure 1.3) [1]. 
 
 
Approximately 70% of cancer deaths occur in low- and middle-income countries where some 
chronic infections have major relevance. Cancer causing infections, such as Hepatitis B/C virus 
and HPV, were responsible for up to 25% of cancer cases in these countries in 2012 [1].  
 
1.1.3 Human Papillomaviruses (HPVs) 
 
HPV infection-associated cancers were responsible for approximately 54% of cancers attributable 
to infections among women worldwide in 2012 (Figure 1.4) [1]. It has previously been reported 
that in 99% of cervical cancers, HPV genomes can be detected, up to 70% of which belong either 
to the HPV types HPV16 or HPV18 [5, 6].  
Figure 1.3 | Cancer cases attributable to 
infections among both sexes worldwide in 
2012. Shown by infectious agents. Data source: 





Papillomaviruses (PVs) are a diverse group of small non-enveloped viruses with a double stranded 
circular DNA genome [7]. PVs infect a range of different species including reptiles, birds, 
marsupials, and mammals, displaying a tropism for mucosal and cutaneous epithelia [8]. Up to date 
more than 300 different PV types were identified including 210 human papillomaviruses (HPVs) 
as well as 170 animal papillomaviruses (PaVE: Papillomavirus Episteme) [9].  
Based on nucleotide sequence comparison (at least 10% difference), the 210 HPV types are 
phylogenetically divided into five different genera, which are denominated with Greek letters: 
alpha-, beta-, gamma-, mu- and nu-types [10, 11]. Additionally, HPVs are often referred to as 
cutaneous types or mucosal types. The cutaneous HPVs exclusively infect cells of the skin, causing 
benign papillomas, of which most manifestations are common plantar and flat warts [12]. The 
mucosal HPVs infect mucosal cells, responsible for benign warts or malignancies in penis, vagina, 
vulva, anus, cervix and head and neck. Most cervical cancers are caused by genital HPV types of 
the alpha-genus [6]. According to clinical pathologies, the alpha HPV types are further classified 
into “low-risk” cutaneous types, “low-risk” mucosal types, and “high-risk” types. The “low-risk” 
cutaneous types (e.g. HPV 3, HPV 10 and HPV61 etc.) and “low-risk” mucosal types (e.g. HPV 6, 
HPV11 and HPV 13 etc.) cause benign warts or no apparent cellular transformation [13]. The 
“high-risk” types (e.g. HPV 16, HPV 18 and HPV 45) with oncogenic potential are etiologically 
confirmed as “human carcinogens”. On the basis of epidemiological data, HPV 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58 59, 69, 73 and 82 are responsible for 99.7% of cervical cancers and therefore 
are referred to as “oncogenic types” by the World Health Organization (WHO) [14].  
 
1.1.3.1 Genomic organization of HPVs 
 
The double stranded circular DNA genome of PVs ranges from 6953 base pairs (bp) [Chelonia 
mydas papillomavirus type 1 (CmPV1)] to 8607 bp [Canine papillomavirus type 1 (CPV1)] in 
Figure 1.4 | Cancer cases attributable to 
infections among females worldwide in 
2012. Shown by infectious agents. Data 




length [15]. The genomes are functionally divided into three parts: the upstream regulatory region 
(URR), the early region and the late region (Figure 1.5). Although the URR does not contain 
protein coding sequences, it harbors the viral origin of replication and several early promoter and 




Figure 1.5 | Genomic organization of the mucosal high-risk HPV16. Viral gene expression is under the 
control of the upstream regulatory region (URR, yellow). The location and functions of early (blue) and late 
genes (green) are shown. AL: polyadenylation (late); AE: polyadenylation (early). ORI: origin of replication. 
Figure adapted from [16].  
 
The early region contains an early promoter (p97 in HPV16 and p105 in HPV18) and encodes five 
to six early viral genes (E1, E2, E4, E5, E6 and E7) that are transcribed as polycistronic mRNAs 
[17]. The cutaneous HPV types typically lack the E5 gene [18]. The proteins encoded by these 
early genes play a role in viral replication and transcription (E1, E2 and E4) or are essential for 
transformation of host cells (E5, E6 and E7). The early region also contains the late promoter (p670 
in HPV16 and p765 or p811 or p829 in HPV18) within the E7 open reading frame (ORF), which is 
active at final stages of the virus life cycle. It is required for the gene expression of the viral capsid 
proteins L1 and L2, which are encoded in the late region of all HPV genomes [17, 19]. 
 
1.1.3.2 HPV life cycle 
 
The life cycle of HPVs is coupled to the differentiation process of the infected keratinocyte, 
presenting in a distinct spatial and temporal pattern [16] (Figure 1.6). The HPV infection initially 
occurs in keratinocytes in the basal layer of the epithelium via skin abrasion or micro-wounds, 
which can arise during scarification or sexual intercourse [20]. The entry of virus into the host 
cells mainly depends on the attachment of the C-terminus of the L1 protein to heparan sulfate 
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proteoglycans (HSPGs) and laminin on the cell surface [20, 21]. After the internalization of the 
virus, an uncoating process takes place in the endosome. L1 proteins are degraded during the 
lysosomal transport of the viral particle into the nucleus whereas the viral L2/DNA complexes 
enter the host cell nucleus [22, 23]. 
In basal layers of infected epithelia, the viral genomes are established in the nucleus as low-copy 
episomes (20-100 per cell). Low levels of the early genes E1 and E2 and the other early genes E6 
and E7 are expressed. E1 and E2 are required for the genome replication of the virus, which takes 
place along with the host cell DNA replication. Since the viral DNA does not encode proteins 
required for DNA synthesis, it uses the host cell replication machinery [6]. The E7 protein binds to 
the family of retinoblastoma-associated protein (pRb) proteins leading to their dissociation from 
transcription factors that control the host cell cycle. This leads to the continuous synthesis of the 
viral as well as host DNA [24] upon which the host cell activates the tumor suppressor p53, which 
usually induces apoptosis. However, the E6 protein targets p53 for proteasomal degradation and 
hence, the HPV-infected cells do not undergo apoptosis [25, 26]. E6 also increases telomerase 
activity promoting immoderate cell divisions [27]. HPV E6 and E7 thus synergistically act to 
sustain continuous proliferation of the host cells and in turn viral DNA replication. The expression 
of E6 and E7 genes upon high-risk HPV infections is associated with the immortalization and 
transformation of cells, which are therefore called viral oncogenes. 
 
 
Figure 1.6 | Life cycle of HPV in infected epithelial tissue. The virus infects the basal layer of epithelia via 
micro-wounds. E1 and E2 proteins mediate the replication of the viral genome coinciding with the host cell 
division. E6 and E7 are expressed in the suprabasal layer, where they promote re-entry of the infected 
keratinocytes into the S-phase of the cell cycle and simultaneously inhibit apoptosis. Amplification of the 
viral genome takes place in the granular region of the epithelium resulting from the concerted action of E1, 
E2, E4 and E5. Finally, expression of the late genes L1 and L2 in the top layer results in the assembly of 
infectious particles which are then released from dead keratinocytes through a desquamation process. Figure 




A shift in the viral gene expression profile takes place with progressing differentiation of infected 
keratinocytes. With the concerted action of E1, E2, E4 and E5, the viral genome is dramatically 
amplified resulting in thousands of viral copies per cell. In the granular layer, the late viral 
promoter is activated. Here, the late genes L1 and L2 are expressed and the assembly of virus 
particles takes place. The capsid of every virus particle is usually formed by 360 L1 protein 
subunits that are organized into 72 pentameric capsomeres as well as a variable number of L2 
protein subunits [28]. Furthermore, L2 (together with E2) is required to ensure the successful 
DNA packaging and capsid assembly [29]. Finally, the newly formed viral particles are passively 
shed from the cornified epithelia. Viral DNA can also persist in non-dividing keratinocytes of the 
basal epithelial layer for long periods of time, resulting in a dormant infection that can be re-
activated, e.g. due to hormonal changes in the host [30]. 
 
1.1.3.3 HPV-induced carcinogenesis 
 
HPV infections are ubiquitous in the majority of sexually active people (>80%). In general, HPV 
infections can be potentially cleared by the host’s immune system. However, in some cases high-
risk HPVs can modulate the immune response of host cells facilitating immune evasion, after 
which HPVs persist for longer time spans (from several months up to years) [31]. During this time, 
the expression of E6 and E7 in chronically infected cells leads to an accumulation of gene 
mutations due to numerous uncontrolled cell divisions, as well as chromosomal instability and 
inhibition of apoptosis. Continuous and repeated infection with HPVs therefore leads to the 
development of neoplastic lesions [6]. At the uterine cervix, these lesions are referred to as 
cervical intraepithelial neoplasia (CIN). Classifications have been established to stage cervical 
lesions based on their risk of developing into invasive carcinoma, such as the histological staging 
from mild to severe dysplasia classified as CIN 1 to 3. HPV-induced premalignant cervical 
intraepithelial lesions (CIN 1) can progress into high-grade intraepithelial lesions (CIN 2/3) and 
eventually into invasive cervical carcinoma (CaCx), where the viral genomes are integrated into 





Figure 1.7 | Schematic overview of HPV-induced carcinogenesis. HPV DNA is maintained episomally and 
the viral life cycle is still completed in cervical intraepithelial neoplasia stages 1 and 2 (CIN 1 and 2). Upon 
progression into CIN 3 lesions, the early gene expression is deregulated and no progeny virus is produced. 
Upon further progression into cervical cancer lesions (CaCx), the viral genome is integrated into the host 
genome after which E6 and E7 are predominantly expressed. Figure adapted from [33]. 
 
 HPV-induced carcinogenesis 
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In CIN 1/2 lesions, the viral genome is episomal and the HPV life cycle is still completed [34]. In 
the majority of cases, these lesions regress spontaneously. However, in cases where the lesions 
persist, the viral gene expression undergoes a deregulation and no progeny virus is produced any 
longer. At these stages, i.e. CIN 3, virus DNA begins to integrate into the host genome resulting in 
the loss of E2, which disrupts its transcriptional control over E6 and E7 [35]. After integration, E6 
and E7 are exclusively produced throughout all layers of the infected epithelia, increasing cell 
division rates and the accumulation of mutations. These lesions ultimately progress to carcinomas. 
Notably, only a minority of high-risk HPV-infected individuals (1%) develop carcinomas during 
their life-time [36]. 
 
With an estimated 569,847 new cases and 311,365 deaths worldwide in 2018, cervical cancer 
represented the fourth most commonly diagnosed cancer and the fourth leading cause of cancer 
death in women worldwide (Figure 1.2A). Although cervical cancer incidence rates are declining 
in many high-income countries, incidence and mortality of this disease remain high and are 
predicted to further increase in low- and middle-income countries where effective screening 
programs are absent [2, 37-39]. Therefore, development and execution of new strategies for 
effective treatment and prevention are important and urgent. 
 
1.1.4 Prevention and therapy of cervical cancer 
 
Comprehensive cervical cancer control includes primary prevention (vaccination against HPV), 
secondary prevention (screening and treatment of pre-cancerous lesions), tertiary prevention 
(diagnosis and treatment of invasive cervical cancer) and palliative care [40]. 
 
Prophylactic vaccination 
The most effective protection against diseases can be achieved by preventing their initial 
establishment. In the case of cervical cancer, this can be accomplished by prophylactic vaccination. 
There are currently three licensed vaccines protective against HPV. All of them are based on 
virus-like particles (VLPs) of the HPV major capsid protein L1 and lead to a strong seroconversion 
with antibody titers much higher than obtained by natural infection [41]. The bivalent Cervarix 
(GlaxoSmithKline) contains antigens of HPV16 and 18, which are known to cause at least 70% of 
all cervical cancers. The quadrivalent Gardasil (Merck) protects against two additional HPV types, 
6 and 11, which cause roughly 90% of anogenital warts. The nonavalent Gardasil9 (Merck), the 
most recently developed vaccine, comprises the four HPV types (6, 11, 16 and 18) of the 
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quadrivalent vaccine and protects against five additional oncogenic HPV types (31, 33, 45, 52, 58), 
thereby covering a further 20% of HPV infection-associated cervical cancers. 
All HPV vaccines are very safe and effective in preventing infections with HPV [42]. However, 
the vaccines cannot treat established HPV infections or HPV-associated disease. HPV vaccines 
work best if administered prior to exposure to HPV. Therefore, the WHO recommends that 
primary prevention begins with HPV vaccination of girls aged between 9 and 13 years, before 
they become sexually active [40]. Moreover, vaccination is directed against specific HPV types and 
is therefore not able to prevent 100 percent of HPV-induced cervical cancers. In many countries 
where HPV vaccines are introduced, screening programs often still need to be developed or 
strengthened. 
 
Screening for cervical cancer 
In many cases of HPV infection, the development of invasive cervical carcinomas can be 
prevented by screenings that detect the presence of abnormal cervical cells and pre-cancerous 
lesions. Screening and treatment of pre-cancer lesions in women who are sexually active is a cost-
effective way to prevent cervical cancer. There are currently three different recommended types 
of screening tests, including HPV testing for high-risk HPV types (detection of DNA or RNA), 
visual inspection with Acetic Acid (VIA), and conventional (Pap smear) test and liquid-based 
cytology (LBC) [40]. Because pre-cancerous lesions take many years to develop, screening is 
recommended for women from age 30 and regularly afterwards. When pre-cancerous lesions are 
detected, these can easily be treated, and cancer development can be avoided. Screening can also 
detect cancer at an early stage and treatment has a high potential for cure. For treatment of pre-
cancer lesions, the use of cryotherapy and Loop Electrosurgical Excision Procedure (LEEP) are 
recommended [40]. For advanced lesions, women should be referred for further investigations and 
adequate management. 
 
Treatment of invasive cervical cancer 
For invasive cervical cancer, the currently recommended standard treatment consists of surgery 
frequently combined with radiation therapy or cisplatin-based chemo- and radiation-therapy [40, 
43]. Palliative care is also an essential part of cancer management to relieve unnecessary pain and 
suffering due to the disease. 
In addition to preventive vaccines, several researches are focused on the development of 
therapeutic HPV vaccines. In general, these therapeutic vaccines focus on the HPV E6 and E7 
oncogenes. Since sustained expression of the viral E6 and E7 is considered to be required for 
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maintaining the malignant phenotype of cervical cancer cells, it is hoped that immune responses 
against the two oncogenes might eradicate established tumors [44]. 
 
In high-income industrialized countries, programs are in place, which enable girls to be 
vaccinated against HPV and women to get screened regularly. However, in low-income 
developing countries, there is limited access to these preventive measures and cervical cancer is 
often not identified until it has further advanced and symptoms develop. In addition, since broad 
vaccination programs were started earliest in 2006 [42] and it takes decades for an initial infection 
to progress to cancer [33], cervical cancer will still be a major health burden for many years to 
come. Furthermore, the resistance of cervical cancer to currently recommended radiation- and 
chemo-therapy remains a problem [45, 46]. Thus, development of novel and effective therapeutic 
strategies has a great significance for the control of HPV-associated cancers. 
 
1.2 Tumor hypoxia 
 
The level of tissue oxygenation is an important biological and clinical aspect with a strong impact 
on the cellular phenotype [47-49]. For carcinomas of the cervix, several studies researched the 
relationship between intratumoral oxygen partial pressure (pO2) and cellular behaviors and 
outcomes [50-52]. Low intratumoral pO2 is reported to be an important prognostic factor of poor 
survival in cervical cancer patients [48, 49, 53-55]. 
 
Ambient air contains 21% oxygen (O2), which is usually used as a standard cell culture condition 
for many in vitro studies, hereafter defined as “normoxia”. However, O2 concentrations of most 
normal healthy mammalian tissues are in the range between 3.5-7% (“physoxia”) [47]. In the 
subregions of tissue with disease, such as acute and chronic vascular disease, pulmonary disease 
and cancer, the O2 concentrations are even lower (“hypoxia”). Tissue hypoxia is usually defined as 
less than 1.5-2% O2 and severe hypoxia or “anoxia” is defined as less than 0.02% O2 [56, 57]. 
Due to the high growth rate of tumor cells and an imbalance in oxygen supply and consumption, 
solid tumors are heterogeneously oxygenated and often characterized by the presence of regions 
with O2 concentrations significantly below the physiological level [49, 56, 58]. Tumor hypoxia is 
frequently categorized as chronic and acute. Inadequate supply with O2 in tumor cells can be 
caused by large distances from blood vessels (more than 70 µm) that do not allow enough diffusion 
of O2. This diffusion-limited and prolonged hypoxia is termed chronic hypoxia. A state of chronic 
hypoxia can also result from anemia or low O2 levels in the blood (hypoxemia). Intermittent, or 
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acute hypoxia, is often a result of perfusion-limited O2 delivery, e.g. due to structural and 
functional defects of tumor microvasculature [49, 59, 60]. 
 
Tumor hypoxia is usually associated with poor prognosis in patients and high resistance to therapy. 
Hypoxia contributes to malignant progression of tumors since tumor cells extensively adapt to low 
oxygen conditions by adjusting the signaling pathways that control proliferation, cell death, 
angiogenesis, local invasion, and metastatic spread. These cellular adaptations to hypoxia permit 
tumor cells to survive and even finally escape a hostile, growth inhibitory environment [61]. 
Hypoxia-induced proteomic and genomic changes promote tumor resistance. Conversely, the 
selection and clonal expansion of these favourably altered cells further aggravate tumor hypoxia 
and support a vicious circle of increasing hypoxia and malignant progression while concurrently 
promoting the development of a more treatment-resistant disease [61]. The alterations in gene 
expression are mainly regulated by hypoxia-inducible factors (HIFs, see chapter 1.2.1). 
An important aspect of hypoxia-mediated resistance to therapy is the radioprotective effect of 
hypoxia. Ionizing radiation (IR) produces free radicals, for example in DNA that can react with 
oxygen to generate fixed peroxy radicals. Multiple types of DNA damage, including DNA double- 
and single-strand breaks (DNA DSBs/SSBs), DNA base damage and DNA-DNA and DNA-protein 
crosslinks caused by IR results in cancer cell death leading to the desired therapeutic effect [62, 
63]. However, if oxygen is missing during radiation, the produced radicals can be reduced to their 
original composition. In addition to radiation therapy, hypoxic tumor cells are also more resistant 
to many chemotherapeutic or other anticancer drugs. This is partly caused by insufficient drug 
penetration through the hypoxic tumor tissue due to defects of tumor vascularization [64, 65]. 
Additionally, chemotherapeutics frequently target highly proliferative cells and hypoxic tumor 
cells commonly display lower proliferation rates than non-hypoxic tumor cells. Moreover, the 
before-mentioned clonal selection of malignant cells that frequently down-regulate apoptosis 
pathways, contributes to hypoxia-induced resistance to therapy [66].  
Furthermore, hypoxia leads to immune evasion of tumor cells by activating immunosuppressive 
pathways and by repressing the activity of immunocompetent cells. Therefore, hypoxia is also a 
major obstacle for immunotherapies [67]. 
Consequently, in recent years there are studies developing anticancer agents that are effective 
under hypoxia such as hypoxia-activated prodrugs (HAPs) that are activated at hypoxic conditions 
or small molecule inhibitors directly targeting essential hypoxia-triggered molecular events, such 




1.2.1 Hypoxia-inducible factors (HIFs) 
 
A variety of biological responses are triggered in cells suffering from hypoxic conditions, including 
activation of signaling pathways that regulate angiogenesis, cell proliferation and cell death. 
Hypoxia inducible factors (HIFs), especially HIF-1, are considered master orchestrators of the 
cellular adaptation to hypoxia [70, 71]. HIFs are a family of heterodimeric basic helix-loop-helix 
(bHLH) transcription factors composed of two subunits, HIF-α and HIF-β. The beta subunit, 
including HIF-1β [also termed ARNT (aryl hydrocarbon receptor nuclear translocator)], is 
constitutively expressed. The alpha subunit of HIFs exists in three different forms (HIF-1α, HIF-
2α and HIF-3α) encoded by distinct gene loci and are oxygen-labile proteins. 
HIF-α can be up-regulated at the protein level via activation of the phosphatidylinositol 3-kinase 
(PI3K) and Erk mitogen-activated protein kinase (MAPK) pathways (Figure 1.8) or at the mRNA 
level via STAT3 and nuclear factor-κB (NF-κB) signaling [72, 73]. HIF-1α and HIF-2α share 80% 
of sequence homology, contain similar structural domains, and are regulated in a similar manner. 
However, HIF-1α is ubiquitously expressed, whereas HIF-2α occurs in specific cell types [74]. 
HIF-1α and HIF-2α have two oxygen-dependent degradation domains (ODD domains) located in 
the center of the protein that are important for the proteolytic regulation under normoxia. These 
domains are absent in the HIF-1β protein. HIF-3α has a different structural organization. Several 
variants of HIF-3α are generated by alternative splicing of mRNA or use of different transcription 
start sites. Studies about HIF-3α are limited, but there are indications for diverging functions of 
HIF-3α variants in the regulation of the activity of other HIFs [75-78]. 
 
The functionality of HIFs depends on post-translational modifications (PTMs) of the HIF-α 
subunits. In well-oxygenated cells (Figure 1.8, Normoxia), HIF-α subunits (for example HIF-1α) 
are hydroxylated on proline residues by prolyl-4-hydroxylases (PHDs), whose activity is 
dependent on the substrates oxygen, 2-oxoglutarate (2-OG, a Krebs cycle intermediate) and on the 
cofactor Fe2+. Proline hydroxylations proceed in combination with acetylation by the ARD1 
acyltransferase in HIF-α. These structural changes on HIF-α allow the binding to the von Hippel–
Lindau protein (pVHL) which functions as an E3 ubiquitin ligase targeting HIF-α for proteasomal 
degradation [79, 80]. In addition, HIF-α undergoes asparaginyl hydroxylation (at the end of the C-
terminus of HIF-1α and HIF-2α) by factor inhibiting HIF (FIH) under non-hypoxic conditions, 
which prevents binding of HIF-α to co-activators such as p300 and its paralogue CREB-binding 
protein (CBP) [81-83]. Under hypoxia (Figure 1.8, Hypoxia), PHD and FIH activity is substrate-
limited (lacking O2), resulting in rapid HIF-α stabilization, accumulation, nuclear translocation 
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and dimerization with the stably expressed HIF-1β. The HIF-1 heterodimer then binds to DNA 
motifs termed hypoxia-response elements (HREs) with the consensus sequence G/ACGTG within 
the promoter of target genes. With the help of cofactors like p300/CBP and DNA polymerase II, 
HIF-1 regulates the expression of its target genes under hypoxia.   
Several interactions between HIF-α and its partner proteins are also required for its activation. 
The conformational changes induced by the chaperone protein HSP90 promote the binding of 
HIF-α to HIF-1β, and the further dimerization. Inhibition of HSP90 leads to ubiquitination of 
HIF-α and its subsequent proteasomal degradation [84, 85]. The formation of a ternary complex 
between HIF-1α, the mouse double minute 2 homolog (MDM2) and the tumor suppressor p53 
induces the ubiquitination of HIF-1α and its destruction by the proteasome [86, 87].  
 
Figure 1.8 | Schematic overview of the regulation of HIF-1. HIF-α protein synthesis is regulated by two 
main signaling pathways: PI3K/Akt and Erk MAPK, activated by growth factors and cytokines. In non-
hypoxic tissues, proline hydroxylations lead to HIF-α degradation by the proteasome or to the inhibition of 
recruitment of its coactivators. Under hypoxia, HIF-α is stabilized and translocalizes into the nucleus where 
it binds to HIF-1β and regulates gene expression. Figure adapted from [80]. 
 
In human cancers, HIF-α is overexpressed as a result of intratumoral hypoxia as well as genetic 
alterations, such as gain-of-function mutations in oncogenes (for example ERBB2 and SRC) and 
loss-of-function mutations in tumor-suppressor genes (for example p53, pVHL and PTEN) [70]. 
HIF-1 activates the transcription of a wide range of genes involved in angiogenesis (VEGF, 
ANGPT2), erythropoiesis (EPO), oxygen sensing (PHD2, PHD3), cell proliferation/survival (CTGF, 
REDD1), metabolism (SLC2A1, glycolytic genes and LDHA), autophagy (BNIP3, BNIP3L), 
EMT/migration/invasion (ZEB1 and 2, TWIST1, MMP9) and immune evasion (CD39, CD47), 




1.2.2 Metabolic alteration in cancer cells 
 
One feature of tumor cells is an altered metabolism that is significantly different from normal cells. 
Normal cells use glycolysis to generate approximately 10% of the cells’ ATP (adenosine 
triphosphate), whereas the other 90% of ATP is primarily produced from mitochondrial oxidative 
phosphorylation (OXPHOS). In tumor cells however, more than 50% of ATP is generated by a 
high rate of glycolysis followed by lactic acid fermentation and the remaining ATP is produced in 
mitochondria (Warburg effect) [88]. Moreover, tumor cells tend to use glycolysis for synthesising 
ATP even in aerobic conditions (in the presence of sufficient O2), which is called aerobic 
glycolysis [89]. The Warburg effect is associated with glucose uptake and utilization [90, 91]. 
Aerobic glycolysis produces 2 molecules of ATP per molecule glucose substrate, whereas the 
OXPHOS produces 38 molecules of ATP per molecule glucose. Therefore, tumor cells require a far 
higher intake of glucose through glucose transporters during glycolysis to produce sufficient ATP 
[92, 93]. Aerobic glycolysis is less efficient than OXPHOS in terms of ATP production, but leads to 
the increased generation of several additional metabolites that are precursors of the synthesis of 
lipids, amino acids and nucleotides. All of these macromolecules are essential for highly 
proliferating cancer cells, since they need to double their biomass for each cell division [89].  
Under hypoxic conditions, cells are even more dependent on glycolysis and inhibit mitochondrial 
respiration to reduce the amount of O2 molecules that are consumed. HIFs, particularly HIF-1 [94], 
play an important role in glucose metabolism of tumors by stimulating glycolysis by 
transactivating genes encoding glucose transporters like Glut1 (also known as SLC2A1) and Glut3 
used in extracellular glucose uptake [95]. HIF-1 can also induce the expression of genes 
responsible for glycolytic breakdown of intracellular glucose like phosphofructokinase (PFK) and 
aldolase [96]. Moreover, HIF-1 down-regulates OXPHOS in mitochondria by transactivating 
pyruvate dehydrogenase kinase (PDK) [97]. 
Apart from regulation of glucose metabolism, hypoxic cells carry out cellular alterations 
concerning glutamine metabolism, fatty acid metabolism and maintenance of adequate redox 
balance to cope with the demanding nature of oxygen deprivation [98]. 
 
1.2.3 Hypoxia-induced autophagy 
 
As an energy- and nutrient-limited condition, hypoxia can affect neoplastic cells in one of two 
ways, either by acting as a stressor that diminishes growth (slowing of proliferation) or leads to 
cell death (apoptosis, or necrosis) or by serving as a selective factor that finally results in malignant 
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progression and increased resistance to radiation therapy and other cancer treatments [49, 58, 61, 
99]. Autophagy is a self-destructive process by which eukaryotic cells degrade and recycle cellular 
macromolecules and organelles, and is frequently induced under hypoxic conditions [100-107]. 
For tumor cells, autophagy is a double-edged sword on cell fates [108, 109]: i) Cancer cells 
suffering limited nutrient supplies under cellular stresses can utilize autophagy to break down and 
recycle unnecessary or dysfunctional cellular components for survival; such improved autophagic 
capabilities will actually benefit the cancer cells [110-115]. ii) Cells that undergo an extreme 
amount of stress experience cell death either through necrosis or through apoptosis. Prolonged 
and excessive autophagy activation leads to a high turnover rate of proteins and organelles. A rate 
above the survival threshold will kill cancer cells [116, 117]. Hypoxia-induced autophagy can 
either promote cell survival or cell death, further linked to hypoxia tolerance in tumors [102, 118]. 
 
1.2.3.1 The autophagy signaling pathway 
 
Autophagy is a natural mechanism of the cell that allows the orderly degradation and recycling of 
cellular components [119-121]. Three forms of autophagy are commonly described: chaperone-
mediated autophagy (CMA), microautophagy and macroautophagy. Cellular cargo protein or 
materials can be sequestered into autophagosomes, which fuse with lysosomes, resulting in 
lysosomal degradation (macroautophagy, simply referred to as autophagy hereafter) [122, 123]. 
Proteins can directly be targeted to lysosomes (microautophagy) [123, 124] or bound by 
chaperones (such as HSC70 and HSP90) (chaperone-mediated autophagy, CMA) [125-127]. 
Autophagy is usually activated by conditions of nutrient deprivation but has also been associated 
with physiological and pathological processes such as differentiation, development, stress, 
infection, neurodegenerative diseases and cancer. Autophagy is a highly and finely regulated 
process. The kinase mTOR is a critical regulator of autophagy induction, with activated mTOR 
(PI3K-I/Akt and Erk MAPK signaling) suppressing autophagy, and negative regulation of mTOR 
(AMPK and genotoxic stress/p53 signaling) promoting it [128]. The core autophagy-related (Atg) 
complexes in mammals are ULK1 protein kinases, Atg9-WIPI1 and Vps34-Beclin1 class III PI3-
kinase complexes, and the Atg12 and LC3 conjugation systems. Cargo protein or materials are 
sequestered in the form of bulk cytoplasm (in nonselective autophagy) or particular targets 
including intact organelles [in selective types of autophagy such as selective mitochondria 
degradation (mitophagy)]. Some critical components of the autophagy pathway and autophagic 




Figure 1.9 | Schematic representation of autophagy in mammalian cells. 1. The initial sequestering structure, 
the phagophore, expands to sequester cargo. LC3-II is recruited to the autophagosomal membrane for 
helping membrane elongation. The cargo is enclosed within the double-membrane bounded autophagosome 
through p62/SQSTM1 [129, 130]. The autophagosome fuses with an available lysosome in time, providing 
access to a wide range of hydrolases that break down the inner autophagosome vesicle (called an 
autolysosome) along with the cargo. The resulting macromolecules are released back into the cytosol for 
reuse. 2. Mitophagy removes damaged or unneeded mitochondria from a cell following damage or stress. 
Figure inspired by the diagram of autophagy signaling from Cell Signaling Technology, Inc. 
 
The conversion of LC3-I to LC3-II via PE conjugation is critical for autophagosome formation. 
Atg4 cleaves pro-LC3 (MAP1-light chain 3, LC3) to form LC3-I which then is conjugated to the 
phosphatidylethanolamine (PE) by Atg7 for the generation of LC3-II (lipidated LC3) [131]. 
Adaptor protein p62/SQSTM1 binds to ubiquitinated proteins and LC3-II for mediating autophagy 
via localizing into autophagic compartments, transporting ubiquitinated proteins and organelles, 
(Figure 1.9 ①) and eventually is degraded in autolysosomes along with the cargo [132]. Thus, the 
increase of LC3-II and the decrease of p62 are two markers of autophagy. 
 
Mitophagy is a selective autophagic process specifically designed for the removal of damaged or 
unneeded mitochondria from a cell [133-135] (Figure 1.9 ②). This process promotes turnover of 
mitochondria and prevents accumulation of dysfunctional mitochondria, which can lead to 
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oxidative stress and cellular degeneration. Upon mitochondrial damage, the protein PINK, which 
is continually degraded in the healthy state through the action of PARL, is stabilized and recruits 
the E3 ubiquitin ligase Parkin to initiate mitophagy. Polyubiquitination of mitochondrial 
membrane proteins by Parkin results in the recruitment of autophagy p62/SQSTM1, NBR1, and 
Ambra1 that bind to LC3 via their LC3-interacting region (LIR). In addition, increasing evidence 
indicates a critical role of BNIP3 (BCL2 interacting protein 3), which also contain LIRs, in 
mitophagy [104, 106, 136]. BNIP3 can promote mitophagy by triggering the translocation of 
Parkin to the mitochondria [137] or by directly recruiting autophagic machinery by an ubiquitin-
independent mechanism to induce autophagosome formation [136] (Figure 1.9 ②).  
Under hypoxic conditions, mitochondria are usually dysregulated and subsequently reorganized 
through mitochondrial fusion/fission [138]; dysfunctional or unneeded mitochondria are removed 
by mitophagy [106, 139, 140]. BNIP3 can induce mitophagy by disrupting the Bcl-2/Beclin-1 
complex contributing to survival rather than cell death under hypoxia [106]. Increased expression 
of BNIP3 under hypoxia is mainly regulated by the transcription factor HIF-1α [141] and can be 
directly suppressed by the tumor suppressor p53 [142]. 
 
1.3 The tumor suppressor p53 
 
p53 was first identified as a host protein of approximately 53 kilodalton (kDa) that bound to the 
large T-antigen of simian virus 40 (SV40) in transformed rodent cells in 1979 [143, 144]. It was 
initially classified as an oncogene due to the use of mutated cDNA following purification of tumor 
cell mRNA [145]. In 1989, scientists recognized that wild-type p53 (wt p53), encoded by TP53, 
suppresses growth and oncogenic transformation in cell culture [146]. That p53 is a tumor 
suppressor was confirmed in 1990 by the finding that patients with Li–Fraumeni syndrome, which 
predisposes to diverse tumor types, had inherited TP53 mutations [147], and further confirmed in 
1992 by experiments showing that Trp53 (encoding mouse p53) knockout mice are prone to 
develop tumors [148]. Subsequent studies have demonstrated that the TP53 gene is the most 
frequently mutated gene in human cancers [149, 150], indicating that p53 plays a crucial role in 
preventing cancer formation. 
p53 has been described as a “cellular gatekeeper” [151] or “guardian of the genome” [152] because 
of its central role in cell cycle arrest and DNA repair. p53 prevents genome mutation and 
maintains genomic integrity by serving as a stress sensor, responding to DNA damage [induced by 
either UV, ionizing radiation (IR), or chemical agents such as hydrogen peroxide (H2O2)]. Upon 
DNA damage, p53 is activated and induces cell cycle arrest at the restriction point at the end of 
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the G1 phase [153]. This cell cycle arrest at this point allows the cell to fix the damage prior to the 
next cell division. If DNA damage proves to be irreparable, p53 may also initiate programmed cell 
death (apoptosis). 
 
1.3.1 The structure of p53 
 
In humans, p53 is encoded by the gene TP53 located on the short arm of chromosome 17 (17p13.1) 
[154, 155]. The TP53 gene contains 11 exons and 10 introns [155, 156]. In addition to the full-
length protein (p53α), the human TP53 gene encodes at least 15 protein isoforms, ranging in size 
from 3.5 to 43.7 kDa [157]. The full-length p53 protein consists of 393 amino acids (aa). Based on 
the sum of masses of the amino acid residues, the actual mass of p53 is only 43.7 kDa. The name 
p53 is however describing its apparent molecular mass (approximately 53 kDa) in SDS-PAGE 
analysis. Due to the high number of proline residues in the p53 protein, its migration is slowed 
down on SDS-PAGE, thus making it appear bigger than it actually is [158]. 
The 393 amino acids of p53 protein are divided into several structural and functional domains 
(Figure 1.10). The N-terminus of p53 contains two tandem transcriptional activation domains 
(TADs), TAD1 (residues 1-40) and TAD2 (residues 40-60). C-terminal to the TADs lies the 
proline-rich domain (PRD) that encompasses residues 61-94. Residues 102-292 represent the 
central core of p53, comprising the DNA-binding domain (DBD) that is responsible for sequence-
specific binding of this protein to p53 response elements (p53REs) in DNA. The consensus 
sequence of p53REs is classically defined as two DNA half sites of PuPuPuC(A/T)-(T/A)GPyPyPy 
(Pu represents A or G and Py represents C or T) with a spacer of 0-13 bp between half sites. p53 
binds cooperatively to p53REs as a tetramer (dimer of dimers), the formation of which depends on 
the oligomerization domain (OD) comprising residues 324-355 in the C-terminal region (residues 
301 -393). p53 tetramerization is also essential for its C-terminal acetylation [159]. The C-terminal 
region also contains a nuclear localization signal (NLS) and a nuclear export signal (NES) that 
facilitate the nuclear-cytoplasmic shuttling of p53. Finally, the extreme C-terminus (residues 363-
393) holds a basic lysine-rich carboxy-terminal domain (CTD). This basic region furthermore 
comprises the main acetylation sites including Lys370, Lys372, Lys373, Lys381 and Lys382 [160]. 
These sites also undergo ubiquitination, modulating p53 stabilization and sequence-specific DNA 




Figure 1.10 | Schematic overview of the structure of the p53 protein and its post-translational modifications. 
The N-terminus of p53 contains two tandem transcriptional activation domains (TADs), TAD1 (residues 1-
40) and TAD2 (residues 40-60), followed by a proline-rich region (PRD). The central core domain contains 
the DNA-binding domain (DBD). The C-terminal region contains the nuclear localization signal (NLS) 
followed by the oligomerization domain (OD), the nuclear export signal (NES) and a basic carboxy-terminal 
domain (CTD). The main post-translational modifications (PTMs) by the indicated enzymes known to affect 
p53 function are shown. Phosphorylation sites are prevalent in the TADs, whereas acetylation sites occur in 
the DBD, OD and CTD. Methylation sites are enriched in the CTD. The PRD contains few well-studied 
PTMs. Figure adapted and modified from [163]. 
 
1.3.2 The regulation of p53 abundance and activity 
 
The regulation of p53 responding to stress signals is achieved by the control of i) protein stability, 
ii) protein activity and iii) cellular localization. These are tightly regulated by extensive post-
translational modifications (PTMs) of p53 by different enzymes (Figure 1.10). Approximately fifty 
amino acid residues of p53 are subjected to PTMs. A single residue can be modified by multiple 
enzymes in a mutually exclusive manner, resulting in an antagonism between different 
modifications. The PTMs of p53 include phosphorylation, ubiquitination, acetylation, methylation, 
sumoylation, hydroxylation, glycosylation, neddylation and polyribosylation [164].  
PTMs either influence the conformation of p53, modulating protein oligomerization or its 
interaction with partners, or the functionality of p53 directly. Moreover, the interplay between 
the diverse PTMs is essential for the p53-mediated response (such as proper gene expression) and 
cell fate. 
 
Regulation of p53 abundance 
p53 is presented at low levels in unstressed cells. These low levels are due to a continuous 
degradation of p53 after protein synthesis [165]. Depending on the cellular context, several E3 
ubiquitin ligases are thought to be the rate-liming factors in the regulation of p53 protein 
expression. MDM2 (also called HDM2 in humans) is regarded as the master regulator of p53 
protein levels in a variety of cellular systems [166] (Figure 1.10). MDM2 binds to the TAD of p53 
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and covalently attaches ubiquitin to p53 thus marking it for degradation by the proteasome. This 
binding also inhibits p53 transactivation function by blocking the recruitment of essential 
transcriptional machinery components [167, 168]. Additionally, MDM2 can regulate p53 
localization by transporting it from the nucleus to the cytosol. MDM2 itself is transcriptionally 
induced by the p53 protein [169, 170]. Thus, p53 and MDM2 set up a feedback loop that ensures 
that cellular p53 levels are kept low in the absence of stress. In response to stress signals, p53 is 
stabilized by inhibition of MDM2, through any of several mechanisms: stress-induced PTMs of 
both MDM2 and p53, which disrupt MDM2-binding; oncogene-induced sequestration of MDM2 
by the tumor suppressor ARF (alternate reading frame); and nucleolar-stress-triggered ribosomal 
protein binding and inhibition of MDM2-mediated ubiquitination of p53. 
Other E3 ubiquitin ligases, like Pirh2, COP1 and ARF-BP1, also negatively regulate p53 protein 
levels and antagonize p53 function [171]. Certain pathogens can also influence the p53 protein. 
One such example, are cells infected with high-risk HPV (described in chapter 1.1.3.2), such as 
HPV16 and HPV18, in which the viral E6 protein promotes the binding of p53 to the E3 ubiquitin 
ligase E6-AP (encoded by UBE3A), which ubiquitinates p53 efficiently and causes the proteasomal 
degradation of p53. Of note, ubiquitination levels of p53 are not exclusively regulated by the 
forward reaction of the ligases. The ubiquitination of p53 is reversible. A family of proteases, the 
deubiquitinases (DUBs), three of which, USP7 (or HAUSP), USP10 and USP42, can cleave 
ubiquitin off p53, thereby protecting it from ubiquitin-proteasome-dependent degradation [172-
175]. 
 
Activation of p53 
The critical event leading to the activation of p53 protein is the phosphorylation of its N-terminal 
domain. The N-terminal TAD of p53 contains many phosphorylation sites and can be considered 
as the primary target for protein kinases transducing stress signals (Figure 1.10). The protein 
kinases that are known to target the TAD of p53 can be roughly divided into two groups. A first 
group of protein kinases belongs to the MAPK family (JNK1-3, Erk1-2 and p38 MAPK), which is 
known to respond to several types of stress, such as membrane damage, oxidative stress, osmotic 
shock, heat shock, etc. A second group of protein kinases (ATR, ATM, CAK, CHK1-2, DNA-PK 
and TP53RK) is implicated in the genome integrity checkpoint, a molecular cascade that detects 
and responds to DNA damage caused by genotoxic stress.  
Phosphorylation of the N-terminal region of p53 by the protein kinases, for example DNA 
damage-induced phosphorylation at ser15 and ser20, disrupts MDM2-p53 interaction [176]. Other 
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proteins, such as Pin1, are then recruited to p53 and induce a conformational change in p53, 
which further prevents MDM2-p53 interaction, promoting both the accumulation and activation 
of p53. Phosphorylation also allows for the binding of transcriptional coactivators, such as 
acetyltransferases p300 and PCAF (p300/CBP-associated factor), which then acetylate the carboxy-
terminal end of p53 (Figure 1.10), exposing the DBD of p53, allowing it to activate or repress 
specific genes [177, 178]. Deacetylase enzymes, such as Sirt1 and Sirt7, can deacetylate p53, 
leading to an inhibition of apoptosis [179]. MDM2 can recruit histone deacetylase 1 (HDAC1) to 
p53 and facilitate HDAC1-mediated deacetylation of p53 [180]. Some activated oncogenes can 
stimulate the transcription of proteins that bind to MDM2 and inhibit its activity. p19ARF, the 
alternate reading frame product of the p16/INK4A locus, interacts with MDM2 upon oncogenic 
stress and sequesters it in the nucleolus and thus away from p53 [181, 182]. The above-mentioned 
protein kinases like ATM and ATR can promote the degradation of MDM2 to activate p53 [183]. 
Other PTMs, like methylation, sumoylation and neddylation, can also influence the activation of 
p53. p53 is, for instance, methylated at lys370 by SMYD2, at lys372 by SETD 7/9, and at lys382 by 
SETD8 (Figure 1.10). Methylation of these sites either impairs acetylation of p53 or its DNA 
binding and transcriptional activity. 
 
The activity of p53 depends on its localization and both nuclear import and export of p53 are 
tightly regulated [184]. The nuclear-cytoplasmic shuttling of p53 is regulated by the nuclear 
localization signal (NLS) and the nuclear export signal (NES). p53 is synthesized in the cytoplasm 
and needs to be transported into the nucleus to exert its transcriptional activity responding to 
several types of cellular stress. Upon cellular stress, like DNA damage, p53 is imported into the 
nucleus through the NLS and activates its target genes [185]. p53 tetramerization masks the NES 
and thereby blocks its nuclear export [186]. Several proteins can modulate p53 localization. One of 
the most important of these modulations is MDM2-mediated nuclear export of p53.  
 
1.3.3 p53-induced transcriptional programs involved in different responses 
 
In addition to the aforementioned functions in cell cycle arrest, DNA repair and apoptosis upon 
DNA damage, p53 elicits several other cellular responses including senescence, autophagy and cell 
metabolism, responding to a broad range of cellular stresses. p53 can be modulated by oncogenic 
stress, ribosome dysfunction, spindle damage, telomere attrition, ribonucleotide depletion, 
nutrient deprivation, hypoxia, oxidative stress, osmotic shock and heat/cold shock [187, 188] 
(Figure 1.11). In response to these myriad of cellular stress signals, p53 regulates the diverse 




Figure 1.11 | Schematic overview of p53-activating signals and p53-triggered cellular responses. A host of 
different stress signals can activate p53, including nutrient deprivation, hypoxia, oxidative stress, 
hyperproliferative signals, DNA damage, ribonucleotide depletion, replicative stress and telomere attrition. 
p53 activation by these signals can consequently promote cellular responses of cell cycle arrest, DNA repair, 
senescence and apoptosis. Beyond triggering these classical responses, p53 that is activated by various 
stressors can modulate several additional biological processes including autophagy, metabolism control, stem 
cell biology, tumor microenvironment crosstalk and invasion and metastasis. Regulation of these processes 
by p53 may impinge on the canonical functions, such as apoptosis or senescence. Similarly, classical 
responses may affect novel functions. Figure adapted from [188]. 
 
Activated p53 binds to sequence-specific DNA as a tetramer. The sites of p53REs are frequently 
found in either the promoters or the first introns of its target genes. Once p53 tetramers are bound 
to DNA, they can activate the transcription of numerous protein-coding and non-protein-coding 
genes (e.g. microRNAs or lncRNAs), which is a function of fundamental importance for p53-
mediated cellular responses. 
 
The cell fates specified by activated p53 depend on cell type and the nature and extent of the 
stresses. Under conditions of lower levels of stress causing damage, p53 activates its target genes, 
such as CDKN1A (p21) and GADD45A, to engage a temporary program of cell cycle arrest and 
DNA repair to allow cells to pause and repair the damage incurred, thereby preventing 
inappropriate proliferation of cells carrying damaged DNA. p53 can also maintain genomic 
stability at the chromosomal level, by limiting the accumulation of cells with aberrant 
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chromosomal numbers [189-191]. Therefore, p53 is also considered to be “a guardian of ploidy” 
[192]. Another protective, pro-survival mechanism is the ability of p53 to activate antioxidant 
genes, such as TIGAR, GPX1 and SESN1-2 (sestrins 1 and 2), which inhibit the accumulation of 
reactive oxygen species (ROS), thereby maintaining genomic integrity [193, 194]. 
In response to severe or sustained stress signals, p53 drives irreversible cell fates, such as cell death 
(apoptosis) and permanent cell cycle arrest (senescence). p53-induced apoptosis involves the 
transcriptional activation of components of both the intrinsic and extrinsic death pathways, 
including BAX, FAS, APAF1 and PUMA, amongst others, which collaboratively promote cell 
death [195, 196]. In the cases responding to potent stress, p53 induces cellular senescence through 
transcriptional induction of target genes such as CDKN1A, PML (promyelocytic leukemia protein) 
and PAI1 (plasminogen activator inhibitor) [195, 197]. 
p53 can promote oxidative phosphorylation (through SCO2) [198] and inhibit glycolysis (through 
TIGAR, GLUT1 and 4) [199, 200], opposing oncogenic metabolic reprogramming (known as the 
Warburg effect, see chapter 1.2.2) [201]. p53 can also induce autophagy to provoke cell death by 
activating genes such as DRAM1, AMPK, SESN1 and SESN2. As described in chapter 1.2.3, 
autophagy is a double-edged sword on cell fates. The role of autophagy depends on the cell type 
and the nature of the stress. 
In addition to activating transcription, p53 can inhibit the expression of genes such as CDC2, 
CDC25C and TERT [202, 203]. 
 
1.3.4 Transcription-independent activities of p53 in apoptosis and autophagy 
 
Besides its role as a transcription factor, p53 has additional functions, such as exonuclease activity 
[204] and its cytoplasmic roles in apoptosis and autophagy [205, 206]. In response to apoptosis-
inducing stress signals, p53 can participate directly in the intrinsic apoptosis pathway by shuttling 
to mitochondria where it interacts with the members of the Bcl-2 family, leading to robust 
mitochondrial outer membrane permeabilization (MOMP), unleashing the enzymatic apoptotic 
machinery of caspases and of chromatin degradation [207, 208].  
p53 has a dual role in regulating autophagy. As mentioned above, activated nuclear p53 
upregulates the expression of pro-autophagy target genes [201]. Cytoplasmic p53 is able to repress 
autophagy via transcription-independent effects on the AMPK/mTOR-dependent pathway [206]. 
p53 can also post-transcriptionally down-regulate LC3 mRNA to reduce autophagy [209]. In 
addition, negative regulation of autophagy by p53 involves its functions as a transrepressor. p53 
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can directly suppress BNIP3 expression to inhibit hypoxia-induced autophagy [142] (see chapter 
1.2.3.1). 
 
1.3.5 Hypoxia and p53 in HPV-positive cervical cancer cells 
 
Hypoxia is one of the stresses that have been shown to affect p53 signaling. Hypoxia very 
differently influences p53 protein levels and its consequences for cellular functions seem to be 
dependent on the cell line, the severity and the duration of oxygen deprivation [210-212]. 
Cervical cancers often display strongly reduced O2 content, with a median O2 concentration of 
1.18%. Therefore, hypoxia is frequently detected in cervical cancer patients and has a negative 
impact on patient prognosis [48, 49]. Nevertheless, functional studies of HPV-positive cancer cells 
under hypoxic conditions are rare. In these few studies, the regulation of p53 in hypoxic HPV-
positive cells is controversial. In primary cervical epithelial cells infected with the HPV16 E6 and 
E7 genes, low-oxygen conditions stimulate apoptosis as well as the induction of p53 protein. Cell 
lines derived from HPV16-associated human cervical squamous cell carcinomas display resistance 
to hypoxia-induced apoptosis although p53 protein level increased under hypoxia [51]. Recently, 
it has been reported that despite efficient E6/E7 repression, p53 protein levels did not increase in 
HPV16-positive cancer cell lines under hypoxia, but even decreased further [50]. In sharp contrast 
to their senescent phenotype when E6/E7 is deficient and p53 is reconstituted under normoxia, 
hypoxic HPV-positive cancer cells enter a dormant state, characterized by an evasion of cellular 

















1.4 Aims of study 
 
Although studies have investigated the divergent regulation of the p53 tumor suppressor by 
hypoxia, the dynamics of p53 during different periods of hypoxic conditions in cervical cancer 
cells is still not well explored. The role of p53 for this cellular adaptation under hypoxic conditions 
was not well studied. The effect of p53 regulation on downstream responses during hypoxia 
remains elusive. In addition, the mechanisms controlling the regulation of p53 by hypoxia in 
HPV-positive cervical cancer cells are diverse [213, 214]. Which downstream pathway of p53 
signaling contributes to the fate of hypoxic cells is not fully understood, yet. The aims of this 
present study therefore are: 
i) To determine time-dependent changes in p53 in hypoxic HPV16-positive cervical cancer cells 
ii) To analyze how this mechanism is mediated  
iii) To reveal the role of p53 regulation in cellular adaptation to hypoxia 
iv) To explore the effect of p53 regulation on downstream pathway responses in hypoxic cells 
v) To identify which downstream pathway contributes to the behavior of hypoxic cells 
The elucidation of the underlying mechanism and pathway will provide important new insights 
into cellular adaptation to hypoxia and should be relevant for prospective therapeutic methods, 









2.1 Regulation of p53 by hypoxia in HPV16-positive cervical cancer cells 
 
2.1.1 p53 protein levels under hypoxia (24 h) in HPV16-positive cervical cancer cells 
 
In order to investigate the effect of hypoxia on the tumor suppressor p53 in HPV16-positive 
cervical cancer cells, the SiHa and CaSki cell lines were incubated under normoxic conditions (N, 
21% O2) or hypoxic conditions (H, 1% O2) for 24 hours (h).  
qPCR analyses revealed a strong down-regulation of HPV16 E6/E7 oncogene expression under 
hypoxia in both SiHa and CaSki cells (Figure 2.1A). These results are consistent with the previous 
findings reported by Hoppe-Seyler et al. [50]. The transcript of vascular endothelial growth factor 
(VEGF) that is known to be transcriptionally up-regulated under hypoxia [215] was used as a 
hypoxia control gene. The strong up-regulation of VEGF under hypoxia (1% O2) (Figure 2.1A) 
indicates that the hypoxic treatment was efficient. Despite efficient E6/E7 repression, p53 protein 
levels did not reconstitute in HPV16-positive cancer cells under hypoxia, but were actually 
completely depleted (Figure 2.1B). The down-regulation of p53 protein coincides with the 
accumulation of hypoxia-inducible factor-1α (HIF-1α) (Figure 2.1B). The hypoxic stabilization of 
HIF-1α protein is considered a major event in the cellular response to hypoxia and was previously 
described [216]. The strong up-regulation of HIF-1α under hypoxia (1% O2) also indicates that the 
hypoxic incubation was effective under the chosen conditions. 
 
 
Figure 2.1 | Levels of E6/E7 oncogene transcripts and p53 protein in HPV16-positive cervical cancer cells 
under normoxia and hypoxia. HPV16-positive SiHa and CaSki cells were cultured for 24 h at the indicated 
O2 concentrations (normoxia: 21% O2 and hypoxia: 1% O2). Total RNA and total protein were extracted. (A) 
qPCR analyses of HPV16 E6/E7 transcripts. Transcript levels of VEGF were monitored as marker for 
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hypoxia. 18S rRNA served as internal control for normalization. Error bars indicate the SD of three 
independent experiments. Respective transcript levels under normoxia were arbitrarily set to 1 and set as 
control for the calculation of significant differences (Two-tailed Student’s t test was employed, **p < 0.01, 
***p < 0.001). (B) Western Blot analyses using antibody against p53. HIF-1α was used as marker for hypoxia, 
and GAPDH served as a loading control. 
 
To conclude, the above results indicate that hypoxia (1% O2 for 24 h) strongly affects p53 protein 
levels in HPV16-positive cervical cancer cells. To further analyze this finding, the effect of 
different periods of hypoxia on p53 protein levels was determined. 
 
2.1.2 Time-dependent changes of p53 protein levels in hypoxic HPV16-positive cancer cells 
 
In order to determine time-dependent changes of p53 under hypoxia in HPV16-positive cervical 
cancer cells, time course experiments were performed. SiHa and CaSki cells were therefore 
incubated under hypoxia for different periods of time.  
As depicted in Figure 2.2, the expression of the HPV16 oncogenes E6/E7 was continuously down-
regulated under hypoxic conditions (0, 6, 24, 48, and 72 h). Interestingly, different from the stable 
or slightly increased p53 protein levels under normoxic conditions, p53 protein showed a biphasic 
regulation in hypoxic HPV16-positive cancer cells. Here, p53 levels rapidly and strongly decreased 
to complete depletion under hypoxia (6-24 h), then recovered to baseline (p53 protein levels 
under normoxia) after 48 h. Prolonged hypoxia (72, 96, and 120 h) markedly increased p53 protein 






Figure 2.2 | Levels of E6/E7 oncogene transcripts and p53 protein in hypoxic HPV16-positive cancer cells. 
HPV16-positive SiHa and CaSki cells were cultured for the indicated time periods at 21% O2 or at 1% O2. 
Total RNA and total protein were extracted after respective time intervals. (A) and (B) qPCR analyses of 
HPV16 E6/E7 transcripts in SiHa (A) and CaSki cells (B). 18S rRNA served as internal control for 
normalization. Error bars indicate the SD of three independent experiments. The 0 h value of E6/E7 
expression was set as a control for the calculation of significant differences (Two-tailed Student’s t test was 
employed, *p < 0.05, **p < 0.01, ***p < 0.001 and n.s., statistically not significant). (C) and (D) Western Blot 
analyses using antibody against p53. GAPDH served as a loading control. (S, short exposure; L, long 
exposure) 
 
These results show a new regulation pattern of p53 protein by hypoxia in HPV16-positive cancer 
cells. During different periods of hypoxia, p53 protein was not unidirectionally regulated in SiHa 












2.2 Mechanism of biphasic regulation of p53 protein in hypoxic HPV16-positive cervical 
cancer cells  
 
2.2.1 Transcript levels of p53 in hypoxic HPV16-positive cervical cancer cells 
 
To decipher the mechanism underlying the biphasic regulation of p53 in hypoxic HPV16-positive 
cervical cancer cells, first the transcript levels of the p53 gene (TP53) were analyzed. Neither 
during short-term nor under prolonged hypoxia, any fluctuation was found at TP53 mRNA levels 
in SiHa or CaSki cells (Figure 2.3). Hypoxia had no significant effects on TP53 mRNA levels at 6 h 
in either SiHa or CaSki cells. Hypoxia reduced the TP53 mRNA levels by half in SiHa cells after 24 
h, after which p53 transcript levels remained relatively stable at this decreased amount under 
hypoxia in SiHa cells (Figure 2.3A). In hypoxic CaSki cells, TP53 mRNA levels showed a 




Figure 2.3 | Transcript levels of p53 in hypoxic HPV16-positive cancer cells. SiHa (A) and CaSki cells (B) 
were cultured for the indicated time periods at 1% O2. Total RNA was extracted after respective time 
intervals. (A) and (B) qPCR analyses of p53 transcripts. 18S rRNA served as internal control for 
normalization. Error bars indicate the SD of three independent experiments. The 0 h value of TP53 
expression was set as a control for the calculation of significant differences (Two-tailed Student’s t test was 
employed, *p < 0.05, **p < 0.01 and n.s., statistically not significant). 
 
These findings show that the TP53 transcript levels are not consistent with the time-dependent 
changes observed for p53 protein in hypoxic HPV16-positive cancer cells, indicating that the 





2.2.2 Hypoxia affects p53 protein stability in HPV16-positive cancer cells 
 
To determine whether the reduction of p53 protein levels under hypoxia was attributable to a 
post-translational modulation, SiHa and CaSki cells were incubated with cycloheximide (CHX), an 
inhibitor of protein synthesis [217]. Pre-incubation under hypoxia reduced p53 protein half-life 
assayed by a CHX-chase experiment (Figure 2.4). Calculation of the half-life of p53 protein was 
described in chapter 5.4. Here, the half-life of p53 protein decreased from 8.41 minutes (min) 
under normoxia to 4.64 min under hypoxia in SiHa cells, and from 9.04 min under normoxia to 




Figure 2.4 | p53 protein stability in HPV16-positive cancer cells under normoxia and hypoxia. SiHa (A) and 
CaSki cells (B) were incubated at 21% O2 or at 1% O2, respectively, for indicated time and treated afterward 
with/without cycloheximide (CHX, 10 mg/mL) for up to 30 min. Total protein was extracted after respective 
time intervals. (A and B, top) Western Blot analyses using antibody against p53. GAPDH served as a loading 
control. (S, short exposure; L, long exposure) (A and B, bottom) The grayscale of p53 from (A) and (B) was 
quantified using the ImageJ software. The relative grayscale values of p53 normalized to the respective (21% 
O2 or 1% O2) 0-time point were plotted on an xy diagram with log(2)-transformed x-axis to visualize the 
protein half-life. Error bars are SD, and n = 2 independent experiments.  
 
These results suggest that hypoxia affects p53 protein levels by post-translationally targeting it for 





2.2.3 Proteasomal degradation is not solely responsible for the reduction of p53 levels in 
hypoxic HPV16-positive cancer cells 
 
Since hypoxia affects p53 protein stability in HPV16-positive cancer cells, which cellular pathway 
for protein degradation is involved in the initial hypoxic reduction of p53 was determined next. 
MG132, an inhibitor of the 26S proteasome [218], was used to block the proteasomal degradation 
pathway, which plays an important role in p53 degradation both in the presence and absence of 
HPV oncoproteins (see chapter 1.1.3.2 and 1.3.2). As demonstrated in Figure 2.5, the p53 protein 
levels in hypoxic SiHa and CaSki cells could not be fully rescued to the comparable levels detected 
under normoxic conditions when incubated with MG132, indicating that in HPV16-positive 





Figure 2.5 | Effect of MG132 on the hypoxic decrease of p53 in HPV16-positive cancer cells. SiHa (A) and 
CaSki cells (B) were incubated at 21% O2 or at 1% O2 for 0 h or 16 h prior to the treatment with 10 μM 
MG132. Total protein was extracted after 24 h. (A) and (B) Western Blot analyses using antibody against p53. 
GAPDH served as a loading control.  
 
2.2.4 Lysosomal degradation is required for the down-regulation of p53 in hypoxic HPV16-
positive cancer cells 
 
Besides the ubiquitin/proteasome system, the autophagy-lysosome-dependent pathway is another 
important cellular system for protein degradation [119-121, 219, 220] (see chapter 1.2.3.1). 
Cellular cargo protein or cellular debris can be surrounded with a crescent-shaped isolation 
membrane (phagophore), which forms a closed double-membrane autophagosome. The 
autophagosome fuses with a lysosome to become an autolysosome, where its sequestered content 
is degraded (macroautophagy, simply referred to as autophagy hereafter) [122, 123]. Proteins can 
directly be targeted to lysosomes (microautophagy) [123, 124] or bound by chaperones (such as 
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HSC70 and HSP90) (chaperone-mediated autophagy, CMA) [125-127]. Of note, afore-used MG132 
is not a selective inhibitor for proteasomes. It can also inhibit the function of lysosomes [218, 221, 
222]. The autophagy-lysosome-dependent pathway was therefore suspected to be involved in the 
initial hypoxic reduction of p53. 
The lysosomal inhibitors chloroquine (CQ) and Bafilomycin A1 (Baf A1) were next used to assess 
the putative role of autophagy-lysosome-dependent degradation on the hypoxic reduction of p53 
protein. The adaptor protein p62/SQSTM1, a marker of autophagy, is a representative cargo 
protein sequestered in autophagosomes and degraded in the autolysosome [132] (Figure 1.9). In 
this experiment, both CQ and Baf A1 prevented the decrease of p62 in hypoxic HPV16-positive 
cancer cells (Figure 2.6), indicating that the degradation by autolysosomes was blocked efficiently 
under these conditions. As further shown in Figure 2.6, the autolysosome inhibitor CQ [223, 224] 
prevented the p53 degradation triggered by hypoxia. Bafilomycin A1, which inhibits the fusion of 
autophagosomes and lysosomes [225-227], however, only prevented the degradation of p62 but 
not p53, suggesting that, unlike p62, p53 was not sequestered by autophagosomes, but degraded 




Figure 2.6 | Effect of lysosomal inhibitors on hypoxic reduction of p53 and p62 in HPV16-positive cancer 
cells. SiHa (A) and CaSki cells (B) were cultivated for 24 h under normoxia (21% O2) or hypoxia (1% O2), in 
either the absence (−) or the presence (+) of 50 μM chloroquine (CQ) or 0.5 μM Bafilomycin A1 (Baf A1). 
Total protein was extracted and Western Blot analyses using antibodies against p53 and p62 were performed. 
GAPDH served as a loading control. 
 
Furthermore, p53 levels increased in a dose-dependent fashion in hypoxic cells incubated with CQ 






Figure 2.7 | Dose-dependent effect of lysosomal inhibitors on p53 and p62 protein in hypoxic HPV16-
positive cancer cells. SiHa cells were cultivated for 24 h under normoxia (21% O2) or hypoxia (1% O2), in 
either the absence (-) or the presence of chloroquine (CQ, 25, 50, 100 μM) (A) or Bafilomycin A1 (Baf A1, 4, 
6 μM) (B). Total protein was extracted and Western Blot analyses using antibodies against p53 and p62 were 
performed. Actin served as a loading control. 
 
qPCR analyses showed that hypoxia reduced the TP53 mRNA levels by about 50% in SiHa cells 
after 24 h. With the treatment of CQ, the TP53 mRNA level showed a minor increase but was not 
statistically significant in hypoxic SiHa cells (Figure 2.8). Baf A1 had no effect on the TP53 mRNA 
levels in SiHa cells. These findings revealed that the restoration of p53 protein levels by CQ was 
not due to an increase of mRNA levels.  
Unexpectedly, treatment with CQ reduced the transcript levels of HPV16 E6/E7 under normoxia 




Figure 2.8 | Effect of lysosomal inhibitors on TP53 and HPV16 E6/E7 transcript levels in HPV16-positive 
cancer cells under normoxia and hypoxia. SiHa cells were cultivated for 24 h under normoxia (21% O2) or 
hypoxia (1% O2), in either the absence (−) or the presence (+) of 50 μM chloroquine (CQ) or 0.5 μM 
Results 
 |37 
Bafilomycin A1 (Baf A1). Total RNA was extracted. qPCR analyses of TP53 and HPV16 E6/E7 levels. 18S 
rRNA served as internal control for normalization. Respective transcript levels of normoxic control samples 
were arbitrarily set to 1. Error bars indicate the SD of three independent experiments. (For calculation of 
significant differences, vs. respective normoxic control or hypoxic control, two-tailed Student’s t test was 
employed, *p < 0.05, ***p < 0.001 and n.s., statistically not significant).  
 
2.2.5 Autophagy is not responsible for the depletion of p53 in hypoxic HPV16-positive cancer 
cells 
 
In order to determine the effect of autophagy (macroautophagy) on the depletion of p53 in 
hypoxic HPV16-positive cancer cells, specific small interfering RNA (siRNA) was used to silence 
the autophagy-related genes ATG12 and p62/SQSTM1 [228-232]. Autophagy requires the covalent 
attachment of the protein Atg12 to Atg5 through an ubiquitin-like conjugation system involving 
also Atg7 as an E1-like activating enzyme and Atg10 as an E2-like conjugating enzyme. The 
Atg12-Atg5 conjugate then promotes the conjugation of LC3-I to the phosphatidylethanolamine 
for the generation of LC3-II, which is recruited to the autophagosomal membrane for helping 
membrane elongation. p62/SQSTM1 is a multifunctional ubiquitin-binding protein. It acts as a 
cargo protein that targets other proteins that bind to it for autophagy-lysosome-dependent 
degradation. p62/SQSTM1 also functions as a scaffolding/adaptor protein in concert with TNF 
receptor-associated factor 6 to mediate activation of NF-κB in response to upstream signals. 
Western Blot analyses showed that the expression of Atg12 and p62 were efficiently knocked 
down by specific siRNAs (Figure 2.9). The reduction of p62 after silencing of ATG12 may be 
attributable to a compensatory increase of lysosomal degradation that is independent of the 
autophagosome. With the silencing of ATG12 or p62/SQSTM1, p53 protein levels were not 
rescued under hypoxia (Figure 2.9). These results suggest the formation of autophagosomes is not 






Figure 2.9 | Effect of silencing of Atg12 or p62 on p53 in HPV16-positive cancer cells. CaSki cells were 
transfected with scrambled control, Atg12- or p62-specific siRNA. 48 h post transfection, the cells were 
cultured for 24 h at 21% O2 or at 1% O2. Total protein was extracted after this time. Western Blot analyses 
were performed using antibodies against p53, Atg12 and p62. GAPDH served as a loading control. (S, short 
exposure; L, long exposure) 
 
Collectively, these results indicate that autophagy is not responsible for the depletion of p53, 
whereas lysosomal degradation is required for the down-regulation of p53 in hypoxic HPV16-
positive cancer cells.  
 
In summary, in spite of continuous down-regulation of HPV16 E6/E7 oncogenes under hypoxia, 
p53 protein does not immediately reconstitute, but instead shows a biphasic regulation [rapidly 
and strongly depleted under hypoxia (24 h), then recovered after prolonged hypoxia]. The initial 
reduction of p53 protein is mediated via a lysosome-dependent mechanism in hypoxic HPV16-










2.3 Role of the biphasic regulation of p53 protein in the evasion of senescence by hypoxic 
HPV16-positive cancer cells  
 
2.3.1 Hypoxic HPV16-positive cancer cells do not enter senescence  
 
Repression of E6/E7 oncogenes in HPV-positive cells results in the rapid induction of cellular 
senescence, a central tumor-suppressive, irreversible pathway [233, 234]. Mechanistically, 
inhibition of E6/E7 expression activates p53 signaling, which in turn is required for senescence 
[235, 236]. RNA interference (RNAi)-mediated E6/E7 repression under normoxia leads to the 
emergence of HPV-positive cells staining strongly positive for SA-β-Gal (Senescence-Associated β-
Galactosidase, a marker of cellular senescence [237]) [50]. 
Since HPV16 E6/E7 continuously decreased under hypoxia (Figures 2.2A and 2.2B) and p53 
protein displayed a biphasic regulation and markedly increased after prolonged hypoxia (Figures 
2.2C and 2.2D), the question whether hypoxic HPV16-positive cancer cells go into senescence was 
next investigated.  
The SA-β-Gal staining assay showed that E6/E7-repressed hypoxic cells did not show strong SA-β-
Gal staining (Figure 2.10A), indicating no induction of senescence. Under normoxic conditions, 
among SiHa cells, SA-β-Gal-positive cells increased from 7.99 ± 1.71% at 24 h to 10.42 ± 0.48% at 
72 h; among normoxic CaSki cells, SA-β-Gal-positive cells increased from 1.74 ± 0.21% at 24 h to 
6.11 ± 0.98% at 72 h. Compared to the normoxic cells, hypoxic HPV16-positive cancer cells 
possessed a decreased percentage of SA-β-Gal-positive cells (3.32 ± 1.35 at 24 h and 5.19 ± 1.73 at 
72 h in SiHa cells; 1.84 ± 0.04 at 24 h and 3.06 ± 0.73 at 72 h in CaSki cells) (Figure 2.10B).  
Compared to the cells at 24 h of hypoxia, the percentage of SA-β-Gal-positive cells at 72 h showed 
a minor increase but not statistically significant in hypoxic HPV16-positive cancer cells. These 
results indicate senescence was not induced despite efficient E6/E7 repression and p53 







Figure 2.10 | Hypoxia modulates senescence in E6/E7-repressed HPV16-positive cancer cells. (A) SiHa and 
CaSki cells were cultured under normoxia (21% O2) or hypoxia (1% O2). After 24 h or 72 h, cells were 
stained for the expression of the senescence marker SA-β-Gal. Scale bar: 300 μm. Scheme lower left: 
Treatment protocol. (B) The percentages of SA-β-Gal-positive cells were quantified using the ImageJ 
Analyze Particles program. Error bars indicate the SD of three independent experiments. (Two-tailed 
Student’s t test was employed, *p < 0.05, **p < 0.01 and n.s., statistically not significant)  
 
2.3.2 Regulation of p53 responsive genes in hypoxic HPV16-positive cancer cells 
 
p53 is a key regulator of the cellular senescence response [235, 236, 238-240]. Preliminary 
experiments of cell fractionation analysis with SiHa cells indicate that in normoxic cells, p53 
protein was uniformly distributed in both cytoplasm and nucleus. At 24 h of hypoxia, there was 
no detectable p53 protein in either cytoplasm or nucleus in SiHa cells. After prolonged hypoxia 
(72 h), however, the restored p53 protein was predominantly localized in the nucleus (Figure 3.7). 
In light of the obtained data, demonstrating that hypoxic HPV16-positive cancer cells evade 
senescence despite reconstituted p53 protein levels, the biphasic regulation of p53 under hypoxia 
was hypothesized to have different effects on downstream pathways in the p53 network. To 
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understand how downstream genes of p53 signaling respond, p53 responsive genes involved in 




Figure 2.11 | Schematic overview of p53 responsive genes involved in different functional pathways and 
cellular outcomes. Induction of p53 triggers multiple cellular programs ranging from transient responses, 
such as DNA repair, autophagy and cell cycle arrest, to terminal fates such as cell death (apoptosis) and 
permanent cell cycle arrest (senescence). Shown are representative p53-responsive genes involved in the 
respective responses. Red arrows: transactivation; blue line: transrepression. 
 
Meanwhile, to know the extent to which hypoxia modulates p53 responsive genes, siRNA was 
used to knock down HPV16 E6/E7 under normoxia. Western Blot analysis (preliminary result) 
showed that when E6/E7 is inhibited under normoxia by RNAi, p53 protein was strongly 
reconstituted (Figure 2.12). In E6/E7-repressed hypoxic HPV16-postive cancer cells, p53 protein 






Figure 2.12 | Effect of HPV16 E6/E7 silencing and hypoxia on the protein levels of p53 in HPV16-positive 
cancer cells. The E6/E7 expression was silenced by RNAi under normoxia in SiHa cells (si-16E6E7) and total 
protein was extracted 48 h after transfection. In parallel, cells were cultured for the indicated time periods 
under normoxia (21% O2) or hypoxia (1% O2) and total protein was extracted after respective time intervals. 
(top) Western Blot analysis using antibody against p53. GAPDH served as a loading control. (S, short 
exposure; L, long exposure) (bottom) The grayscale of p53 from indicated samples was quantified using the 
ImageJ software. The relative grayscale values of p53 were normalized to the si-scramble group or 0 h value, 
respectively.  
 
2.3.2.1 Genes whose products control p53 levels (MDM2 and PPM1D)  
 
The protein encoded by MDM2 is a nuclear-localized E3 ubiquitin ligase, which targets p53 for 
nuclear export and proteasomal degradation. As described in chapter 1.3.2, MDM2 is itself 
transcriptionally regulated by p53. 
qPCR analyses showed that RNAi-mediated HPV16 E6/E7 repression under normoxia resulted in 
increases in MDM2 mRNA levels. Under hypoxic conditions, MDM2 showed responses that 
mirrored p53 protein dynamics (decreased first, then recovered, Figure 2.13), indicating a 






Figure 2.13 | Transcript levels of MDM2 and PPM1D in HPV16-positive cancer cells. The E6/E7 expression 
was silenced by RNAi under normoxia in SiHa and CaSki cells (si-16E6E7) and total RNA was extracted 48 h 
after transfection. In parallel, cells were cultured for the indicated time periods under normoxia (21% O2) or 
hypoxia (1% O2) and total RNA was extracted after respective time intervals. (A) and (B) qPCR analyses of 
MDM2 and PPM1D transcripts. 18S rRNA served as internal control for normalization. Error bars indicate 
the SD of three independent experiments. The si-scramble group or 0 h value of gene expression was set as a 
control (set to 1.0).  
 
Protein phosphatase magnesium-dependent 1 delta (ppm1d)/wild-type p53 induced phosphatase 1 
(WIP1) encoded by PPM1D is a member of the PP2C family of serine/threonine protein 
phosphatases, negative regulators of cell stress response pathways. The expression of PPM1D is 
induced in a p53-dependent manner in response to various environmental stresses. WIP1 
negatively regulates the activity of p38 MAPK through which it reduces the phosphorylation of 
p53, and in turn suppresses p53-mediated transcription and apoptosis. WIP1 thus mediates a 
feedback regulation of p38-p53 signaling that contributes to growth inhibition and the suppression 
of stress induced apoptosis. The results of qPCR analyses showed that PPM1D (WIP1) remained 






2.3.2.2 Transcripts encoding apoptotic proteins (APAF1, BAX and PUMA)  
 
APAF1 (apoptotic peptidase activating factor 1) encodes a cytoplasmic protein (Apaf1) that 
initiates apoptosis. Upon binding dATP and cytochrome c, Apaf1 forms an oligomeric apoptosome. 
The apoptosome binds and cleaves caspase 9 preproprotein to release its mature, activated form. 
Activated caspase 9 stimulates the subsequent caspase cascade committing the cell to apoptosis. 
Apaf1 could also be a pro-survival molecule [241].  
The results of qPCR analyses showed that APAF1 was not strongly impaired (slightly decreased 
then marginally increased) in hypoxic CaSki cells, whereas in hypoxic SiHa cells, APAF1 was 
transiently increased (∼2 fold) at 6 h of hypoxia then showed a response that mirrored p53 protein 





Figure 2.14 | Transcript levels of APAF1, BAX and PUMA in HPV16-positive cancer cells. The E6/E7 
expression was silenced by RNAi under normoxia in SiHa (A) and CaSki cells (B), and total RNA was 
extracted 48 h after transfection. In parallel, cells were cultured for the indicated time periods under 
normoxia (21% O2) or hypoxia (1% O2) and total RNA was extracted after respective time intervals. (A) and 
(B) qPCR analyses of APAF1, BAX and PUMA transcripts. 18S rRNA served as internal control for 
normalization. Error bars indicate the SD of three independent experiments. The si-scramble group or 0 h 
value of gene expression was set as a control (set to 1.0). 
 
The genes BAX and PUMA encode members of the BCL-2 family of proteins. Bax (Bcl-2-
associated X protein) forms a heterodimer with BCL2, and functions as an apoptotic activator. Bax 
can also interact with, and increase the opening of, the mitochondrial voltage-dependent anion 
channel (VDAC), which leads to a loss in membrane potential and the release of cytochrome c.  
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Puma (p53 upregulated modulator of apoptosis) belongs to the BH3-only pro-apoptotic subclass. 
Puma cooperates with direct activator proteins to induce mitochondrial outer membrane 
permeabilization (MOMP) and apoptosis. It can bind to anti-apoptotic Bcl-2 family members to 
induce caspase activation. 
As depicted in Figure 2.14, the transcripts encoding apoptotic proteins Bax and Puma showed a 
tendency that is clearly consistent with the biphasic regulation observed in p53 protein levels. 
Transcripts of BAX and PUMA were repressed by hypoxia (0-24 h) but induced after prolonged 
hypoxia. The recovered mRNA levels of BAX and PUMA under prolonged hypoxia were 
comparable to the levels under RNAi-mediated E6/E7 repression under normoxia (Figure 2.14). 
 
Preliminary observations showed that under hypoxia (24 h), cleavage of Poly (ADP-ribose) 
polymerase (PARP) (MW: 89 kD), which is a marker of apoptosis [242, 243], was not induced 
(Figure 3.9). Cleaved-PARP was slightly induced after prolonged hypoxia (72 h, Figure 3.9). These 
data suggest that apoptosis was not induced under short-term hypoxia. 
 
2.3.2.3 Genes involved in cell cycle arrest and DNA repair (GADD45A and XPC)  
 
GADD45A (growth arrest and DNA damage inducible alpha) is a member of a group of genes 
whose transcript levels are increased following stressful growth arrest conditions and treatment 
with DNA-damaging agents. GADD45 proteins play important roles in regulation of cell cycle 
arrest and are also involved in DNA nucleotide excision repair and maintenance of genome 
stability.  
The results of qPCR analyses showed that GADD45A showed a slight increase in SiHa cells and a 
two-fold increase in CaSki cells at 24 h of hypoxia (Figure 2.15). After prolonged hypoxia, 
GADD45A was strongly increased in SiHa cells (20 fold at 48 h, 10 fold at 72 h of hypoxia, Figure 
2.15A), whereas it was decreased again in CaSki cells (decreased by half at 72 h of hypoxia, Figure 
2.15B). 
 
The protein encoded by XPC is a key component of the XPC complex, which plays an important 
role in the early steps of global genome nucleotide excision repair (NER). XPC is important for 
damage sensing and DNA binding, and shows a preference for single-stranded DNA. 
qPCR analyses showed that the mRNA levels of XPC displayed a tendency that well mirrored p53 
protein dynamics (decreased first, then recovered, Figure 2.15). XPC mRNA levels showed a 
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dramatic reduction of almost 80% at 24 h of hypoxia in SiHa cells and a decrease of almost 50% at 
6 h of hypoxia in CaSki cells (Figure 2.15). After prolonged hypoxia, the transcript levels of XPC 







Figure 2.15 | Transcript levels of GADD45A and XPC in HPV16-positive cancer cells. The E6/E7 expression 
was silenced by RNAi under normoxia in SiHa (A) and CaSki cells (B), and total RNA was extracted 48 h 
after transfection. In parallel, cells were cultured for the indicated time periods under normoxia (21% O2) or 
hypoxia (1% O2) and total RNA was extracted after respective time intervals. (A) and (B) qPCR analyses of 
GADD45A and XPC transcripts. 18S rRNA served as internal control for normalization. Error bars indicate 
the SD of three independent experiments. The si-scramble group or 0 h value of gene expression was set as a 
control (set to 1.0). 
 
2.3.2.4 Genes associated with p53-dependent senescence (PML and YPEL3)  
 
Activation of the p53 signaling pathway is a classical cellular response leading to senescence when 
exposure to stresses occurs. Senescent cells are characterized by increased expression of certain 
p53 targets, such as p21, PML, PAI-1, and Yippee-like-3 (YPEL3) [239], all of which are 
recognized as senescence markers, and in turn are able to induce senescence themselves [244-249]. 
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PML localizes to nuclear bodies where it functions as a transcription factor and tumor suppressor. 
PML nuclear bodies (PML-NBs) accumulate in senescent cells. PML is induced by several factors, 
including oncogenic stress and p53 activation [238, 248]. In turn, PML regulates the p53 response 
to oncogenic signals [248]. PML recruits p53, p16, and the pRb/E2F complex to PML-NBs and 
hence regulates the transcription of downstream target genes of these factors, resulting in cellular 
senescence [248, 250]. 
YPEL3, a member of the putative zinc finger motif coding gene family, is a p53-regulated gene. 
YPEL3 expression induced by stress leads to the recruitment of p53 to a cis-acting DNA response 
element located near the YPEL3 promoter. Induction of YPEL3 leads to a significant decrease in 
cell viability and triggers premature senescence [239]. 
The results of qPCR analyses showed that in SiHa cells, the transcript levels of PML and YPEL3 
were decreased under hypoxia and showed only a marginal recovery after prolonged hypoxia 
(Figure 2.16A). In hypoxic CaSki cells, PML mRNA levels were continuously decreased, whereas 
the transcript level of YPEL3 showed a response that mirrored p53 protein dynamics (Figure 
2.16B). The mRNA levels of PML and YPEL3 showed minor increases under RNAi-mediated 




Figure 2.16 | Transcript levels of PML and YPEL3 in HPV16-positive cancer cells. The E6/E7 expression was 
silenced by RNAi under normoxia in SiHa (A) and CaSki cells (B), and total RNA was extracted 48 h after 
transfection. In parallel, cells were cultured for the indicated time periods under normoxia (21% O2) or 
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hypoxia (1% O2) and total RNA was extracted after respective time intervals. (A) and (B) qPCR analyses of 
PML and YPEL3 transcripts. 18S rRNA served as internal control for normalization. Error bars indicate the 
SD of three independent experiments. The si-scramble group or 0 h value of gene expression was set as a 
control (set to 1.0). 
 
These results indicate that down-regulation of p53 by hypoxia (24 h) allows inactivation of genes 
associated with cell death (apoptosis) and cellular senescence. 
 
2.3.2.5 CDKN1A (p21) involved in both cell cycle arrest and senescence  
 
CDKN1A (cyclin dependent kinase inhibitor 1A) encodes p21 (also named Waf1/Cip1), a potent 
cyclin-dependent kinase (Cdk) inhibitor. The expression of CDKN1A is tightly controlled by p53, 
through which p21 mediates the p53-dependent cell cycle G1 phase arrest in response to a variety 
of stress stimuli. Besides its role for cell cycle arrest, p21 is also required for p53-dependent 
cellular senescence [251, 252]. 
CDKN1A mRNA levels showed fluctuations (increased 6 fold at 24 h, then decreased to normal 
level at 48 h, but increased 4 fold again at 72 h of hypoxia) in hypoxic SiHa cells (Figure 2.17A). In 
hypoxic CaSki cells, CDKN1A mRNA levels showed minor increases (Figure 2.17B). RNAi-
mediated HPV16 E6/E7 repression under normoxia resulted in increased CDKN1A mRNA levels 





Figure 2.17 | Transcript levels of CDKN1A (p21) in HPV16-positive cancer cells. The E6/E7 expression was 
silenced by RNAi under normoxia in SiHa (A) and CaSki cells (B), and total RNA was extracted 48 h after 
transfection. In parallel, cells were cultured for the indicated time periods under normoxia (21% O2) or 
hypoxia (1% O2) and total RNA was extracted after respective time intervals. (A) and (B) qPCR analyses of 
CDKN1A transcripts. 18S rRNA served as internal control for normalization. Error bars indicate the SD of 
three independent experiments. The si-scramble group or 0 h value of CDKN1A expression was set as a 




2.3.2.6 Genes involved in autophagy (DRAM1, BNIP3 and TIGAR)  
 
DRAM1 (DNA damage-regulated autophagy modulator 1) is regulated as part of the p53 tumor 
suppressor pathway. It encodes a lysosomal membrane protein DRAM that is required for the 
induction of autophagy by the p53 signaling pathway mediating autophagic cell death [253]. 
The results of qPCR analyses showed that in SiHa cells the transcript levels of DRAM1 were not 
strongly induced at the early stage of hypoxia (0-24 h) but increased after prolonged hypoxia (∼4 
fold at 48 and 72 h) (Figure 2.18A). In hypoxic CaSki cells, the DRAM1 mRNA levels (Figure 
2.18B) showed a response that mirrored p53 protein dynamics (Figure 2.2D), but its recovery after 
prolonged hypoxia was not as strong as the levels detected in hypoxic SiHa cells. The mRNA levels 
of DRAM1 showed minor increases under RNAi-mediated E6/E7 repression under normoxia in 
both SiHa and CaSki cells (Figures 2.18A and 2.18B). 
 
BNIP3 (BCL2 interacting protein 3) encodes a mitochondrial protein that contains a Bcl-2 
homology 3 (BH3) domain and a carboxyl-terminal transmembrane (TM) domain. BNIP3 is 
regarded as a pro-apoptotic factor, interacting with anti-apoptotic proteins, such as Bcl2 and Bcl-
xL [254-256]. Although linked to cell death, the normal function of BNIP3 appears to be in 
mitochondrial autophagy (mitophagy) [104, 257]. Accumulating evidence suggests that BNIP3 can 
protect against cell death by inducing mitophagy [106, 136, 137, 258] (see chapter 1.2.3.1). 
Increased expression of BNIP3 under hypoxia is mainly regulated by the transcription factor HIF-
1α and can be directly suppressed by p53. 
As depicted in Figure 2.18, the transcript levels of BNIP3 were strongly induced under hypoxia. 
The BNIP3 transcripts increased about tenfold already after 6 h of hypoxic incubation in SiHa cells. 
The induction of BNIP3 reached the peak (∼20 fold) at 24 h of hypoxia in SiHa cells (Figure 
2.18A). In hypoxic CaSki cells, the transcript levels of BNIP3 increased roughly five fold after 6 h 
of hypoxic incubation. It increased ∼20 fold and ∼28 fold at 24 h and 48 h of hypoxia, respectively 
in CaSki cells (Figure 2.18B). BNIP3 was repressed under RNAi-mediated E6/E7 inhibition under 







Figure 2.18 | Expression of genes involved in autophagy in HPV16-positive cancer cells. The E6/E7 
expression was silenced by RNAi under normoxia in SiHa (A) and CaSki cells (B), and total RNA was 
extracted 48 h after transfection. In parallel, cells were cultured for the indicated time periods under 
normoxia (21% O2) or hypoxia (1% O2) and total RNA was extracted after respective time intervals. (A) and 
(B) qPCR analyses of DRAM1, BNIP3 and TIGAR transcripts. 18S rRNA served as internal control for 
normalization. Error bars indicate the SD of three independent experiments. The si-scramble group or 0 h 
value of gene expression was set as a control (set to 1.0). 
 
TIGAR (TP53 induced glycolysis regulatory phosphatase), also known as C12orf5, is regulated as 
part of the p53 tumor suppressor pathway [259], thereby controlling apoptosis, autophagy and 
metabolism [199, 260]. Containing a bisphosphate domain similar to the glycolytic enzyme 
fructose-2,6-bisphosphatase (FBPase-2), TIGAR converts fructose-2,6-bisphosphate to fructose-6-
bisphosphate. Fructose-2,6-bisphosphate functions as a potent allosteric activator of 6-
phosphofructo-1-kinase (PFK), a rate-limiting enzyme of glycolysis [261]. Hence, TIGAR blocks 
glycolysis, thereby redirecting cellular glucose metabolism into the pentose phosphate shunt. 
TIGAR also protects cells from oxidative stress as it reduces the production of reactive oxygen 
species (ROS) in cells [199, 262]. Loss of TIGAR induces autophagy and apoptosis [263, 264], and 
its expression protects cells from DNA damaging ROS-related cell death [265]. 
Under hypoxic conditions, the transcript levels of TIGAR showed responses that mirrored p53 
protein dynamics (decreased first, then recovered, Figure 2.18). The mRNA levels of TIGAR 
showed minor increases under RNAi-mediated E6/E7 repression under normoxia in both SiHa and 
CaSki cells (Figure 2.18). 





In summary, hypoxic HPV16-positive cancer cells do not enter senescence despite efficient E6/E7 
repression and p53 reconstitution. Hypoxia activates cellular programs involved in transient 
responses, such as cell cycle arrest and DNA repair. p53 downstream genes associated with 
terminal fates such as cell death (apoptosis) and permanent cell cycle arrest (senescence) are 
inactivated by hypoxia (24 h). Genes involved in promoting autophagy are strongly induced in 
hypoxic HPV16-positive cancer cells. The balance in downstream gene profiles of reconstituted 
p53 after prolonged hypoxia may contribute to cellular homeostasis and select cells resistant to 
apoptosis. 
 
2.4 The evasion of hypoxic HPV16-positive cancer cells from senescence is attributable to 
the induction of autophagy 
 
Autophagy (macroautophagy) is a self-destructive process by which eukaryotic cells degrade and 
recycle cellular macromolecules and organelles to provide nutrients for cell metabolism, 
particularly under conditions of nutrient deprivation [100, 101]. Cancer cells suffering limited 
nutrient supplies under cellular stresses may utilize autophagy for survival; such improved 
autophagic capabilities will benefit the cancer cells [110-115] (see chapter 1.2.3). Autophagy is 
essential to suppress cellular stress and has previously been shown to induce a dormant state, and 
prevent senescence [266-269]. Hypoxia-induced autophagy is further linked to hypoxia tolerance 
and tumor cell survival [102]. Genes involved in promoting autophagy were strongly induced, 
whereas a gene related to repression of autophagy (TIGAR) was not induced by hypoxia (Figure 
2.18). It was therefore tested whether autophagy is involved in the evasion of hypoxic HPV16-
positive cancer cells from senescence. 
 
2.4.1 Hypoxia induces autophagy in HPV16-positive cervical cancer cells 
 
The increase of LC3-II and the decrease of p62 are two markers of autophagy (described in chapter 
1.2.3.1). As demonstrated in Figure 2.19, hypoxia induced autophagy in HPV16-positive cancer 
cells, as indicated by the increase of LC3-II and the quantitative reduction of p62. Preliminary 
observations showed that the mRNA levels of LC3A, LC3B and p62 remained stable under hypoxia, 







Figure 2.19 | Protein levels of LC3-II, p62 and p53 in hypoxic HPV16-positive cancer cells. HPV16-positive 
SiHa (A) and CaSki cells (B) were cultured for the indicated time periods at 1% O2. Total protein was 
extracted after the respective time intervals. (A) and (B) Western Blot analyses using antibodies against LC3-
II, p62 and p53. GAPDH served as a loading control. 
 
2.4.2 p53 overexpression inhibits hypoxia-induced autophagy 
 
As shown in Figure 2.19, LC3-II and p62 decreased after the reduction of p53. Tasdemir et al. 
showed that depletion of p53 facilitates autophagy in several cell lines, in response to several 
distinct stimuli [206]. 
In order to investigate whether the induction of autophagy observed in hypoxic HPV16-positive 
cancer cells is triggered by p53 depletion, p53 was overexpressed prior to hypoxic incubation. 
Compared to cells transfected with empty vector, overexpression of p53 diminished hypoxia-
induced autophagy, as shown by the increased amounts of p62 at 1% O2 (Figures 2.20 and 3.13). 




Figure 2.20 | Effect of overexpression of p53 protein on p62. SiHa cells were transfected with/without an 
empty vector control (control) or wild-type (wt) p53. 48 h post transfection, the cells were cultured for 24 h 
at 21% O2 or at 1% O2. Total protein was extracted. Western Blot analyses using antibodies against p53 and 




2.4.3 Inhibition of autophagy induces senescence in hypoxic HPV16-positive cancer cells 
 
The above evidence raises the possibility that hypoxia-associated initial reduction of p53 facilitates 
the induction of autophagy to allow HPV16-positive cervical cancer cells to evade senescence.  
In order to investigate whether inhibition of autophagy induces senescence, SiHa and CaSki cells 
were incubated with the autophagy inhibitor chloroquine (CQ). Although the hypoxic cells 
treated with CQ did not stain strongly positive for SA-β-Gal, these cells showed the characteristic 
morphological signs of senescence (for example cell enlargement, flattening) and an apparent 
inability to grow when switched back to normoxic culture conditions (Figures 2.21 and 3.14). 




Figure 2.21 | Analyses of cellular senescence upon treatment with autophagy inhibitor CQ in HPV16-
positive cancer cells. SiHa cells were cultivated for 48 h under normoxia (21% O2) or hypoxia (1% O2), in 
either the absence (top) or the presence (bottom) of 50 μM chloroquine (CQ). Cells for senescence assays 
(SA-β-Gal staining) subsequently cultured under normoxia. Scale bar: 300 μm. Scheme left: Treatment 
protocol. 
 
In summary, hypoxia-associated initial reduction of p53 facilitates the induction of autophagy. 
The evasion of hypoxic cells from senescence appears to be attributable to the induction of 
autophagy. 
 
Taken together, these findings revealed a new regulation pattern of p53 during hypoxia and 
provide new insights into the effect of p53 regulation on downstream pathway responses and 
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cellular adaptation. In spite of continuous down-regulation of HPV16 E6/E7 oncogenes under 
hypoxia, p53 protein does not immediately reconstitute, but shows a biphasic regulation [rapidly 
and strongly depleted under hypoxia (24 h), then recovered after prolonged hypoxia]. p53 is 
predominantly degraded via a lysosome-dependent mechanism in hypoxic cells. Down-regulation 
of p53 by hypoxia (24 h) helps to avoid the boost of downstream genes associated with terminal 
fates such as cell death (apoptosis) and permanent cell cycle arrest (senescence). The balance in 
downstream gene profiles of reconstituted p53 after prolonged hypoxia may contribute to cellular 
homeostasis and select cells resistant to apoptosis. Hypoxic activation of cellular programs 
involved in transient responses, such as DNA repair and autophagy protect cells from committing 
to an irreversible fate. Hypoxia-associated initial reduction of p53 facilitates the induction of 
autophagy to allow HPV16-positive cervical cancer cells to evade senescence. Inhibition of 








The tumor suppressor p53, a pivotal regulator of cellular responses, functions as a stress-activated 
transcription factor. p53 regulates numerous cellular responses including cell cycle arrest, DNA 
repair, apoptosis, senescence, autophagy and metabolism. Oxygen deprivation (hypoxia) is one of 
the stresses that have been shown to affect p53 signaling. 
Cervical cancers often display strongly reduced O2 content, with a median O2 concentration of 
1.18%. Therefore, hypoxia is frequently detected in cervical cancer patients and has a negative 
impact on patient prognosis [48, 49]. Nevertheless, functional studies of HPV-positive cancer cells 
under hypoxic conditions are rare. In these few studies, the regulation of p53 by hypoxia in HPV-
positive cells appears to be controversial and the role of p53 in the cellular adaptation to hypoxia 
remains elusive [50, 51, 213, 214, 270]. This PhD thesis describes for the first time a biphasic 
regulation of p53 under hypoxic conditions in HPV16-positive cervical cancer cells and reveals 
the mechanism controlling this regulation of p53 by hypoxia. This study provides also new 
insights into the effect of p53 regulation on p53 downstream pathway responses and cellular 
adaptation under hypoxia. The biphasic regulation of p53 and its role in cellular adaptation to 
hypoxia will be discussed in this section. 
 
3.1 Using standard O2 concentration and serial duration of hypoxia for systematic study  
 
Although different studies have been performed to investigate the regulation of p53 under 
hypoxia in the context of HPV, the methods used in these studies to obtain hypoxic conditions are 
widely divergent. The O2 concentration used ranges from 0.02% to 1% [50, 51, 213, 214]. In all 
tested cell lines, the duration of hypoxic incubation was only up to 24 h. Under the different 
experimental conditions in these studies using completely different O2 concentrations, p53 protein 
showed multiple trends under hypoxia in the investigated HPV-positive cell lines.  
As mentioned above, cervical cancers display reduced O2 content with a median O2 concentration 
of 1.18%. Moreover, cancer cells are differentially exposed to hypoxia for minutes to hours or 
even days [271-275]. Therefore, this PhD thesis conducted experiments using a standard O2 
concentration (1% O2) for hypoxic conditions to systematically investigate the dynamics of p53 




3.2 Regulation of HPV16 E6/E7 oncogenes and p53 protein under hypoxia (1% O2) 
 
Under normoxic conditions, the HPV oncoproteins E6 and E7 target the tumor suppressors p53 
and pRb for degradation and inactivation, respectively. Sustained expression of the viral E6 and E7 
genes is considered to be required for maintaining the malignant phenotype of HPV-positive 
cervical cancer cells 
 
3.2.1 Repression of HPV16 E6/E7 oncogenes under hypoxia 
 
In this study, HPV16 oncogenes E6 and E7 were found repressed under hypoxic conditions 
(Figures 2.1 and 2.2). The HPV oncogenes normally induce cell proliferation. This process 
consumes cellular energy in the form of ATP and needs a sufficient nutrient supply. Preliminary 
observations found that under hypoxia, the supply of energy (cellular ATP levels) was limited in 
SiHa cells (Figure 3.1A) and cell numbers reached a plateau after 24 h (Figure 3.1B), suggesting 
hypoxia inhibits the proliferation of SiHa cells. The decrease in relative ATP levels after 24 h of 
normoxia in SiHa cells may be due to a reduced cell metabolic activity resulting from overgrowth 
of cells under normoxic culture conditions. 
Hypoxic down-regulation of HPV E6/E7 oncogenes might serve as a survival strategy of the 
infected cells under stress. In other words, the cells down-regulate HPV oncogenes and instead of 




Figure 3.1 | Relative ATP Levels and cell numbers in HPV16-positive SiHa cells under normoxia and 
hypoxia. SiHa cells were cultured for the indicated times at 21% O2 or at 1% O2. Relative ATP levels (A) and 
cell numbers (B) were determined after respective time intervals. For each assay, initial values (time point 4 
h) were set to 1.0. 
 
CaSki cells possess more than 500 viral genome copies, of which however only few are expressed, 
whereas the SiHa cell line was reported to contain only 1-2 copies of HPV16 [276, 277]. 
Furthermore, both E6 and E7 have very short half-lives of less than 60 min [278]. Thus, transcript 
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levels of HPV16 E6/E7 oncogenes were used to investigate hypoxic regulation of HPV E6/E7 
oncogenes in cervical cancer cells (Figures 2.1 and 2.2). 
 
3.2.2 Biphasic regulation of p53 protein in hypoxic HPV16-positive cancer cells 
 
The down-regulation of HPV oncogenes upon hypoxia was hypothesized to reconstitute p53 
protein and reactivate pRb. Hoppe-Seyler et al. reported that phosphorylated pRb levels decreased 
and pRb protein remained stable when E6/E7 oncogenes were repressed under hypoxia (24 h) [50]. 
These results coincided with the fact that under hypoxia the pace of cervical cancer cell growth 
was slowed down, with cell numbers reaching a plateau after 24 h (Figure 3.1B). After prolonged 
hypoxia, phosphorylated pRb levels might continue to be down-regulated, as indicated by the 
cessation of cell growth. 
 
In spite of the strong down-regulation of HPV16 E6/E7 oncogenes under hypoxia, p53 protein did 
not immediately reconstitute, but rather showed a biphasic regulation (rapidly and strongly 
depleted first, then markedly recovered after prolonged hypoxia) (Figure 2.2). 
Expression and activation of the tumor suppressor p53 can be influenced by diverse cellular 
stresses. The abundance and activity of p53 depend on cell type and the nature and extent of the 
stresses. Among the studies investigating the regulation of p53 under hypoxia in the context of 
HPV, severe hypoxic conditions (0.02% O2 or < 0.2% O2) are prone to induce p53 [51, 213] and a 
standard hypoxic condition (1% O2) represses p53 at 24 h [50, 214]. In this study, p53 protein was 
decreased at 24 h of hypoxia (1% O2). Prolonged hypoxia (> 48 h) induced p53 in these cells 
(Figure 2.2). The divergent regulation patterns of p53 under hypoxia can be explained by the use 
of different severity and duration of oxygen deprivation [51, 210-212]. The difference in the 
course of biphasic regulation and the extent of recovery of p53 under hypoxia could be due to the 
different cell types. 
 
3.3 Different glucose levels and cell types  
 
Different glucose levels 
As described in chapter 1.2.2, one feature of tumor cells is an altered glucose metabolism that is 
significantly different from normal cells. Tumor cells tend to use glycolysis for obtaining ATP 
(Warburg effect). It is well known that hypoxia activates glycolysis and inhibits mitochondrial 
respiration. The Warburg effect is associated with glucose uptake and utilization [90, 91]. Altered 
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glucose metabolism is therefore suspected to influence the regulation of p53 under hypoxic 
conditions. 
Preliminary observations found that higher levels of glucose delayed the course of the biphasic 
regulation of p53 protein in hypoxic HPV16-positive cancer cells (Figure 3.2B). When CaSki cells 
were cultured in medium containing higher glucose levels (2 g/L), the reduction and the recovery 
of p53 appeared later (at 12 h and 72 h of hypoxia, respectively, Figure 3.2B) than those observed 
in cells cultured in medium containing physiological serum glucose levels (1 g/L) (at 6 h and 48 h 




Figure 3.2 | Effect of different levels of glucose on the course of the biphasic regulation of p53 protein in 
hypoxic HPV16-positive CaSki cells. CaSki cells were cultured in the medium containing different levels of 
glucose (A, 1 g/L and B, 2 g/L) for the indicated time periods under normoxia (21% O2) or hypoxia (1% O2). 
Total protein was extracted after respective time intervals. Western Blot analyses were performed using 
antibody against p53. GAPDH served as a loading control.  
 
When SiHa cells were cultured in medium devoid of glucose or serum (0 g/L), the hypoxic 
depletion of p53 protein was advanced by the glucose deprivation (already appeared at 4 h of 
hypoxia, Figure 3.3A), but not by serum deprivation (Figure 3.3B). These preliminary data suggest 






Figure 3.3 | Effect of glucose deprivation or serum deprivation on depletion of p53 in hypoxic SiHa cells. 
SiHa cells were grown in medium containing 1 g/L glucose and 10% FCS (control group, con). The absence 
(−) or presence (+) of glucose (A) or FCS (B) in the medium is indicated. Cells were cultured for 4 h or 24 h 
under normoxia (21% O2) or hypoxia (1% O2). Total protein was extracted after respective time intervals. 
Western Blot analyses were performed using antibody against p53. GAPDH served as a loading control. 
 
Different cell types 
In addition to the severity as well as the duration of oxygen deprivation, previous studies suggest 
that the regulation of p53 by hypoxia also depends on the cell line. Preliminary experiments using 
the HPV-negative hepatocellular carcinoma cell line HepG2 (wild-type p53) showed that during 
different periods of hypoxia, the tendency of a biphasic regulation of p53 protein could also be 
observed in hypoxic HepG2 cells (Figure 3.4). This implied that the biphasic regulation of p53 




Figure 3.4 | p53 protein levels in HPV16-negative HepG2 cancer cells under normoxia and hypoxia. HepG2 
cells were cultured in medium containing low levels of glucose (1 g/L) for the indicated time periods under 
normoxia (21% O2) or hypoxia (1% O2). Total protein was extracted after respective time intervals. Western 
Blot analysis was performed using antibody against p53. GAPDH served as a loading control. (S, short 




When HepG2 cells were cultured in medium containing higher glucose levels (4.5 g/L), p53 
protein levels gradually decreased in HepG2 cells (Figure 3.5). This suggests that glucose levels 




Figure 3.5 | p53 protein levels in HPV16-negative HepG2 cancer cells under normoxia and hypoxia. HepG2 
cells were cultured in medium containing high levels of glucose (4.5 g/L) for the indicated time periods 
under normoxia (21% O2) or hypoxia (1% O2). Total protein was extracted after respective time intervals. 
Western Blot analysis was performed using antibody against p53. α-tubulin served as a loading control. (S, 
short exposure; L, long exposure)  
 
It has been shown that the loss of p53 function contributes to the metabolic switch of glucose 
metabolism from oxidative mitochondrial respiration to glycolysis [279]. As described in chapter 
1.3.3, p53 modulates the balance between the utilization of the respiratory and glycolytic 
pathways but in an opposite way to hypoxia, by promoting oxidative phosphorylation and 
dampening glycolysis [201]. As shown in Figure 2.18, TIGAR which lowers fructose-2,6-
bisphosphate levels to inhibit glycolysis was decreased in hypoxic HPV16-positive cancer cells. 
Thus, hypoxic initial down-regulation of p53 may facilitate the metabolic switch to glycolysis in 
HPV16-positive cancer cells. 
 
3.4 Mechanisms underlying the regulation of p53 in hypoxic HPV16-positive cancer cells 
 
3.4.1 p53 transcript levels and protein stability  
 
In this study, the tendency of p53 transcript levels (Figure 2.3) are not accompanied by time-
dependent changes of p53 protein (Figure 2.2). Acute hypoxia (6 h) had no significant effects on 
TP53 mRNA levels (Figure 2.3). The decrease in TP53 mRNA levels under hypoxia (after 24 h in 
SiHa cells and after 48 h in CaSki cells, Figure 2.3) could be due to an overall down-regulation of 
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gene expression, which might be impaired by limited energy and cellular material under hypoxic 
stress, in HPV16-positive cancer cells. 
Among reports that describe the regulation of p53 by hypoxia, most argue for p53 stabilization 
under hypoxia. However, Wang et al. showed that increased p53 protein levels by hypoxia were 
due to an increase in p53 mRNA levels [280]. Galban et al. showed an increased p53 mRNA 
translation under hypoxia without any change in mRNA levels [281]. pVHL (Von Hippel Lindau 
protein), which is a transcriptional target of HIF-1 and therefore induced under hypoxia, could 
enhance p53 translation in a way involving the RNA-binding protein HuR [281]. A transcriptional 
repression of the human p53 gene was shown when HIF-1a was accumulated by CoCl2 [282]. Fu et 
al. reported that accumulation of HIF-1α by CoCl2 inhibited the expression of p53 in HPV18-
positive HeLa cells [270]. 
Hypoxia reduced the TP53 mRNA levels by half in SiHa cells at 24 h (Figure 2.3A). One therefore 
cannot exclude that the depletion of p53 protein at 24 h under hypoxia was partially due to 
decreased transcription in SiHa cells (Figures 2.2C and 2.3A). However, treating HPV16-positive 
cancer cells with CHX, an inhibitor of eukaryotic protein synthesis [217], pre-treating with 
hypoxia was found to decrease p53 protein half-life (Figure 2.4). This suggested that down-
regulation of p53 protein under hypoxia (0-24 h) was attributable to decreased p53 protein 
stability in HPV16-positive cancer cells. 
 
For further studies, it would be interesting to perform a CHX-chase experiment after prolonged 
hypoxia (48 or 72 h) to detect whether p53 stability was increased under prolonged hypoxia in 
HPV16-positive cancer cells. Despite a decrease in p53 mRNA levels, p53 protein was recovered 
after prolonged hypoxia (Figures 2.2 and 2.3). As mentioned before, hypoxia-induced pVHL could 
enhance p53 translation [281]. Hence, one could hypothesize that prolonged hypoxia may increase 
p53 translation and protein stability.  
 
3.4.2 Proteasomal degradation and lysosomal degradation 
 
As described in chapter 1.3.2, localization and stability of p53 protein are tightly regulated by a 
variety of post-translational modifications (PTMs). Protein stability, as well as localization, are 
regulated by mono-ubiquitination and poly-ubiquitination mediated by ubiquitin ligases. MDM2 
is regarded as the master regulator not only of p53 protein levels but also of p53 localization in a 
variety of cellular systems (see chapter 1.3.2). Additionally, in cells infected with HPV, such as 
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HPV16 and HPV18, the viral E6 protein promotes the binding of p53 to the E3 ubiquitin ligase 
E6-AP, which ubiquitinates p53 efficiently and causes the proteasomal degradation of p53. 
Hengstermann et al. described a complete switch from MDM2 to HPV E6-mediated degradation 
of p53 in cervical cancer cells [283]. Thus, proteasomal degradation plays a key role in the 
regulation of p53 protein levels.  
However, in this study, the p53 protein levels in hypoxic HPV16-positive cancer cells could not be 
fully increased to comparable levels detected under normoxic conditions when incubated with 
MG132 (Figure 2.5). As mentioned in chapter 2.2.4, MG132 is not a selective inhibitor for 
proteasomes. It can also inhibit the function of lysosomes [218, 221, 222]. One can therefore 
conclude that in HPV16-positive cancer cells the reduction of p53 levels by hypoxia was not 
(solely) mediated via proteasomal degradation. 
 
Besides the ubiquitin/proteasome system, the autophagy-lysosome-dependent pathway is another 
important cellular system for protein degradation (see chapter 1.2.3.1 and 2.2.4).  
Hoppe-Seyler et al. showed that hypoxic HPV-positive cells do not appear to switch from E6-
dependent to MDM2-dependent p53 degradation, given that treatment with Nutlin-3, a potent 
inhibitor of the MDM2/p53 interaction [284], did not appreciably increase p53 levels in HPV-
positive cancer cells [50]. Vakifahmetoglu-Norberg et al. reported that suppression of 
macroautophagy promotes the degradation of mutant p53 through chaperone-mediated autophagy 
(CMA) in a lysosome-dependent fashion [285]. Hence, lysosome-mediated degradation was 
suspected to play a role in the regulation of p53 protein in hypoxic HPV16-positive cancer cells. 
Here, the autolysosome inhibitor CQ [223, 224] could prevent the p53 degradation triggered by 
hypoxia in HPV16-positive cancer cells. Bafilomycin A1, which inhibits the fusion of 
autophagosomes and lysosomes [225-227], however, only prevented the degradation of p62 but 
not p53, suggesting that, unlike p62, p53 was not sequestered by autophagosomes, but degraded 
via the lysosomal pathway (Figure 2.6).  
 
In normoxic HPV-positive cancer cells, the p53 levels are predominantly dependent on E6/E6-AP-
mediated proteolytic p53 degradation [25, 286, 287]. In this study, under hypoxia, the E6/E6-AP-
dependent ubiquitination system was impaired, as indicated by the repression of E6 oncogene and 
the diminishment of E6-AP (Figures 2.2 and 3.6). Moreover, hypoxic HPV-positive cells did not 
switch from E6-dependent to MDM2-dependent p53 degradation [50]. These clues suggest that 




Vakifahmetoglu-Norberg et al. reported that susceptibility to ubiquitination determines the 
degradation pathways of wild-type (wt) and mutant p53 proteins [285]. The wt p53 protein, which 
was susceptible to ubiquitination, was subjected to proteasomal degradation. The mutant p53, 
which was degraded through chaperone-mediated autophagy (CMA) in a lysosome-dependent 
manner, was not ubiquitinated [285]. Furthermore, interestingly, Gogna et al. described that the 
conformation of wt p53 is oxygen-dependent and exists in mutant conformation in hypoxic 
tumors [288]. Hypoxia is known to induce the disappearance of homeodomain-interacting protein 
kinase 2 (HIPK2), resulting in an increased p53 “mutant-like” conformation [289]. Moreover, 
chaperones (such as CHIP [290], HSP90, and HSP70 [291]) interact with p53 under stress 
conditions. These considerations raise the possibility that p53 was subjected to chaperone-
mediated lysosomal degradation in hypoxic HPV-positive cancer cells.  
 
The exact mechanism by which the lysosome-dependent pathway induces the down-regulation of 
p53 in hypoxic HPV16-positive cervical cancer cells is not determined yet. It would be interesting 
to investigate whether the ubiquitination of p53 is impaired under hypoxia and whether a lower 
ubiquitination rate of p53 contributes to lysosomal degradation. In addition, the cofactors 
contributing to p53 degradation in hypoxic HPV-positive cancer cells could be determined by 
immunoprecipitation followed by mass spectrometry analysis (IP-MS). 
 
3.4.3 Autophagy (macroautophagy) is not required for p53 degradation 
 
Tasdemir et al. showed that many different inducers of autophagy (for example starvation and 
rapamycin) stimulated proteasome-dependent degradation of p53 through a pathway relying on 
the E3 ubiquitin ligase MDM2 [206]. Inhibition of p53 degradation prevented the activation of 
autophagy (macroautophagy) in several cell lines, in response to several distinct stimuli [206]. The 
group found that autophagy is not required for depletion of p53. Rather, depletion of p53 seems to 
be necessary for the induction of autophagy [206].  
Here, inhibition of autophagy (macroautophagy) by silencing ATG12 or p62/SQSTM1 did not 
rescue p53 levels under hypoxia (Figure 2.9). Overexpression of p53 prevented hypoxia-induced 
autophagy in HPV16-positive cancer cells (Figures 2.20 and 3.13).  
Moreover, Hoppe-Seyler et al. showed that p53 levels were not restored in hypoxic HPV-positive 
cancer cells upon activation of mTOR signaling, which represses autophagy [292], and did not 
decrease upon inactivation of mTOR signaling in normoxic cells [50].  
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These results are consistent with the conclusion by Tasdemir et al. [206], suggesting autophagy is 
not responsible for the depletion of p53, whereas depletion of p53 is required for induction of 
autophagy. However, hypoxic HPV16-positive cancer cells utilized a lysosome-dependent 
pathway, but did not rely on MDM2-proteasome-dependent degradation to remove p53, “the 
brake of autophagy”. 
 
3.4.4 Restoration of p53 after prolonged hypoxia 
 
The regulation of p53 protein by hypoxia depends on the duration of oxygen deficiency. Here, p53 
protein markedly increased after prolonged hypoxia (Figures 2.2C and 2.2D). The biphasic 
regulation of p53 under hypoxia may be caused by different PTMs of p53 protein during different 
stages of hypoxia, such as phosphorylation on different sites of p53. The dynamically changing 
PTMs of p53 under hypoxia may cause nuclear-cytoplasmic shuttling of p53 and 
nuclear/cytoplasmic redistribution of p53, which is critical for p53 degradation [293] and has a 
major role in the regulation of autophagy [206].  
MDM2 acts not only as an E3 ligase modulating p53 protein levels but also as a regulator 
controlling p53 localization [166]. HPV E6-mediated degradation of p53 required the nuclear 
export function of MDM2 [294]. It was proposed that hypoxic suppression of MDM2-mediated 
nuclear export of p53 plays a key role in p53 stabilization under hypoxia [295]. Decrease of MDM2 
levels by hypoxia has indeed been observed in several studies [213, 296, 297].  
Although MDM2 transcript levels were induced after prolonged hypoxia in SiHa cells (Figure 
2.13A), preliminary experiments that investigated the changes of E3 ligases of p53 protein showed 




Figure 3.6 | Protein levels of E6-AP and MDM2, E3 ligases of p53, in SiHa cells under normoxia and hypoxia. 
SiHa cells were cultured for the indicated time periods at the indicated O2 concentrations (normoxia: 21% 
O2 and hypoxia: 1% O2). Total protein was extracted after respective time intervals. Western Blot analysis 




As already mentioned in chapter 2.3.2, preliminary experiments of cell fractionation analysis with 
SiHa cells indicate that after prolonged hypoxia, the restored p53 was predominantly localized in 
the nucleus (72 h, Figure 3.7). These preliminary results suggest that prolonged hypoxia could 




Figure 3.7 | Cellular localization of p53 and MDM2 in SiHa cells under normoxia and hypoxia. SiHa cells 
were cultivated for 24 h or 72 h under normoxia or hypoxia. Nuclei were extracted. Shown are immunoblots 
of p53 and MDM2 protein levels. TBP and GAPDH served as loading controls for cytoplasmic (Cyto) and 
nuclear (Nucl) proteins, respectively. (L, long exposure; S, short exposure) 
 
Stabilization via phosphorylation of p53 on serine 15 is also frequently observed under hypoxia 
and could be a result of the activation of ataxia-telangiectasia mutated (ATM) or ataxia-
telangiectasia mutated and Rad3-related kinases (ATR) by hypoxia [298, 299]. Serine 15 
phosphorylation of p53 has also been reported to prevent its interaction with MDM2 [176]. One 
could hypothesize that prolonged hypoxia may increase PTMs of p53 that promote p53 stability 
and lead to the nuclear localization of p53 in HPV16-positive cancer cells. It would be interesting 
to explore the dynamics of PTMs of p53 protein during different periods of hypoxic conditions in 
HPV16-positive cancer cells (phosphorylation, ubiquitination, acetylation, and hydroxylation). 
 
According to all that has been observed by us, the following model can be hypothesized (Figure 
3.8). During different periods of hypoxia, p53 protein shows a biphasic regulation [rapid and 
strong depletion under hypoxia (0-24 h), then recovery after prolonged hypoxia] in HPV16-
positive cancer cells. Under hypoxic conditions (0-24 h), since the E6/E6-AP-dependent 
ubiquitination system is impaired, p53 protein is predominantly degraded via a lysosome-
dependent mechanism in HPV16-positive cancer cells. After prolonged hypoxia, with the 
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elimination of inhibitory factors (E6/E6-AP and MDM2), p53 protein is stably synthesized and 
transported into the nucleus in HPV16-positive cancer cells. 
 
 
Figure 3.8 | Schematic overview of the biphasic regulation of p53 protein in HPV16-positive cancer cells. 
(Left) Under hypoxic conditions (0-24 h), MDM2 promotes nuclear export of p53. p53 protein is 
predominantly degraded via a lysosome-dependent mechanism in HPV16-positive cancer cells. (Right) 
After prolonged hypoxia, p53 protein is stably synthesized and transported into the nucleus in HPV16-
positive cancer cells. 
 
3.5 Downstream effects of the hypoxia-induced biphasic regulation of p53 protein in 
HPV16-positive cancer cells 
 
The effect of hypoxia on p53 has been studied for decades. The regulation of p53 by hypoxia has 
usually been linked to induction of apoptosis [51, 211] or selection of cells resistant to cell death 
[51, 142].  
Although the best-studied functions of p53 relate to its control of cell cycle arrest and cell death, 
accumulating evidence suggests that this protein represents a pleiotropic regulator in the stress-
induced cellular response networks. Diverse activities of p53 are important not only in DNA 
repair, induction of cell cycle arrest and apoptosis but also in senescence, autophagy and 
metabolism. The effect of p53 regulation on these cellular responses in hypoxic cervical cancer 
cells remains elusive. Moreover, the dynamics of p53 during different periods of hypoxic 
conditions in cervical cancer cells are still not well explored. The effect of p53 dynamics on 
downstream responses (target gene expression and cellular outcomes) in hypoxic HPV16-positive 




In this study, target genes of p53 displayed different expression dynamics in response to the 
biphasic regulation of p53 in hypoxic HPV16-positive cervical cancer cells. Some of them showed 
responses that mirrored p53 protein dynamics (decreased first, then recovered), including MDM2, 
BAX, PUMA, XPC, YPEL3 and TIGAR in both SiHa and CaSki cells (Figures 2.13, 2.14, 2.15, 2.16 
and 2.18). Other p53 target genes, like PPM1D (WIP1), APAF1 and DRAM1, showed a relatively 
stable tendency or minor increases. The different expression dynamics of these p53 target genes 
may be determined by their distinct mRNA half-lives. Porter et al. reported that patterns of p53 
target gene expression responding to stress cluster into groups with stereotyped temporal 
behaviors, including pulsing and rising dynamics. These behaviors correlate statistically with the 
mRNA decay rates of target genes: short mRNA half-lives produce pulses of gene expression [300]. 
Melanson et al. also reported that the expression of most p53-induced transcripts was rapidly 
reversible, consistent with active mRNA decay. Short-lived p53 targets were induced faster, 
reaching maximum transcript levels earlier than the stable p53 targets [301]. 
The different fold change in expression of p53 target genes, such as MDM2, BAX, and DRAM1 
(Figures 2.13, 2.14 and 2.18), when p53 protein recovered in SiHa and CaSki cells may be due to 
the different amounts of recovered p53 protein in these cells (Figure 2.2). Furthermore, the 
transactivation activity of hypoxia-induced p53 was impaired under hypoxia [296, 302-305]. The 
transactivation activity of p53 under prolonged hypoxia in SiHa and CaSki cells may be different, 
thereby resulting in different transcript levels of p53 target genes. 
The role of target gene expression dynamics for downstream responses and cellular outcomes/ 
fates will be discussed in the following parts. 
 
3.5.1 Control of p53 levels 
 
Despite increases in MDM2 mRNA levels, p53 protein was strongly reconstituted upon repression 
of HPV16 E6/E7 mediated by RNAi in normoxic SiHa cells (Figures 2.12 and 2.13). The 
reconstitution of p53 protein may be due to PTMs (such as serine 15 phosphorylation) on p53, 
which prevent its interaction with MDM2, even though MDM2 was induced in E6/E7-specific 
siRNA-transfected SiHa cells. 
Under hypoxic conditions, the remaining MDM2 at 24 h of hypoxia (Figure 3.7) may cause 
nuclear export of p53 in hypoxic HPV16-positive cancer cells. As discussed in chapter 3.4.4, 
although MDM2 transcript levels were induced after prolonged hypoxia in SiHa cells (Figure 
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2.12A), preliminary experiments showed that MDM2 protein levels were diminished after 
prolonged hypoxia in SiHa cells (Figures 3.6 and 3.7). The decrease in MDM2 protein levels might 
be caused by its auto-ubiquitination, which allows for its degradation by the proteasome [306].  
 
WIP1 (PPM1D), a phosphatase, negatively regulates the activity of p38 MAP kinase, MAPK/p38, 
through which it reduces the phosphorylation of p53, and in turn suppresses p53-mediated 
transcription and apoptosis. This phosphatase thus mediates a feedback regulation of p38-p53 
signaling contributing to inhibition of growth and the suppression of stress-induced apoptosis. 
Here, PPM1D remained relatively stable in hypoxic HPV16-positive cancer cells (Figure 2.12). It 
has already been reported that hypoxia had no effect on PPM1D [307]. This phosphatase might 
help to dephosphorylate p53 protein leading to its interaction with MDM2 and nuclear export 
under hypoxia (0–24 h). 
 
3.5.2 Cell death (apoptosis) 
 
As for the analyses of p53 target genes associated with apoptosis in hypoxic SiHa cells, APAF1 was 
transiently increased (∼2 fold) at 6 h of hypoxia (Figure 2.13). This can be explained by a possible 
transient transcriptional activation of Apaf1 by p53 at 6 h of hypoxia in SiHa cells. It was proposed 
that Apaf1 has a pro-survival effect. Ferraro et al. found that Apaf1-depleted cells exhibit low Bcl-
2 and Bcl-XL expression, under an apoptotic stimulus, rapidly releasing cytochrome c [241]. Loss 
of Apaf1 impairs cell homeostasis and leads to an enhanced responsiveness to stressful conditions. 
Compared with wild-type cells, Apaf1-depleted cells are more fragile and have a lower threshold 
to stress [241]. 
In addition, cytochrome c-initiated activation of Apaf1 is a crucial step in the mitochondrial 
signaling pathway for the activation of death-executing caspases in apoptosis. Decreased oxygen 
levels cause dysfunction and reorganization of mitochondria, major places of oxygen consumption 
[97] and induce mitochondrial autophagy (mitophagy) [106, 139, 140]. These effects may influence 
the release of cytochrome c and then impair the formation of the apoptosome by Apaf1 in hypoxic 
HPV16-positive cancer cells. 
  
Repression of BAX and PUMA under hypoxia (0-24 h, Figure 2.14) might help to avoid MOMP 
and the release of cytochrome c and inhibit apoptosis when E6/E7 is repressed in hypoxic HPV16-
positive cancer cells. As discussed in chapter 1.3.4, p53 itself can translocate to mitochondria to 
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trigger MOMP and cytochrome c release. Furthermore, Sansome et al. reported that hypoxia 
induces p53 translocation toward mitochondria [308]. Thus, rapid and strong degradation of p53 
by hypoxia (0-24 h) might serve as a protective strategy of the hypoxic HPV16-positive cancer 
cells to avoid the pro-apoptotic functions of p53 and to prevent mitochondrial functions of p53 
(induction of mitochondrial membrane permeabilization and cytochrome c release). 
Under conditions of sustained hypoxia, the up-regulation of BAX and PUMA by hypoxia-induced 
p53 may promote apoptosis, thus contributing to the selection of HPV16-positive cervical cancer 
cells resistant to apoptosis.  
 
It has previously been reported that hypoxic conditions contribute to the selection of cells with 
reduced apoptotic potential [51, 309]. Hoppe-Seyler et al. reported that hypoxia induced HPV-
positive cancer cells enter a dormant state [50]. Upon reoxygenation, the growth arrest of the 
HPV-positive cancer cells was overcome and cells resumed proliferation [50], suggesting that the 
hypoxic HPV-positive cancer cells were viable.  
Previous lab results (a FACS analysis using propidium iodide (PI) dye) obtained by Dr. Khalkar 
found that no G1 arrest of the HPV-positive cells was observed under hypoxia (24 h), indicating 
an inhibition of apoptosis. As mentioned in chapter 2.3.2.2, in this study, preliminary observations 
showed that under hypoxia (24 h), cleavage of PARP was not induced in HPV16-positive cancer 










These data suggest that apoptosis was not induced in hypoxic HPV16-positive cancer cells. The 
resistance to apoptosis of cervical cancer cells SiHa and CaSki under hypoxia might be due to pre-
accumulation of several mutations that favour cell proliferation/survival and inhibit apoptosis 
under stress conditions [51]. After prolonged hypoxia, some cancer cells facing a severe hypoxic 
condition with limited energy and nutrient supplies may however go into apoptosis. The selected 
Figure 3.9 | Cleavage of PARP in hypoxic 
HPV16-positive cancer cells. SiHa and 
CaSki cells were cultured for the 
indicated time periods at 1% O2. Total 
protein was extracted after respective 
time intervals. Western Blot analyses 
using antibodies against PARP, cleaved 
PARP (c-PARP) and p53 are shown. 
GAPDH served as a loading control. 
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hypoxic HPV16-positive cervical cancer cells resistant to stress conditions may serve as reservoirs 
for cancer recurrence upon reoxygenation. 
 
3.5.3 Cell cycle arrest and DNA repair 
 
Hypoxia is known to induce cell cycle arrest, drive genomic instability, and alter DNA damage 
repair pathways [210, 310-312]. The inhibition of growth is a cellular response to hypoxia induced 
via the induction of the cyclin-dependent kinase inhibitors p21 and p27 as well as via the 
de/hypo-phosphorylation of pRb [311]. Hypoxia-induced replication stress was shown to induce 
activation of ATM and ATR, the DNA damage response (DDR) apical kinases, and 
phosphorylation of downstream targets such as Chk1, Chk2, and p53, albeit in the absence of 
detectable DNA damage [298, 299, 313]. As described in chapter 3.2.1, the pace of cervical cancer 
cell growth was slowed down under hypoxia, with cell numbers reaching a plateau after 24 h 
(Figure 3.1) suggesting hypoxia caused a proliferative halt in HPV-positive cancer cells. 
 
In the analyses of expression of genes involved in cell cycle arrest and DNA repair, despite the 
depletion of p53 under hypoxia (24 h, Figure 2.2), GADD45A increased at 24 h of hypoxia (Figure 
2.15). After prolonged hypoxia, GADD45A was more increased in SiHa cells (Figure 2.15A), 
whereas it was decreased again in CaSki cells (Figure 2.15B).  
CDKN1A (p21) mRNA levels showed fluctuations in hypoxic SiHa cells (Figure 2.17A). In hypoxic 
CaSki cells, CDKN1A mRNA levels showed minor increases (Figure 2.17B). RNAi-mediated 
HPV16 E6/E7 repression under normoxia resulted in increased CDKN1A mRNA levels 
(approximately 3 fold) in both SiHa and CaSki cells (Figure 2.17). 
It is important to note that the transcriptions of GADD45A and CDKN1A are mediated by both 
p53-dependent and -independent mechanisms, a fact that can explain the divergent changes of 
GADD45A and CDKN1A mRNA levels in hypoxic HPV16-positive cancer cells. GADD45A is also 
transcriptionally regulated by ATF4 (activating transcription factor-4) [314]. ATF4 is a 
transcription factor translationally regulated by severe hypoxic stress [315, 316]. p21 has also been 
described to be induced by hypoxia in a p53-independent manner. Hypoxia causes a HIF-1α-
dependent increase in the expression of the cyclin-dependent kinase inhibitor p21 [317]. 
Moreover, several studies reported that cell cycle arrest under hypoxia occurred independently of 
p53 [210, 311]. Therefore, hypoxia and p53 may act synergistically to induce cell cycle arrest via 
regulation of GADD45 α and p21 during different time periods in HPV16-positive cancer cells. 
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As discussed in chapter 3.2.1, due to the limited energy and nutrient supplies under hypoxic 
conditions, induction of cell cycle arrest instead of proliferation might serve as a survival strategy 
of HPV16-positive cancer cells. 
 
It has been reported that exposure to hypoxia results in a rapid stop of DNA synthesis in the 
absence of DNA damage [318]. Sustained exposure to hypoxia induces DNA damage [319]. Acute 
or short-term hypoxia (0-24 h), however, may not cause DNA damage in HPV16-positive cancer 
cells. DNA damage and DNA repair may rather occur after prolonged hypoxia (72 h). As a DNA 
damage sensor, the regulation of XPC might occur dependent on the severity and the duration of 
hypoxia.  
Besides the induction of the DNA damage response (DDR) under hypoxic conditions, hypoxic cells 
can acquire a “mutator” phenotype (decreased DNA repair, an increased mutation rate and 
increased chromosomal instability) [310]. As observed in Figure 2.15, after prolonged hypoxia, the 
recovered XPC mRNA levels were no more than two fold as high compared to the 0 h values in 
HPV16-positive cancer cells. A decrease in DNA repair might contribute to the accumulation of 




In this study, HPV16 E6/E7 continuously decreased under hypoxia (Figures 2.2A and 2.2B) and 
p53 protein displayed a biphasic regulation and markedly increased after prolonged hypoxia 
(Figures 2.2C and 2.2D). Hypoxic HPV16-positive cancer cells did not stain positive for the 
senescence marker SA-β-Gal despite efficient E6/E7 repression and p53 reconstitution. Neither at 
24 h of hypoxia nor after prolonged hypoxia (72 h) was senescence induced (Figure 2.10). 
 
Activation of the p53 signaling pathway is a classical cellular response leading to cellular 
senescence when exposure to stresses occurs. Senescent cells are characterized by increased 
expression of certain p53 targets, such as p21, PML, PAI-1, and YPEL3, all of which are 
recognized as senescence markers, and in turn are able to induce senescence themselves [244-249]. 
Here, unlike the increases in transcript levels under RNAi-mediated E6/E7 repression under 
normoxia, the downstream target genes of p53 (PML, YPEL3, and CDKN1A) associated with p53-
dependent senescence were not stably expressed during hypoxia (decreased or fluctuated, Figures 




De Stanchina et al. showed that loss of PML reduces the propensity of cells to undergo apoptosis 
or senescence in response to the activation of p53 signaling, in spite of the induction of several 
downstream target genes of p53 [238]. Moreover, Purvis et al. proposed that in addition to the 
amplitude of p53 signaling, PTMs of p53 and cofactors binding to p53, the dynamics of p53 protein 
can be a critical part of p53 signaling, directly affecting the course of downstream pathway 
programs and influencing cell fate decisions [320]. Cells exposed to sustained p53 signaling 
frequently undergo senescence, whereas cells that experience oscillating p53 dynamics recover 
from stress. Sustained increases in expression of p53 downstream target genes (PML, YPEL3, and 
CDKN1A) are required for cellular senescence [320]. The biphasic regulation of p53 protein 
resulting in fluctuations of the expression of p53 downstream target genes (PML, YPEL3, and 
CDKN1A) may contribute to an evasion of senescence. The sustained stable expression of PML, 
YPEL3, and CDKN1A under RNAi-mediated E6/E7 repression under normoxia might be able to 
induce senescence in HPV16-positive cancer cells. 
 
3.5.5 Autophagy and metabolism 
 
Depending on the nature and extent of the inducing stress, the p53 tumor suppressor may regulate 
the same process differently to attain distinct cellular outcomes [114, 115, 209, 321]. As described 
in chapter 1.3.3 and 1.3.4, many studies indicate the different role for p53 in regulation of 
autophagy. p53 can positively regulate autophagy and can also inhibit it [115, 142, 206, 322]. The 
role of autophagy depends on the cell type and the nature of the stress. 
 
3.5.5.1 Role of p53 depletion (at 0-24 h of hypoxia) for the induction of autophagy and 
metabolic switch  
 
In this study, obvious evidence suggested that autophagy was induced in hypoxic HPV16-positive 
cancer cells, including the induction of BNIP3 (Figure 2.18), which is critical for mitophagy (see 
chapter 1.2.3.1), the increase of LC3-II and the reduction of p62 (Figure 2.19). As already 
mentioned in chapter 2.4.1, LC3 and p62 were post-translationally regulated by hypoxia (Figure 
3.10). The different tendency of LC3-II in hypoxic SiHa (Figure 2.19A) and CaSki cells (Figure 
2.19B) may be due to the different conversion rate of LC3-I to LC3-II and the different 






Figure 3.10 | Transcript levels of autophagy-related genes in hypoxic SiHa cells. HPV16-positive SiHa cells 
were cultured for the indicated time periods at 1% O2. Total RNA was extracted after respective time 
intervals. qPCR analyses of LC3A, LC3B, and p62 transcripts are shown. Transcript levels of VEGF were 
monitored as marker for hypoxia. 18S rRNA served as internal control for normalization. Error bars indicate 
the SD of duplicate wells from one experiment. The 0 h value of gene expression was set as a control (set to 
1.0). 
 
In this study, LC3-II and p62 decreased after the reduction of p53 in hypoxic HPV16-positive cells 
(0-24 h under hypoxia, Figure 2.19). Tasdemir et al. showed that depletion of p53 activates 
autophagy in several cell lines, in response to distinct stimuli [206]. Here, overexpression of p53 
prevented hypoxia-induced autophagy in HPV16-positive cancer cells (Figures 2.20 and 3.13). 
Thus, the degradation of p53 by hypoxia (0-24 h) might be a strategy of HPV16-positive cancer 
cells to remove the brake of autophagy, contributing to the survival under energy-limited hypoxic 
conditions. 
 
As described in chapter 1.2.3.1, hypoxia usually causes dysfunction and reorganization of 
mitochondria [97] and induces mitophagy [106, 139, 140]. The MTT assay is a colorimetric assay 
widely used for measuring cell metabolic activity [324]. It is primarily based on the ability of 
mitochondrial reductase to reduce the water-soluble yellow tetrazolium dye MTT to generate 
water-insoluble purple-coloured formazan crystals [325, 326] (Figure 3.11A). The conversion of 
MTT to formazan depends on the metabolic rate and number of functional mitochondria. 
Preliminary results of MTT assay showed that the generation of formazan was decreased in 
hypoxic SiHa cells (Figure 3.11B), negatively correlated with the cell numbers (Figure 3.1B). One 
could speculate that the functional mitochondria and metabolic activity were decreased in 





Figure 3.11 | MTT assay in HPV16-positive SiHa cells under normoxia and hypoxia. (A) Mitochondrial 
reduction of MTT to blue formazan product. [Picture from https://en.wikipedia.org/wiki/MTT_assay 
(edition of 18.10.2019)] (B) SiHa cells were cultured for the indicated time at 21% O2 or at 1% O2. MTT 
assay was performed after respective time intervals. Scheme left: Treatment protocol. 
 
BNIP3 plays a critical role in the induction of mitophagy via several distinct mechanisms, 
promoting turnover of mitochondria and preventing accumulation of dysfunctional mitochondria, 
which can lead to oxidative stress and cellular degeneration. Increased expression of BNIP3 under 
hypoxia is mainly regulated by the transcription factor HIF-1α [141, 327, 328]. p53 can inhibit the 
activity of HIF-1 due to competition for co-activators [329-331]. p53 can directly suppress the 
expression of BNIP3 [142]. Rapid depletion of p53 under hypoxia (0-24 h) might therefore be a 
strategy of HPV16-positive cancer cells to remove the competitor of HIF-1 to release the 
expression of HIF-1 target genes, such as BNIP3, that promote cellular adaptation to hypoxic 
conditions. 
 
As described in chapter 1.2.2 and 3.3, glycolysis is an important altered metabolism for hypoxic 
cancer cells. TIGAR, induced by p53, can lower fructose-2,6-bisphosphate level to inhibit 
glycolysis [199]. Decrease of TIGAR by hypoxia through p53 depletion (0-24 h, Figure 2.18) may 




3.5.5.2 Role of restored p53 after prolonged hypoxia for the maintenance of cellular 
homeostasis and selection of cell resistant to stress conditions 
 
The preliminary results in Figure 3.12 show that after prolonged hypoxia (72 h), both p62 and 
LC3-II were decreased in SiHa cells. Upon treatment with autophagy inhibitor CQ, hypoxic 
reduction of p62 and LC3-II were blocked. As depicted in Figure 2.18, the transcription of BNIP3 
remained induced after prolonged hypoxia (72 h) in HPV16-positive cancer cells. This suggests 











As discussed in chapter 1.2.3, for tumor cells autophagy is in itself a double-edged sword on cell 
fates [108, 109]. Scherz-Shouval et al. reported that p53 confers increased survival in the face of 
chronic starvation in many cell types. p53 increases cell fitness by maintaining better autophagic 
homeostasis, adjusting the rate of autophagy to changing circumstances by post-transcriptionally 
down-regulating LC3. Loss of p53 in chronically starved cancer cells impairs autophagic flux and 
causes excessive LC3 accumulation and aberrant autophagosome accumulation, culminating in 
apoptosis [209]. This implies that a proper autophagic flux is critical for cell survival.  
 
HPV16-positive cancer cells may face a severe condition to survive after prolonged hypoxia. Cells 
undergoing an extreme amount of stress experience cell death either through necrosis or through 
apoptosis. Prolonged activation of autophagy leads to a high turnover rate of proteins and 
organelles. A rate above the survival threshold will kill cancer cells [116, 117]. Continued loss of 
p53 after prolonged hypoxia might lead to an excessive autophagic flux. Recovery of p53 would 
enable reduced, yet sustainable/affordable autophagic flux. Restoration of p53 could be another 
strategy of HPV16-positive cancer cells to increase cell fitness and enhance cell survival by 
Figure 3.12 | Effect of autophagy inhibitor 
chloroquine (CQ) on hypoxic reduction of p53, p62 
and LC3-II in HPV16-positive SiHa cells. SiHa cells 
were cultivated for 24 h or 72 h under normoxia or 
hypoxia in either the absence (-) or the presence (+) 
of 50 μM chloroquine (CQ). Shown are 
immunoblots of p53, p62, and LC3-I protein levels. 
GAPDH served as a loading control.  
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maintaining better autophagic homeostasis, adjusting the rate of autophagy to changing 
circumstances under prolonged hypoxia.  
Given the role of TIGAR for inhibiting autophagy and protecting cells from oxidative stress, the 
recovery of TIGAR after prolonged hypoxia in HPV16-positive cancer cells (Figure 2.18) might 
help to limit the autophagic flux and reduce the production of ROS, which can be increased in 
cells after prolonged hypoxia [332]. 
 
As depicted in Figure 2.18, the transcript levels of DRAM1 were not strongly induced at the early 
stage of hypoxia (0-24 h) but increased after prolonged hypoxia (at 48 and 72 h) (Figure 2.18). The 
increased DRAM1 mRNA levels at 24 h of hypoxia in SiHa cells when p53 was depleted raises the 
possibility that DRAM1 is regulated by other factors, such as p73 [333], in hypoxic SiHa cells. 
Although DRAM is essential for p53-induced autophagy, this type of autophagy results in cell 
death (apoptosis) [253]. Repression of DRAM1 at the early stage of hypoxia (0-24 h) may avoid cell 
death in HPV16-positive cancer cells. Its recovery after prolonged hypoxia along with the 
induction of BAX and PUMA (Figure 2.14, discussed in chapter 3.5.2) may contribute to the 
selection of cells resistant to cell death. 
 
To summarize, under energy- and nutrient-limited hypoxic conditions, hypoxia and p53 act 
synergistically to induce cell cycle arrest via regulation of genes like GADD45A and CDKN1A 
leading to a temporary halt of proliferation in HPV16-positive cancer cells. The biphasic 
regulation of p53 might serve as a survival and protective strategy of hypoxic HPV16-positive 
cancer cells under stress conditions. Under hypoxia (0-24 h), rapid degradation of p53 helps to 
avoid the pro-apoptotic and pro-senescent functions of p53 and facilitate the induction of 
autophagy and the metabolic switch to glycolysis. After prolonged hypoxia, the restored p53 
might be used to maintain cellular homeostasis and select cells resistant to stress conditions. The 
biphasic modulation on p53 downstream target genes that coincide with p53 protein dynamics 
may contribute to enhance cellular adaptation and protect cells from committing to an irreversible 
fate. 
 
3.6 The evasion of hypoxic HPV16-positive cancer cells from senescence is attributable to 
the induction of autophagy 
 
3.6.1 p53 overexpression inhibits hypoxia-induced autophagy 
 
It has previously been shown that inhibition of p53 degradation prevented the induction of 
autophagy [206, 209]. Here, overexpression of p53 indeed diminished hypoxia-induced autophagy 
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in HPV16-positive cancer cells, as shown by the increased amounts of p62 under hypoxic 




Figure 3.13 | Effect of overexpression of p53 protein on p62. CaSki cells were transfected with an empty 
vector control (control) or wild-type (wt) p53. 48 h post transfection, the cells were cultured for the 
indicated time periods at 1% O2. Total protein was extracted after the respective time intervals. Western 
Blot analyses using antibodies against p53 and p62. GAPDH served as a loading control. 
 
However, the exact mechanism of inhibition of hypoxia-induced autophagy upon overexpression 
of p53 in hypoxic HPV16-positive cancer cells is not determined yet. 
Autophagy is a highly regulated process in eukaryotic cells, controlled by several kinases including 
AMPK, which induces autophagy [334], and mTOR, which suppresses autophagy [292]. Tasdemir 
et al. showed that depletion of p53 resulted in AMPK activation and mTOR inhibition in cells. 
Inhibition of autophagy by p53 was accompanied by reduced activation of AMPK, as well as 
increased activation of mTOR, underscoring the impact of p53 on the AMPK/mTOR axis [206].  
AMP-activated protein kinase (AMPK) is a sensor of cellular energy levels and plays a key role in 
the regulation of energy homeostasis [335]. The kinase is activated by an elevated AMP/ATP ratio 
due to cellular and environmental stress, such as heat shock, hypoxia, and ischemia [335]. 
Preliminary results showed that the cellular ATP levels were decreased under hypoxia in SiHa 
cells (Figure 3.1), suggesting the supply of energy was limited in hypoxic SiHa cells. Demonstrated 
by Hoppe-Seyler et al., mTOR signaling is impaired under hypoxia in HPV-positive cancer cells 
[50]. These data suggest that the AMPK/mTOR axis may be involved in the hypoxia-induced 
autophagy in HPV16-positive cancer cells. It would be interesting to investigate whether 
inhibition of autophagy by p53 overexpression requires the AMPK/mTOR axis. 
p53 can also suppress BNIP3 expression to inhibit hypoxia-induced autophagy [142]. 




Scherz-Shouval et al. described that p53 reduces autophagic flux by post-transcriptionally down-
regulating LC3 [209]. Overexpression of p53 may block the decrease of p62 by influencing the 
autophagic flux in hypoxic HPV16-positive cancer cells. 
 
3.6.2 Inhibition of autophagy induces senescence  
 
Increasing evidence implies that chemotherapeutic agents exert their anticancer effects not only 
through apoptosis but also by senescence induction in tumor cells [336, 337]. Here, an autophagy 
inhibitor could be a potent agent to restore senescence induction in HPV16-positive cancer cells 
(Figures 2.21 and 3.14). Although the hypoxic HPV16-positive cancer cells treated with CQ did 
not stain strongly positive for SA-β-Gal, these cells showed the typical morphology of senescent 
cells (for example cell enlargement, flattening). Moreover, hypoxic HPV16-positive cancer cells of 
the control group resumed growth upon reoxygenation (replated in fresh media containing no 
drug, subsequently cultured under 21% O2), whereas the hypoxic cancer cells subjected to 
autophagy inhibitor CQ treatment did not grow after reoxygenation (under the same protocol as 
the control group) (Figures 2.21 and 3.14). These results indicate that inhibition of autophagy 




Figure 3.14 | Analyses of cellular senescence upon treatment with autophagy inhibitor CQ in HPV16-
positive cancer cells. CaSki cells were cultivated for 48 h under normoxia (21% O2) or hypoxia (1% O2), in 
either the absence (top) or the presence (bottom) of 50 μM chloroquine (CQ). Cells for senescence assays 





Treatment with CQ in normoxic SiHa cells led to the emergence of cells staining positive for SA-
β-Gal (Figure 2.21) and caused a proliferative halt in CaSki cells (Figure 3.14). This might be due 
to the inhibition of autophagy and an unexpected repressive effect of CQ on HPV16 E6/E7 
oncogenes (Figure 2.8), which is required for maintaining growth [32].  
SA-β-gal is a commonly used biomarker for cellular senescence, which can be detected at pH 6.0 
[237]. This is due to a high level of lysosomal β-galactosidase (β-gal) expressed in senescent cells 
[338-340]. Overexpression of lysosomal β-gal itself is unable to induce senescence [338]. The SA-β-
gal staining may be sensitive to the quality of lysosomes [339]. Chloroquine is a lysosomotropic 
agent, accumulating in the lysosomes and raising their pH [341]. Thus, chloroquine could interfere 
to some extent with the SA-β-Gal staining assay [339].  
 
Another autophagy inhibitor, Bafilomycin A1, was also used to investigate the effect of inhibition 
of autophagy on senescence in HPV16-positive cancer cells. Treatment with Bafilomycin A1 
strongly decreased viability of HPV16-positive cancer cells, with few attached cells when 
senescence assays were performed (Figure 3.15). Bafilomycin A1 is known as an inhibitor of 
Vacuolar-type H+-ATPase (V-ATPase), preventing maturation of autophagic vacuoles by 
inhibiting fusion between autophagosomes and lysosomes [227]. It also functions as a potassium 
ionophore and inhibits mitochondrial respiration [342]. Nanomolar concentrations of Bafilomycin 
A1 cause mitochondrial swelling, loss of mitochondrial membrane potential, as well as induction 
of pyridine nucleotide oxidation. These observations could explain why treatment with 
Bafilomycin A1 dramatically reduced the viability of HPV16-positive cancer cells. 
 
Figure 3.15 | Analyses of cellular senescence upon treatment with Bafilomycin A1 in HPV16-positive cancer 
cells. SiHa and CaSki cells were cultivated for 48 h under normoxia (21% O2) or hypoxia (1% O2), in either 
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the absence (top) or the presence (bottom) of 0.5 μM Bafilomycin A1 (Baf A1). Cells for senescence assays 
(SA-β-Gal staining) subsequently cultured under normoxia. Scale bar: 300 μm. Scheme left: Treatment 
protocol. 
 
Failure of autophagy causes loss of proteostasis, accumulation of dysfunctional mitochondria and 
oxidative stress, resulting in entry into cellular senescence [268]. As discussed in chapter 3.5.5, 
hypoxia-induced autophagy might help to maintain a better cellular homeostasis, clear 
dysfunctional mitochondria in time, and reduce the production of ROS in cells. Inhibition of 
autophagy may prevent utilization of autophagy by hypoxic HPV16-positive cancer cells for 
survival. Thus, the hypoxic HPV16-positive cancer cells treated with autophagy inhibitor cannot 
recover and eventually enter senescence upon reoxygenation. Targeted perturbation of autophagy 
may enable novel pharmacological strategies for preventing cancer recurrence in poorly 
oxygenated regions of HPV-positive tumors. 
 
3.7 Conclusion and perspectives 
 
The p53 tumor suppressor is mutated in a high percentage of tumors. However, many other 
tumors retain expression of wild-type p53, raising the intriguing possibility that they actually 
benefit from it. This PhD thesis, for the first time, reveals a new regulation pattern of p53 by 
hypoxia, a characteristic microenvironment of HPV-positive cervical cancer cells which can 
increase their resistance to radiation therapy and other cancer treatments and is a negative 
prognostic marker in patients [49, 58, 61, 99, 343-345]. Hypoxic HPV16-positive cervical cancer 
cells use the p53 protein by dynamic regulation to reap an advantage to survive stressful 
conditions. 
The dynamics of p53 protein are a critical part of p53 signaling, along with the amplitude of p53 
regulation, directly affecting the course of downstream pathway programs and influencing cell 
fate decisions [320]. Although the effect of hypoxia on p53 tumor suppressor in HPV-positive 
cancer cells has been studied for decades, the dynamics of p53 during different periods of hypoxic 
conditions in cervical cancer cells is still not well explored. The hypoxic HPV-positive cancer cells 
are described entering a dormant state, characterized by an evasion of cellular senescence [50] and 
resistance to cell death [51], the role of p53 for these cellular outcomes and cellular adaptation 
under hypoxic conditions remains elusive. Herein, the dynamics of p53 and the mechanism 
underlying it under hypoxia were explored in HPV16-positive cervical cancer cells. The effect of 
p53 dynamics on downstream responses (target gene expression and cellular outcomes) in hypoxic 
HPV16-positive cervical cancer cells was investigated.  
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Using standard O2 concentration (1%) and serial duration of hypoxic conditions, a biphasic 
regulation of p53 protein in hypoxic HPV16-positive cervical cancer cells was identified. Despite a 
continuous repression of HPV16 E6/E7 oncogenes, p53 protein was rapidly and strongly depleted 
via a lysosome-dependent mechanism under hypoxia, whereas after prolonged hypoxia, it was 
markedly restored in HPV16-positive cervical cancer cells. According to the results provided here, 
the following model can be hypothesized (Figure 3.16). The biphasic regulation of p53 contributes 
to enhance cellular adaptation, along with its downstream target genes and protect hypoxic 
HPV16-positive cervical cancer cells from committing to an irreversible fate. The downstream 
response autophagy is critical for the evasion of senescence by hypoxic HPV16-positive cancer 
cells. Considering the high resistance of hypoxic tumor cells to therapy, the present findings 
provide a basis for future studies addressing the development of new treatment strategies. 
First, the ability of hypoxic HPV-positive cancer cells to induce a temporary halt of proliferation, 
reversibly repressing viral oncogenes expression without entering senescence, should be 
considered in the current development of therapeutic strategies, such as targeted E6/E7 inhibition 
or immunotherapy. Second, since the reduction of p53 protein is mediated via a lysosome-
dependent mechanism, the currently used pharmacological inhibitors, such as Nutlin-3, that are 
dependent on the proteasomal degradation pathway, will be insufficient to increase p53 levels. 
The development and usage of anticancer agents targeting p53 should depend on the cell type and 
the mechanism involved in p53 degradation. Third, the maintenance of cellular homeostasis is 
required for the resistance of HPV16-positive cervical cancer cells to hypoxia. In this regard, the 
anticancer drugs targeting metabolism, such as glycolytic inhibitors could be efficient to overcome 
the hypoxia-induced resistance. In the future, pharmacological strategies such as combination of 
E6/E7 inhibitors, HIF-target drugs and p53 agonists or glycolytic inhibitors could be used to 








Figure 3.16 | Schematic overview of the biphasic regulation of p53 and its effect on downstream responses 
and cellular outcomes in hypoxic HPV16-positive cancer cells. Under hypoxic conditions, HPV16 E6/E7 
oncogenes were continuously repressed, whereas p53 protein showed a biphasic regulation in HPV16-
positive cancer cells. p53 and hypoxia (such as induction of HIF-1) may act synergistically to induce a 
temporary cell cycle arrest and to facilitate the metabolic switch to glycolysis. (Left) At the early stage of 
hypoxia (0-24 h), p53 was predominantly degraded via a lysosome-dependent mechanism. Rapid and strong 
degradation of p53 by hypoxia could avoid the pro-apoptotic or pro-senescent functions of p53 and remove 
the brake of autophagy, which can be utilized by cancer cells for survival under energy and nutrient-limited 
conditions. (Right) After prolonged hypoxia (72 h), with diminished inhibitory factors and increase in PTMs 
for protein stabilization, p53 was stably synthesized and transported into the nucleus. Restored p53 might be 
used by HPV16-positive cancer cells to maintain cellular homeostasis, such as sustainable autophagic flux, 
and to select cells resistant to stress conditions. The biphasic modulation on p53 downstream target genes 
that coincide with p53 protein dynamics may contribute to enhance cellular adaptation and protect cells 
from committing to an irreversible fate. Targeted perturbation of p53 dynamics or autophagy may enable 







4.1 Chemicals and Reagents 
 
2-mercaptoethanol Carl Roth GmbH, Karlsruhe 
2-Propanol Merck Calbiochem, Darmstadt 
6X DNA Loading Dye Fermentas, St. Leon-Rot 
Acetic acid  Merck Calbiochem, Darmstadt 
Acrylamide-Bis (29:1), 30% solution Serva Feinbiochemica, Heidelberg 
Agarose Sigma-Aldrich, Steinheim 
Ammonium acetate Merck Calbiochem, Darmstadt 
Ammonium persulfate Sigma-Aldrich, Steinheim 
Aqua ad iniectabilia  Braun, Melsungen 
Bovine serum albumin fraction V (BSA) Biomol, Hamburg 
Bradford-Reagent (Bio-rad Protein assay) Bio-Rad Laboratories, Munich 
Bromophenol blue Serva Feinbiochemica, Heidelberg 
Complete Protease Inhibitor Cocktail Roche, Mannheim 
Diethylpyrocarbonate (DEPC) Sigma-Aldrich, Munich 
Dithiothreitol (DTT) Sigma-Aldrich, Munich 
DMSO Carl Roth GmbH, Karlsruhe 
dNTPs Set PCR Grade Invitrogen, Karlsruhe 
EDTA  Carl Roth GmbH, Karlsruhe 
EGTA Sigma-Aldrich, Steinheim 
Enhanced Chemiluminescence Substrate (ECL)  PerkinElmer, USA 
Ethanol, absolute  Merck Calbiochem, Darmstadt 
Ethidium bromide, 1% solution  Fluka, Steinheim 
Glycerol  AppliChem, Darmstadt 
Glycine  Gerbu, Gaibach 
HEPES  Carl Roth GmbH, Karlsruhe 
Hydrochloric acid (HCl) 37% Sigma-Aldrich, Munich 
KCl  Merck Calbiochem, Darmstadt 
KH2PO4  Carl Roth GmbH, Karlsruhe 
Methanol  Sigma-Aldrich, Munich 
MgCl2 Merck Calbiochem, Darmstadt 
MgSO4 Serva Feinbiochemica, Heidelberg 
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Milk powder Carl Roth GmbH, Karlsruhe 
MTT Sigma-Aldrich, Munich 
Na2HPO4 Carl Roth GmbH, Karlsruhe 
NaCl Sigma-Aldrich, Steinheim 
NaF Merck Calbiochem, Darmstadt 
NaOH Carl Roth GmbH, Karlsruhe 
Na3VO4 (Sodium ortho-vanadate) Sigma-Aldrich, Deisenhofen 
Nonidet®  P-40 Sigma-Aldrich, Steinheim 
PIPES Sigma-Aldrich, Munich 
Protease Inhibitor Cocktail Complete, EDTA-free Roche, Mannheim 
RiboLock RNase inhibitor Thermo Scientific, St. Leon-Rot 
Sodium acetate (NaAc) Merck Calbiochem, Darmstadt 
Sodium dodecyl sulfate (SDS), ultra pure Carl Roth GmbH, Karlsruhe 
Sodium deoxycholate Merck Calbiochem, Darmstadt 
Sucrose Sigma-Aldrich, Munich 
TEMED Sigma-Aldrich, Steinheim 
Triton®  X-100 Serva Feinbiochemica, Heidelberg 
Trizma base (Tris) AppliChem, Darmstadt 
Tween®  20 Gerbu, Gaibach 
 
4.2 Reagents for the Cultivation of Bacteria 
 
BactoTM Agar  Becton Dickinson, Heidelberg 
BactoTM Trypton Carl Roth GmbH, Karlsruhe 
Yeast extract GERBU, Wieblingen 
Kanamycin BIOTREND Chemikalien, Cologne 
LB Medium  Carl Roth GmbH, Karlsruhe 
 
4.3 Reagents for Cell Culture and Treatment of Human Cells 
 
0.25% Trypsin/EDTA Invitrogen, Karlsruhe 
Bafilomycin A1 Thermo Scientific, St. Leon-Rot 
Chloroquine Sigma-Aldrich, Steinheim 
Cycloheximide Sigma-Aldrich, Steinheim 




Dulbecco’s Modified Eagle’s (HIGH glucose) Medium 
(Glucose: 4.5 g/L) 
Sigma-Aldrich, Steinheim 
Dulbecco’s Modified Eagle’s (NO glucose) Medium 
(Glucose: 0 g/L) 
Gibco/ Life Technologies, Karlsruhe 
Dulbecco’s Phosphate Buffered Saline (PBS) Invitrogen, Karlsruhe 
Fetal calf serum (FCS)  Invitrogen, Karlsruhe 
InSolution MG132 Merck Calbiochem, Darmstadt 
Lipofectamine 2000 Transfection Reagent  Invitrogen, Karlsruhe 
Opti-MEM serum-free medium  Invitrogen, Karlsruhe 
RPMI 1640 medium (Glucose: 2 g/L) Sigma-Aldrich, Steinheim 
Trypan blue  Biochrom, Berlin 




Cell culture flasks (6, 10, 14 cm) TPP, Trasadingen, Switzerland 
Cell culture flasks (25, 75, 175 cm2) Greiner, Frickenhausen 
Cell culture plates (6-well) BD Falcon, Heidelberg 
Cell culture plates (24-well, 96-well) Greiner, Frickenhausen 
Cell scraper Corning Sigma, Munich 
Gloves (Blossom®  Medical Examination gloves) Mexpo International Inc., Union City, 
USA 
Gloves (Dermatril® ) KCL GmbH, Eichenzell 
Needles, sterile, 20G Needles, sterile, 20G 
Nunc®  Cryo Tubes  Sigma-Aldrich, Steinheim 
PCR SingleCap 8er Soft Strips Biozym 
Pipette Tips  Greiner Frickenhausen 
Pipette Tips RAININ LTS (20, 200, 1000 μL)  Mettler-Toledo GmbH, Gießen 
Pipette Tips RAININ LTS sterile with filter (20, 200, 1000 
μL) 
Mettler-Toledo GmbH, Gießen 
Polypropylene Tubes 12 mL  BD Falcon, Heidelberg 
PVDF membranes Immobilon P (0.2 and 0.45 μm)  Milipore, Schwalbach 
Reaction Tubes 0.5 mL blue  Biozym 
Reaction Tubes (0.5, 1.5 and 2.0 mL)  Eppendorf, Hamurg 
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Reaction Tubes (15 and 50 mL)  Greiner, Frickenhausen 
Saran wrap Toppits, Minden 
Scalpels, disposable  Feather Safety Razor, Osaka, Japan 
Syringes, single use 1 mL  Th. Geyer GmbH, Renningen 
TipOne sterile pipette filter tips  Starlab, Ahrensburg 
Whatman 3 MM filter paper  GE Healthcare, Munich 
X-ray films Super RX  Fuji, Japan 
 
4.5 Laboratory equipment 
 
Analytical scales AE 160  Mettler-Toledo GmbH, Gießen 
Autoradiography cassettes  Kodak, Stuttgart 
Bacterial shaker G25  Infors, Bottmingen, CH 
Bio-Trap electrophoresis chamber Renner, Dannstadt 
Centrifuge 5415R  Eppendorf, Hamburg 
Centrifuge 5417R  Eppendorf, Hamburg 
Centrifuge Biofuge pico  Heraeus, Hanau 
Centrifuge Biofuge, Varifuge RF Heraeus, Hanau 
Centrifuge Heraeus Minifuge RF  Heraeus, Hanau 
Centrifuge Megafuge 1.0R  Heraeus, Hanau 
CFX96 Real-Time PCR Detection System Bio-Rad Laboratories, Munich 
Countess®  II FL Automated Cell Counter Life Technologies 
Developing machine CURIX 60  AGFA, Cologne 
EVOS XL Core Cell Imaging System Life Technologies, Calsbad, CA, USA 
Freezer profi line  Liebherr, Ludwigshafen 
Freezer VIPTM Series -86°C  Sanyo, USA 
Fridge Premium  Liebherr, Ludwigshafen 
Gel documentation system GELSTICK  INTAS Science Imaging Instruments 
GmbH, Göttingen 
Incubator C16 Labotect, Göttingen 
Incubator Kelvitron®   Heraeus, Hanau 
InvivO2 400 physiological oxygen workstation Ruskinn Technology Ltd, Bridgend, 
UK 
Liquid nitrogen tank CHRONOS Biosafe  Messer, Griesheim 
Magnetic stirrer MR3000  Heidolph, Rust 
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Microscope CKX41  Olympus, Hamburg 
Microscope Leitz DM RBE Leica, Bensheim 
Microwave  DéLonghi GmbH, Seligenstadt 
Mini PROTEAN®  Tetra-Cell  Bio-Rad, Munich 
Mini-PROTEAN®  3 Cell  Bio-Rad, Munich 
Multichannel Pipettes (20-50 μL, 50-200 μL)  Eppendorf, Hamburg 
Neubauer hemocytometer  Bender&Hobein, Bruchsal 
Overhead shaker REAX2  Heidolph, Rust 
Peltier Thermal Cycler PTC-200  MJ Research, St. Bruno, Canada 
pH-meter 761 Calimatic  Knick, Berlin 
Pipette Boy Acu  Integra Biosciences GmbH, Fernwald 
Pipettes RAININ (2, 10, 20, 100, 200, 1000 μL)  Mettler-Toledo GmbH, Gießen 
Plate Reader Labsystems Multiskan MS  Thermo Scientific, St. Leon-Rot 
Plate reader Synergy 2  BioTek® , Bad Friedrichshall 
Polymax 2040 Heidolph, Schwabach 
Power supply PHERO-stab 500 Biotech-Fischer, Reiskirchen 
Power supply PowerPacTM HC/basic  Bio-Rad, Munich 
Rotating wheel  Neolab, Heidelberg 
Scales BL610  Sartorius, Göttingen 
Semi-dry Transfer unit Hoefer®  Semi-PhorTM  Pharmacia Biotech, Uppsala, Sweden 
Sonifier 250 Branson/Heinemann, Schwäbisch 
Gmünd 
Spectrophotometer NanoDrop®  ND-1000  NanoDrop, USA 
STERI-CULT 200 Incubator  Forma Scientifc, Marietta, USA 
SterilGARD Hood  Baker Company, Sanford, USA 
Thermal Cycler C1000TM  Bio-Rad, Munich 
Thermomixer compact/pico  Eppendorf, Hamburg 
UV table N90  Benda Konrad, Wiesloch 
Vacuum pump VACUSIP  Integra Biosciences GmbH, Fernwald 
Vortexer  Heidolph, Rust 






4.6 Buffers and Solutions 
 
4.6.1 Preparation of cell lysates 
CSKI buffer (pH 6.8) 10 mM PIPES 
100 mM NaCl 
1 mM EDTA 
300 mM Sucrose 
1 mM MgCl2  
0.5% Triton®  X-100 
Store in aliquots at −20°C 
Freshly supplemented with protease and 
phosphatase inhibitors 
Protease and phosphatase inhibitors Complete Protease Inhibitor Cocktail (Roche), 
Store at 4°C 
0.1 M DTT stock solution, Store at -20°C 
20 mM MG132 stock solution (in DMSO), Store 
at -80°C 
500 mM NaF, Store at -20°C 
10 mM Na3VO4, Store at -20°C 
Buffer A 10 mM HEPES pH 7.9 
10 mM KCl 
0.1 mM EDTA pH 8.0 
0.1 mM EGTA pH 7.9 
Store at -20°C 
Freshly supplemented with protease and 
phosphatase inhibitors 
Buffer C 25% (v/v) glycerol 99.5% 
20 mM HEPES pH 7.5 
400 mM NaCl 
1 mM EDTA pH 7.9 
Store at -20°C  
Freshly supplemented with protease and 
phosphatase inhibitors 
 
4.6.2 Western Blot 
Ammonium persulfate (APS) 10% (w/v) 
Anode Buffer I 0.3 M Tris 
10% Methanol 
pH 10.4 
Anode Buffer II 25 mM Tris 
10% Methanol 
Cathode Buffer 25 mM Tris 
40 mM Glycine 
10% Methanol 
pH 9.4 
SDS Loading Dye (5X) 10% (w/v) SDS 
0.03% (w/v) bromophenol blue 
12.5% (v/v) 2-mercaptoethanol 
5 mM EDTA, pH 8.0 
50% (v/v) glycerol 
0.3 M Tris, pH 6.8 
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SDS Running Buffer (10X) 1% SDS 
0.25 M Tris 
1.9 M Glycine 
TBS (10X) 0.5 M Tris  
1.5 M NaCl  
pH 7.5 
TBST (1X) 1X TBS, pH 7.5 
0.1% (v/v) Tween 20 
Blocking Buffer (Western Blot) TBST 
5% (w/v) Milk powder 
Store at 4°C 
 
4.6.3 Agarose gel electrophoresis 
DEPC water 0.1%(v/v) DEPC 
TAE (50X) pH 7.8 2 M Tris Base 
250 mM NaAc 
50 mM EDTA pH 8.0 
adjust to pH 7.8 with acetic acid 
 
4.6.4 Senescence Assay 
Senescence assay fixation buffer 2% formaldehyde 
0.2% glutaraldehyde 
in PBS 
Senescence assay staining buffer (pH 6.0) 40 mM citric acid 
150 mM NaCl 
2 mM MgCl2 
adjusted to pH 6.0 with Na2HPO4 
5 mM K3[Fe(CN)6]* 
5 mM K4[Fe(CN)6]* 
1 mg/mL X-Gal in DMF* 
*freshly added 
chromogenic substrate X-Gal 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside 
** All reagents were generously provided by Felix Hoppe-Seyler, DKFZ Heidelberg. 
 
4.7 DNA and protein size markers 
 
GeneRulerTM DNA Ladder Mix Thermo Scientific, St. Leon-Rot 
PageRulerTM Prestained Protein Ladder Thermo Scientific, St. Leon-Rot 
 
4.8 Universal enzymes 
 
RevertAid Reverse Transcriptase Thermo Scientific, St. Leon-Rot 
Dream TaqTM Green PCR Master Mix (2X) Thermo Scientific, St. Leon-Rot 






CellTiter-Glo®  Luminescent Cell Viability Assay Promega, Mannheim 
MiniPrep Kit Qiagen, Hilden 
RNase-Free DNase Set Qiagen, Hilden 




4.10.1 Oligonucleotides for polymerase chain reactions 
Table 4.1 | Oligonucleotides (primer) for quantitative real-time polymerase chain reactions (qPCR). 
Primer Name Sequence 5’ → 3’ amplicon length (bp) 
18S rRNA fw CATGGCCGTTCTTAGTTGGT 
66 
18S rRNA rev ATGCCAGAGTCTCGTTCGTT 
Apaf1 fw AAGGTGGAGTACCACAGAGG 
116 
Apaf1 rev TCCATGTATGGTGACCCATCC 
Bax fw CCCGAGAGGTCTTTTTCCGAG 
155 
Bax rev CCAGCCCATGATGGTTCTGAT 
BNIP3 fw CAGGGCTCCTGGGTAGAACT 
131 
BNIP3 rev CTACTCCGTCCAGACTCATGC 
CDKN1A (p21) fw TGTCCGTCAGAACCCATGC 
139 
CDKN1A (p21) rev AAAGTCGAAGTTCCATCGCTC 
DRAM1 fw AGTGCTTGGATTGGTGGGATG 
136 
DRAM1 rev GATGGACTGTAGGAGCGTGTA 
GADD45 α fw GAGAGCAGAAGACCGAAAGGA 
145 
GADD45 α rev CACAACACCACGTTATCGGG 
HPV16 E6/E7 fw CAATGTTTCAGGACCCACAGG 
125 
HPV16 E6/E7 rev CTCACGTCGCAGTAACTGTTG 
LC3A fw TCCCGGACCATGTCAACAT 
106 
LC3A rev ACCATGCTGTGCTGGTTCAC 
LC3B fw ACCATGCCGTCGGAGAAG 
115 
LC3B rev ATCGTTCTATTATCACCGGGATTTT 
MDM2 fw GAATCATCGGACTCAGGTACATC 
167 
MDM2 rev TCTGTCTCACTAATTGCTCTCCT 
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Table 4.1 | Oligonucleotides (primer) for qPCR (continued). 
p53 fw CAGCACATGACGGAGGTTGT 
125 
p53 rev TCATCCAAATACTCCACACGC 
p62 fw AGGCGCACTACCGCGAT 
51 
p62 rev CGTCACTGGAAAAGGCAACC 
PML fw CGCCCTGGATAACGTCTTTTT 
127 
PML rev CTCGCACTCAAAGCACCAGA 
ppm1d fw CTGTACTCGCTGGGAGTGAG 
88 
ppm1d rev GTTCGGGCTCCACAACGATT 
Puma fw GCCAGATTTGTGAGACAAGAGG 
136 
Puma rev CAGGCACCTAATTGGGCTC 
TIGAR fw ACTCAAGACTTCGGGAAAGGA 
144 
TIGAR rev CACGCATTTTCACCTGGTCC 
VEGF fw CACACAGGATGGCTTGAAGA 
136 
VEGF rev AGGGCAGAATCATCACGAAG 
XPC fw CTTCGGAGGGCGATGAAAC 
199 
XPC rev TTGAGAGGTAGTAGGTGTCCAC 
YPEL3 fw GTGCGGATTTCAAAGCCCAAG 
170 
YPEL3 rev CCCACGTTCACCACTGAGTT 
 
4.10.2 Oligonucleotides for RNA interference 
Table 4.2 | Oligonucleotides for siRNA-mediated knock-down experiments. 
Name Sequence 5’ → 3’ Source 
si-16E6/E7 * 





Silencer®  Select Pre-designed 
siRNA Atg12 
GCAGCUUCCUACUUCAAUUtt Thermo Scientific, 
St. Leon-Rot 
Silencer®  Select Pre-designed 
siRNA p62/SQSTM1 
CUUCCGAAUCUACAUUAAAtt Thermo Scientific, 
St. Leon-Rot 




* Three different siRNAs, each targeting all three HPV16 E6/E7 transcript classes, were pooled at equimolar 




4.10.3 Oligonucleotides for reverse transcription 
Random primers p(dN)6 * Roche, Mannheim  
Oligo dT22 primers DKFZ, Heidelberg 
* kindly provided by Daniel Hasche, DKFZ Heidelberg 
 
4.11 Provided plasmids 
Table 4.3 | List of protein expression plasmids. CMV: cytomegalovirus. The cryo-conserved bacteria 
harbouring plasmids were kindly provided by Martina Niebler, DKFZ Heidelberg. 
Plasmid Name Properties Source 
pPK-CMV-E3 empty cloning vector 
CMV promoter and enhancer 
C-terminal HA-tag 
PromoKine 
pPK:p53 expression of wild-type p53 under 
a CMV promoter 
M. Niebler, DKFZ Heidelberg 
* Chemically competent bacteria: E. coli One Shot®  Top 10 DH10BTM (Invitrogen, Karlsruhe) 
 
4.12 Antibodies 
Table 4.4 | List of antibodies used for Western Blot analyses. All antibodies were diluted in 5% Milk/TBST 
(w/v). *: generously provided by Felix Hoppe-Seyler, DKFZ Heidelberg. 


























Abcam ab56416 1:1,000 





    
Anti-α-tubulin (DM1A) * 
mouse monoclonal 








BD Pharmingen 610959 1:500 
Anti-LC3 * 
rabbit polyclonal 
Novus Biologicals NB100-2331 1:1,000 








Secondary antibodies    













4.13 Human cell lines 
Table 4.5 | Human adherent cell lines used throughout the presented thesis. 
Cell line Source Properties Reference 
CaSki Cervical carcinoma tumourigenic 
HPV16-positive 
[346] 
SiHa Cervical carcinoma tumourigenic 
HPV16-positive 
[347] 
HepG2 Hepatocellular carcinoma non-tumorigenic [348] 
 
4.14 Software and Databases 
Adobe Illustrator CC Adobe, San Jose, USA 
CFX Manager Bio-Rad Laboratories, USA 
Endnote X7 Thomson, Carlsbad, USA 
ImageJ 1.51j8 National Institute of Health (NIH), USA 
Microsoft Excel 2013 Microsoft, USA 
NCBI-Blast (sequence alignment) https://blast.ncbi.nlm.nih.gov  
NCBI-Gene (gene database) https://www.ncbi.nlm.nih.gov/gene  
NCBI-Nucleotide (nucleotide database) https://www.ncbi.nlm.nih.gov/nucleotide/  
NCBI-Pubmed (literature database) https://www.ncbi.nlm.nih.gov/pubmed/  





5.1 Cultivation and treatment of human cells 
 
5.1.1 Cultivation of human cell lines 
Cervical cancer cell lines CaSki and SiHa were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal calf serum (FCS). Liver cancer cell line HepG2 was grown 
in Dulbecco’s Modified Eagle’s (HIGH glucose) Medium supplemented with 10% fetal calf serum 
(FCS). Cells were cultivated in cell culture flasks until a confluency of 80-90% was reached and 
then passaged or seeded for experiments. All cell lines were maintained in an incubator at 37°C, 5% 
CO2 and 95% humidity. Cell line integrity was confirmed routinely via semi-quantitative PCR for 
viral oncogenes as well as for possible contaminations with Mycoplasma spec. 
 
5.1.2 Passaging and seeding of cells 
In order to detach adherent cells from cell culture vessels, the culture medium was removed and 
cells were washed once with 1x PBS. 1-2 mL of 0.25% trypsin-EDTA was applied to the cells and 
distributed evenly to cover the cell monolayer. The cells were then incubated at 37°C until they 
detached. The trypsin was inactivated by the addition of 5 mL DMEM medium containing 10% 
FCS and cells were transferred into a 15 mL reaction tube and centrifuged for 10 min at 1000 rpm 
(room temperature). Cells were washed once in 1x PBS and resuspended in 10 mL of fresh culture 
medium. For maintenance culture, cells were transferred into culture flasks at a ratio of 1:10 and 
further incubated at 37°C. 
 
For experimental purpose, 50 μL of the respective cell suspensions were stained with an equal 
volume of 0.25% trypan blue in 1x PBS and the cell number per mL was determined in a 
Neubauer hemocytometer or Countess®  II FL Automated Cell Counter (Life Technologies). The 
desired number of cells was transferred into culture vessels and incubated at 37°C. 
Unless otherwise mentioned, CaSki cells were seeded at a density of 1.0*106 per 6 cm culture 
dishes; SiHa and HepG2 cells were seeded at a density of 1.2*106 per 6 cm culture dishes. 
 
5.1.3 Cyroconservation and re-activation of cells 
For long-term storage of cell lines, cells were collected as described in the previous paragraph and 
washed in 1x PBS. Cell pellets of ca. 1-2*106 cells were resuspended in 1 mL of the respective pre-
chilled cryo-medium (60% DMEM, 30% FCS and 10% DMSO) and transferred into cryo tubes 
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which were quickly wrapped in several layers of tissue paper and transferred to -80°C. After 5-10 
days, the cells were transferred into cryo-conservation tanks filled with liquid nitrogen.  
To reactivate cells, cryo tubes were placed at room temperature until cells were thawed. The cells 
were then quickly transferred to 10 mL of cultivation medium. Cells were collected by 
centrifugation and washed with 1x PBS. Cell pellets were then resuspended in fresh culture 
medium and transferred to culture flasks. 
 
5.1.4 Experimental oxygen conditions 
Generally, cells were grown at 21% O2 which is termed normoxia and was used as control 
condition in this study. To monitor the cellular hypoxic reaction, cells were exposed to 1% O2 in 
the incubator C16 (Labotect, Göttingen) or in the InvivO2 400 physiological oxygen workstation 
(Ruskinn Technology Ltd, Bridgend, UK) two days after seeding. Depending on the experimental 
approach, the hypoxia treatment lasted from 0-120 h. During that time, the incubator was always 
closed to prevent reoxygenation of the cells. To ensure a continuous adequate atmosphere, time 
course experiments were all performed in the InvivO2 workstation. 
 
5.1.5 Experimental glucose conditions  
CaSki and SiHa cells were grown in standard glucose conditions of 1 g/L already present in the 
culture medium; HepG2 cells were grown in glucose conditions of 4.5 g/L already present in the 
culture medium, unless otherwise mentioned. 
Only in the experiment to test the effect of glucose on p53 regulation under hypoxia (described in 
chapter 3.3), cells were grown in media containing different amounts of glucose (0, 1, 2, 4.5 g/L). 
 
5.1.6 Treatment of cells with chemical compounds 
Cells were treated with inhibitors or small molecule compounds (see Table 5.1) two days after 
seeding. The compounds were added directly into the medium and the appropriate volume of the 
solvent was applied to control cells. 
 
Table 5.1 | Chemical compounds. 
Compound Solvent 







5.1.7 Transfection of siRNA 
For siRNA-mediated knock-down of proteins, 0.8*106 cells were seeded in 6 cm cell culture dishes 
and incubated over night. Cells were transfected using Lipofectamine 2000. Therefore, 20-40 
pmoles of specific siRNA or scrambled control siRNA were diluted in 500 μL of Opti-MEM. 6 μL 
of Lipofectamine were subsequently diluted in 500 μL of Opti-MEM and incubated for 5 min at 
room temperature. The Lipofectamine suspension was then added to the siRNA solution and 
mixed by pipetting up and down. The mixture was incubated for 20 min at room temperature, 
applied to the cells and distributed evenly. 48 h post transfection, the cells were cultured for 0-24 
h at 21% O2 or at 1% O2. Total protein or total RNA was extracted after this time. 
 
5.1.8 Transfection of expression plasmids 
For transfection of plasmid DNA, 1.0*106 cells were seeded in 6 cm cell culture dishes and 
incubated over night. Cells were transfected using Turbofect in vitro Transfection Reagent. Here, 
the respective plasmid DNA was diluted in 300 μL of Opti-MEM and mixed by vortexing. 4 μL of 
Turbofect were added to each plasmid solution and the suspension was again mixed by vortexing. 
The mix was incubated at room temperature for 15 min, added to the culture dishes and 
distributed evenly. 48 h post transfection, the cells were cultured for 0-24 h at 21% O2 or at 1% O2. 
Total protein was extracted. 
 
5.1.9 Senescence assay 
In the experiment to test the effect of hypoxia on cellular senescence, cells were cultured at 21% 
O2 or at 1% O2 for 24 or 72 h.  
In the experiment to test the effect of inhibitors on senescence, cells cultured with/without 
inhibitors for 48 h at 21% O2 or at 1% O2. Cells were removed from the normoxic or hypoxic 
conditions, split into new 6 cm dishes in a ratio of 1:3 and further kept in standard cell culture 
medium under normoxia for three additional days. 
 
Cells were then washed with PBS and fixed with 1 mL senescence assay fixation buffer for 3 min. 
After removing the fixation buffer and additional washing with PBS, cells were incubated with 
1.5 mL senescence assay staining buffer for 24 h at 37°C in a wet chamber. Senescence assay buffer 
was then removed and PBS was added to the 6 cm dishes. Images of representative cells were 
taken with a brightfield microscope (EVOS XL Core Cell Imaging System, Life Technologies, 




5.1.10 Cell counts and ATP assay 
Cell counts: Cells were cultured for the indicated time periods (4-72 h) at 21% O2 or at 1% 
O2.Viable cell numbers were determined by a standard trypan blue technique, using Countess®  II 
FL Automated Cell Counter (Life Technologies).  
ATP assay: Cells were seeded in 96-well plates at a density of 6*104 cells per well in triplicates. 
Control wells containing medium without cells to obtain a value of background luminescence 
were included. One plate for each time point. 24 h after seeding, cells were cultured for the 
indicated time at 21% O2 or at 1% O2. ATP assay was performed after respective time intervals 
(following the protocol of CellTiter-Glo®  Luminescent Cell Viability Assay): 
1. Equilibrate the plate and its contents at room temperature for approximately 30 minutes. 
2. Add a volume of CellTiter-Glo®  Reagent equal to the volume of cell culture medium present in 
each well. 
3. Mix contents for 2 minutes on an orbital shaker to induce cell lysis. 
4. Allow the plate to incubate at room temperature for 10 minutes to stabilize luminescent signal. 
5. Record luminescence (An integration time of 1 second per well). 
 
5.1.11 MTT assay 
Cells were seeded in 96-well plates at a density of 6*104 cells per well in quadruplicates. One plate 
for each time point. 24 h after seeding, cells were cultured for the indicated time at 21% O2 or at 1% 
O2. MTT assay was performed after respective time intervals (using a 10 mg/mL solution in water): 
1. Add an equal volume of MTT solution (final concentration 0.5 mg/mL) to the existing media 
in the culture. 
2. Incubate the plates at 37°C for 4 hours at 21% O2 or at 1% O2. 
3. After incubation, add 100 µL 2-Propanol into each well. 
4. Wrap plates in foil and shake on an orbital shaker for 15 min. 
5. Read absorbance at OD = 570 nm. Read plate within 1 hour. 
 
5.2 Isolation and analysis of nucleic acids 
 
5.2.1 Isolation of RNA 
Cells were washed once with 1x PBS prior to RNA extraction using the RNeasy Mini Kit. RLT 
lysis buffer was supplemented with 10 μL of 2-mercaptoethanol per mL buffer and 600 μL of 
buffer were added directly to the washed cells. Cells were dislodged from the cultivation vessel 
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with a cell scraper and collected in a 2 mL reaction tube. Cell membranes were disrupted by 
passing the suspension 10 times through a 20G needle. One volume of 70% ethanol (prepared with 
DEPC water) was added to the suspensions, which were then applied to a spin column and 
processed according to the manufacturer’s protocol. The DNase digestion was performed using the 
Qiagen RNase-Free DNase Set. RNA was eluted into 35 μL of RNase-free water and its 
concentration was measured photometrically. 
 
5.2.2 Spectrophotometric determination of nucleic acid concentrations 
The concentrations of RNAs and DNAs were determined photometrically using either a Synergy 2 
plate reader. 
 
5.2.3 Reverse transcription of RNA 
RNA was transcribed into cDNA employing RevertAid Reverse transcriptase with random primers 
using the following protocol: 
 
In a first step, the following components were pipetted into a 0.5 mL soft reaction tube. 
 positive reaction negative control 
RNA 250 ng – 1 μg 250 ng – 1 μg 
Primer (20 μM) 1 μL 1 μL 
RNase-free water Add up to final volume 12.5 μL Add up to final volume 12.5 μL 
 
In order to analyse possible DNA contamination of extracted RNA, reactions without Reverse 
Transcriptase were prepared in parallel and served as negative controls. 
Samples were incubated at 56°C for 5 min in order to allow correct primer annealing to mRNAs. 
The samples were cooled on ice for 1 min before adding the following reagents: 
 positive reaction negative control 
5x RevertAid Buffer 4 μL 4 μL 
dNTPS (10mM) 2 μL 2 μL 
 1 μL RevertAid Reverse Transcriptase 1.5 μL RNase-free water 
0.5 μL RiboLock 
 
Samples were incubated at 42°C for 1 h followed by a 10 min incubation step at 72°C. 
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The generated cDNAs, as well as negative controls, were diluted to a final concentration of 10 
ng/μL (assuming that all of the introduced RNA was transcribed). As an internal control, all cDNA 
samples were analysed for transcripts of human GAPDH by semi-quantitative PCR (RT-PCR). 
Samples showing a signal in the respective negative control were discarded. Samples whose 
integrity was confirmed were analysed for specific gene transcripts by RT-PCR. 
 
Table 5.2 | Oligonucleotides (primer) for RT-PCR. size: expected size of amplified fragments. TA: annealing 
temperature of respective primer pairs. 
Primer Name Sequence 5’ → 3’ size (bp) TA / cycles 
GAPDH fw GCCTTCCGTGTCCCCACTGC 
345 65°C/25 cycles 
GAPDH rev GCTCTTGCTGGGGCTGGTGG 
 
5.2.4 Semi-quantitative polymerase chain reaction 
Semi-quantitative polymerase chain reactions (RT-PCRs) were set up according to the following 
scheme: 
Dream Taq Green 2x Master Mix 10 μL 
cDNA Template 1 μL 
Primer Mix (fw + rev; 20 μM) 1 μL 
ddH2O Add up to final volume 20 μL 
 
Target sequences were amplified in a thermo cycler following the standard amplification protocol: 
 95°C/3’ – [95°C/30’’ – X°C/30’’ – 72°C/Y] x Z – 72°C/10’ 
with X: primer annealing temperature 
Y: elongation time, 1 min/1 kb fragment size 
Z: cycle number 
 
RT-PCR reactions were subjected to agarose gel electrophoresis and amplified fragments were 
visualised at 260 nm wavelength in a documentation device or on a UV table. 
If unspecific RT-PCR products were detected, 3% DMSO were added to the reactions prior to 
amplification in order to favour more specific primer binding. 
 
5.2.5 Agarose gel electrophoresis 
DNA fragments were separated via gel electrophoresis on agarose gels (1-1.5% agarose in 1x TAE 
buffer) containing 10 μL ethidium bromide per 100 mL molten agarose. DNA fragments were 
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visualised under UV light at 260 nm wave-length and their size was determined with the help of a 
size marker (GeneRuler DNA Ladder Mix) that was applied alongside the DNA samples. 
 
5.2.6 Quantitative polymerase chain reaction 
Quantitative real-time PCR (qPCR) was performed using iTaqTM Universal SYBR®  Green Supermix. 
For qPCR, specific primers that yielded fragments of less than 250 bp were employed (see Table 
4.1) 
 
Reactions were set up as follows: 
iTaqTM Universal SYBR®  Green Supermix (2X) 7.5 μL 
Primer Mix (fw + rev; 10 μM) 0.5 μL 
cDNA Template 1 μL 
ddH2O Add up to final volume 15 μL 
 
For every sample, the transcript levels of 18S rRNA was analysed in addition to the respective 
target gene fragment in order to allow the later normalisation of the obtained signal intensities. 
 
Amplification was performed in CFX96 Real-Time PCR Detection System using the following 
program: 
Step Temperature  Time  Cycles  
Polymerase activation and DNA denaturation 95°C 30 sec 1 
Denaturation  95°C 5 sec 
40 
Annealing/Extension + Plate Read 60°C 30 sec 
Melt curve analysis  65°C, 0.5°C increments 5 sec/step 
 
The relative transcript content (Fc value) of individual samples was calculated from obtained Ct 
values, employing the following equation: 
 Fc = 2-ΔΔCt 
with ΔΔCt = (Ct target – Ct reference) control - (Ct target – Ct reference) test 
 
In this study, 18S was used as the reference gene and the control and the test samples were 




5.2.7 Propagation and isolation of expression plasmids 
Plasmids were extracted from 2 mL of cell suspensions using a Miniprep Kit (Qiagen) according to 
the manufacturer’s instructions. Isolated plasmids were resuspended in 50-200 μL TE buffer and 
subsequently used for the transfection of eukaryotic cells. 
Suspensions of bacteria harbouring a plasmid of interest were cryo-conserved by mixing 750 μL of 
suspension with 250 μL of glycerol. These glycerol stocks were stored at -80°C and later used to 
inoculate fresh LB medium. 
 
5.3 Isolation and analyses of proteins 
 
5.3.1 Extraction of proteins 
In order to extract total protein, experimental cells were washed once with ice-cold 1X PBS. 100 
μL of CSKI buffer freshly supplemented with protease and phosphatase inhibitors as described in 
Table 5.3. 
Table 5.3 | Protease and phosphatase inhibitors. 
Agent Function Final concentration 
DTT Reducing agent  1 mM 
Complete protease inhibitor cocktail Protease inhibitor 1X 
MG132  Proteasome inhibitor 1 µM 
NaF  Phosphatase inhibitor 1 mM 
Na3VO4 Phosphatase inhibitor 0.2 mM 
 
The cells were scraped and the cell suspension was transferred into a 1.5 mL reaction tube. The 
suspensions were incubated on ice for 30 min and mixed every 10 min in order to enhance passive 
lysis of cells. The lysates were then centrifuged for 30 min at 13000 rpm and 4°C to remove 
remaining cell debris. Supernatants were then collected in fresh 1.5 mL reaction tubes and stored 
at -80°C until protein quantification. 
 
5.3.2 Separation of nuclear and cytosolic cell fractions 
For protein extractions from different cell fractions, cells were washed once with 1X PBS. 400 μL 
of pre-chilled buffer A freshly supplemented with protease and phosphatase inhibitors were added 
to the cells in culture dishes and cells were dislodged using a cell scrapper. The cell suspension was 
then collected to a 1.5 mL reaction tube and incubated on ice for 15 min. After the hypotonic 
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swelling of the cells, 25 μL of 10% Nonidet P-40 solution was added to the cell suspension and 
vortexed for 10 sec. The homogenate was then centrifuged for 1 min at 13000 rpm and 4°C. The 
supernatant containing cytoplasmic protein was transferred to a fresh 1.5 mL reaction tube and 
stored at -80°C until protein quantification. 
The cell pellet was resuspended in 50 μL of ice-cold buffer C freshly supplemented with protease 
and phosphatase inhibitors and incubated for 15 min at 4°C, during which the nuclear membrane 
was lysed. After 5 min of centrifugation at 13000 rpm and 4°C, the supernatant containing the 
nuclear protein extract was transferred to a fresh 1.5 mL reaction tube and stored at -80°C until 
protein quantification. 
 
5.3.3 Quantification of protein concentrations 
Protein concentrations were determined colorimetrically using Bradford Assay Reagent. 5 μL of a 
1:10 dilution of the respective cleared cell lysates were added to 155 μL water in a 96-well plate 
and mixed with 40 μL of 5x Bradford Reagent. As a standard, a serial dilution of BSA was prepared 
and measured alongside the respective protein samples, in order to determine the sample’s protein 
content. The absorption of the standard and protein samples was determined photometrically in a 
plate reader at a wavelength of 595nm and the samples’ concentrations were calculated according 
to the straight calibration line of the standard. 
 
5.3.4 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated via SDS-polyacrylamide gel electrophoresis (SDS-PAGE) which employs 
discontinuous polyacrylamide gels with a stacking and a resolving fraction. The separation of 
proteins along an electric current is dependent on the proteins’ electrophoretic mobility which is 
determined by protein size and modification. Depending on the expected size of the analysed 
proteins polyacrylamide gels with 10, 12 or 15% acrylamide in the resolving gel and 6% 
acrylamide in the stacking gel were cast as follows: 
 
Resolving gels: Stacking gels: 
0.3 M Tris, pH 8.8 0.25 M Tris, pH 6.8 
10, 12 or 15% Acrylamide-Bis (29:1) 6% Acrylamide-Bis (29:1) 
0.1% SDS 0.1% SDS 
0.1% APS 0.1% APS 




Cleared protein lysates were supplemented with 5x SDS loading dye and incubated at 99°C for 10 
min. 50 μg of denatured protein samples were applied to the acrylamide gel alongside a size 
marker (PageRuler). SDS-PAGE was carried out in 1x SDS running buffer at 80 V for 20-30 min 
until the complete sample volume had migrated into the resolving gel. The voltage was then 
increased to 120 V until the desired size separation according to the marker had taken place. 
 
5.3.5 Immunoblotting and Western blot analyses 
Proteins were separated via SDS-PAGE. Size-separated proteins were then transferred to PVDF 
membranes employing a semi-dry approach. Therefore, acrylamide gels with size-separated 
proteins were incubated in Cathode Buffer for 10 min. In the meantime, PVDF membranes were 
activated in methanol for 10-20 sec and washed briefly in water. Activated membranes were 
equilibrated in Anode Buffer II for 5 min. Together with Whatman papers soaked in Anode Buffer 
I and II or Cathode Buffer, PVDF membranes and acrylamide gels were placed in a semi-dry 
blotting chamber according to Figure 5.1. The transfer of proteins onto PVDF membranes was 
performed for 35 min at 0.2 A per membrane. 
 
Figure 5.1 | Set-up for immunoblotting via semi-dry transfer of proteins. Whatman filter papers (grey), 
acrylamide gels with size-separated proteins (blue) and activated PVDF membranes (green) were 
equilibrated in the indicated transfer buffers. Figure created by Martina Niebler, DKFZ Heidelberg. 
 
After protein transfer, PVDF membranes were blocked with 5% Milk/TBST for 1 h at room 
temperature. The respective primary antibody (see Table 4.4) was diluted in 5% Milk/TBST and 
applied to the blocked membranes. Membranes were incubated with primary antibodies for 12-
18 h on an overhead shaker at 4°C. 
For the detection of specific proteins, overnight-incubated membranes were washed four times 
with 1x TBST. Then the respective HRP-conjugated secondary antibody was added in 5% 
Milk/TBST and incubated with the membranes for 1 h at room temperature. Membranes were 
again washed for four times in 1x TBST. 1 mL of ECL was applied to each membrane and 
incubated for 1 min at room temperature. Proteins were detected via the exposition of medical X-




5.4 Statistical analyses 
Microsoft Excel (Microsoft Office 2013) was used for data analysis. Statistical significance was 
determined by the two-tailed Student’s t test. P-values of ≤0.05 (*), ≤0.01 (**), or ≤0.001 (***) were 
considered statistically significant. 
For calculation of the half-life of p53 protein in Figure 2.4, a linear trendline was added using the 
trendline function in Excel. The line was generally forced through the origin. Calculate the slope 
of degradation line for each condition using the slope function in Excel. Use the following formula 
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v/v Volume percentage 
w/v Weight/volume 
aa Amino acid 
AMPK  AMP activated protein kinase 
Apaf1 Apoptotic peptidase activating factor 1 
APS Ammonium persulfate 
ARNT  Aryl hydrocarbon receptor nuclear translocator 
ATF  Activating transcription factor 
Atg Autophagy-related 
ATM  Ataxia telangiectasia mutated 
ATP Adenosine triphosphate 
ATR Ataxia telangiectasia and Rad3-related 
Baf A1 Bafilomycin A1 
Bax Bcl-2-associated X protein 
bHLH  Basic helix-loop-helix 
BLAST Basic Local Alignment Search Tool 
BNIP3  BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 
bp  Base pairs 
BSA  Bovine serum albumin 
ca. circa 
cAMP  cyclic adenosine monophosphate 
CBP CREB-binding protein 
Cdk Cyclin-dependent kinase 
CDKN1A  Cyclin dependent kinase inhibitor 1A 
cDNA  complementary DNA 
CHX Cycloheximide 
CIN  Cervical intraepithelial neoplasia 
CMA Chaperone-mediated autophagy 
CmPV1  Chelonia mydas papillomavirus type 1 
CMV  Cytomegalovirus 
CO2 Carbon dioxide 
CPV1 Canine papillomavirus type 1 
CQ Chloroquine 
CRE  Calcium/cAMP-responsive element 
CTD Carboxy-terminal domain 
Cyto Cytoplasmic 
DBD DNA-binding domain  
ddH2O doubly distilled water 
DDR DNA damage response 
DEPC  Diethyl-pyrocarbonate 
DMEM  Dulbecco’s modified Eagle’s medium 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNA DSBs/SSBs DNA double- and single-strand breaks 
dNTP Deoxynucleotide triphosphate 
dNTPs  Deoxyribonucleotide triphosphates 
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DRAM1 DNA damage-regulated autophagy modulator 1 
DTT  Dithiothreitol 
DUBs  Deubiquitinating enzymes 
E. coli  Escherichia coli 
e.g.  exempli gratia 
E6-AP E6-associated protein 
ECL  Enhanced Chemiluminescence Substrate 
EDTA  Ethylenediaminetetraacetic acid 
EGTA Ethylene glycol tetraacetic acid 
Erk Extracellular signal-regulated kinase 
et al.  et alii 
EtOH Ethanol 
FCS  Fetal calf serum 
Fig. Figure 
FIH Factor inhibiting HIF 
fw Forward 
GADD45 α Growth arrest and DNA damage inducible alpha 
GAPDH  Glycerinaldehyde 3-phosphate dehydrogenase 
Glut 1-4 Glucose transporter types 1-4 
HDAC1 Histone deacetylase 
HEPES  4-(2-hydroxyethyl)-1-piperazine-ethanesulfonicacid 
HIF Hypoxia-inducible factor 
HIPK2 Homeodomain-interacting protein kinase 2 
HPV(s) Human papillomavirus(es) 
HRE Hypoxia response element 
HRP Horseradish peroxidase 
HSP Heat Shock Protein 
IgG  Immunoglobuline G 
IP  Immunoprecipitation 
JNK  c-Jun terminal kinase 
K Lysine 
kb Kilobases 
KCl  Potassium chloride 
KH2PO4  Potassium dihydrogen phosphate 
LB  Lysogeny broth 
lncRNAs large intergenic non-coding RNAs 
mA  Miliampère 
MAP  Mitogen-activated protein 
MAPK Mitogen-activated protein kinase 
MDM2 Mouse double minute 2 homolog 
MgCl2  Magnesium chloride 
MgSO4  Magnesium sulfate 
MMP Matrix Metalloproteinase 
MOMP Mitochondrial outer membrane permeabilization 
mRNA  Messenger RNA 
mTOR  Mammalian target of rapamycin 
n.s. Not significant 
Na2HPO4  Sodium dihydrogen phosphate 
NaCl  Sodium chloride 
NaOH  Sodium hydroxide 
NER Nucleotide excision repair 
NES Nuclear export signal 
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NF-κB Nuclear factor kappa B 
NLS Nuclear localization signal 
NP-40  Nonidet P-40 
Nucl Nuclear 
O2 Oxygen 
ODD  Oxygen-dependent degradation domain 
ORF(s)  Open reading frame(s) 
ORI  Origin of replication 
OXPHOS Mitochondrial oxidative phosphorylation 
p Probability 
pAE  Early polyadenylation site 
PAGE  Polyacrylamide gel electrophoresis 
pAL  Late polyadenylation site 
PARP Poly (ADP-ribose) polymerase 
PBS  Phosphate-buffered saline 
PCR  Polymerase chain reaction 
PDK Pyruvate dehydrogenase kinase 
PFK Phosphofructokinase  
pg  Picogram 
PHD  Prolyl hydroxylase 
PI3K  Phosphoinositide 3-kinase 
PIPES Piperazine-N,N’-bis(2-ethanesulfonic acid) 
PML Promyelocytic leukemia protein 
PML-NBs PML nuclear bodies 
pmoles  Picomoles 
pO2 Oxygen partial pressure 
Poly A  Polyadenylation 
ppm1d (WIP1) Protein phosphatase magnesium-dependent 1 delta (wild-type 
p53 induced phosphatase 1) 
pRb Retinoblastoma protein 
PRD Proline-rich domain 
PTM Post-translational modification 
Puma p53 upregulated modulator of apoptosis 
PV Papillomavirus  
PVDF  Polyvinylidene fluoride 
pVHL  Von Hippel Lindau protein 
qPCR  Quantitative polymerase chain reaction 
rev Reverse 
RNA  Ribonucleic acid 
RNAi RNA interference 
ROS  Reactive oxygen species 
rpm  rounds per minute 
rRNA ribosomal RNA 
RT  Reverse transcription 
SA-β-Gal Senescence-Associated β-Galactosidase 
SD Standard deviations 
SDS Sodium dodecyl sulfate 
Ser Serine 
si-16E6/E7 Small interfering RNA against HPV16 E6/E7 
si-Atg12 Small interfering RNA against Atg12 
si-p62 Small interfering RNA against p62 
siRNA  Small interfering RNA 
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SMYD2 SET and MYND domain-containing protein 2 
SUMO Small Ubiquitin-related Modifier 
SV40  Simian Virus 40 
TA Annealing temperature 
Tab. Table 
TAD Transcriptional activation domain 
TAE  Tris acetate EDTA 
Taq  Thermus aquaticus 
TBP  TATA-binding protein 
TBS  Tris-buffered saline 
TBST  Tris-buffered saline/Tween20 
TEMED  Tetramethylethylenediamine 
TERT Telomerase reverse transcriptase 
TIGAR TP53 induced glycolysis regulatory phosphatase 
Tris Tris(hydroxymethyl)-aminomethane 
URR  Upstream regulatory region 
USP Ubiquitin specific peptidase 
UV Ultraviolet 
VEGF  Vascular endothelial growth factor 
VLPs Virus-like particles 




°C degree Celsius 
Da  Dalton 
g  gram 
h  hour(s) 
L liter 
M  molar (mole/L) 
m  meter 
min  minute(s) 
mol mole 
sec  second(s) 
V  volt 
%  percent 
 
Prefixes 
Symbol Prefix  Factor 
k  kilo  103 
c  centi  10-2 
m milli  10-3 
µ  micro  10-6 







7.2 Publications and presentations 
 
L. Zhuang, F. Roesl, M. Niebler, Biphasic regulation of p53 in hypoxic HPV16-positive cancer cells. 
manuscript in preparation. 
 
L. Zhuang, F. Roesl, M. Niebler, Biphasic regulation of p53 in hypoxic HPV16-positive cervical 
cancer cells. The N2 Event 2019 – From Research to Application, 13-15th November 2019, Berlin, 
Germany. Poster Presentation. 
 
L. Zhuang, F. Roesl, M. Niebler, Evasion of hypoxic HPV16-positive cervical cancer cells from 
senescence via p53 depletion. Retreat of the DKFZ Research Program “Infection, Inflammation 
and Cancer”, 25-27th March 2019, Schöntal, Germany. Oral Presentation. 
 
L. Zhuang, F. Roesl, M. Niebler, Regulation of p53 by hypoxia in HPV16-positive cervical cancer 
cells. Helmholtz International Graduate School for Cancer Research PhD Poster Presentation, 12-
16th November 2018, Heidelberg, Germany. Poster Presentation. 
 
L. Zhuang, F. Roesl, M. Niebler, Regulation of p53 by hypoxia in HPV16-positive cervical cancer 
cells. Helmholtz International Graduate School for Cancer Research PhD Retreat, 18-20th July 






This dissertation was conducted at the German Cancer Research Center in Heidelberg, Germany, 
in the research group “Viral Transformation Mechanisms” headed by Prof. Dr. Frank Rösl. 
First of all, I would like to express my gratitude to Prof. Dr. Frank Rösl for giving me the 
opportunity to work under his guidance. Thank you for the constant support and your valuable 
feedback during my time as a PhD student. 
I would like to acknowledge to China Scholarship Council (CSC) for supporting me to study and 
pursue my doctoral degree overseas. 
I am also grateful to PD. Dr. Karin Müller-Decker for evaluating my thesis as first referee and 
partaking in my TAC meetings with valuable comments. My gratitude extends to Prof. Dr. Baki 
Akgül for joining my TAC committee with helpful suggestions. Moreover, I would like to thank 
Prof. Dr. Ralf Bartenschlager and Prof. Dr. Martin Müller for taking their time to be part of my 
thesis examination committee. 
Importantly, I would like to thank Dr. Martina Niebler for the great help during my study. Thank 
you for providing things needed for this project and thanks a lot for many helpful discussions and 
critical insights. I am also grateful to you for correcting the manuscript and for modifying every 
poster and report. 
I thank Prof. Dr. Felix Hoppe-Seyler and Prof. Dr. Karin Hoppe-Seyler for generously sharing 
antibodies and reagents. My gratitude also goes to Prof. Dr. Martin Löchelt for good scientific 
discussion and advice and for sharing skills of presentation. 
I would like to thank Regina Ly for organizing the lab. Also thank you for the small gifts during 
German celebration days. My gratitude also extends to Diana Schalk for support in administrative 
matters and Elke Göckel-Krzikalla for providing buffers and reagents. 
I wish to express my gratitude to all former and present members of the F030-lab for the nice 
working atmosphere: Dr. Daniel Hasche, Dr. Matthias Meister, Claudia Savini, Ruwen Yang, 
Yingying Fu, Rui Cao, Sofiya Levytska, Miriam Schäfer, Nadine Gemlin, Ilona Braspenning-Wesch 
and Sonja Stephan. 
Many thanks go to Dr. Graciela Ruiz Ramirez, Joan Crous i Masó and Ilaria Salvato for the nice 
time and talks during lunches. 
I am deeply grateful to Zhangting for your continuous encouragement and motivation at all times. 
Thank you for inspiring me in many talks. 
Finally, I want to thank my parents and my sisters. Thank you for your unconditional love and 
support all over these years! 
